Difference between revisions of "Cancer" - New World Encyclopedia

From New World Encyclopedia
(added article from Wikipedia and credit/category tag)
(update to most recent Wikipedia version)
Line 1: Line 1:
 +
{{Other uses}}
 +
{{Refimprove|date=March 2009}}
 
{{sprotected2}}
 
{{sprotected2}}
{{otheruses}}
+
{{Infobox disease
{{Infobox_Disease
 
 
| Name = Cancer
 
| Name = Cancer
| Image = Normal cancer cell division from NIH-2.svg
+
| Image = Tumor_Mesothelioma2_legend.jpg
| Caption = When normal cells are damaged beyond repair, they are eliminated by [[apoptosis]] (A). Cancer cells avoid apoptosis and continue to multiply in an unregulated manner (B).
+
| Caption = A coronal [[CT scan]] showing [[malignant]] [[mesothelioma|cancer of the lung sac]].<br/>Legend: →&nbsp;tumor&nbsp;←, ★&nbsp;central [[pleural effusion]], 1&3&nbsp;lungs, 2&nbsp;spine, 4&nbsp;ribs, 5&nbsp;[[aorta]], 6&nbsp;[[spleen]], 7&8&nbsp;kidneys, 9&nbsp;liver.
 
| DiseasesDB = 28843
 
| DiseasesDB = 28843
 
| ICD10 =
 
| ICD10 =
Line 16: Line 17:
 
}}
 
}}
  
[[Image:BreastCancer.jpg|thumb|200px|right|[[Mastectomy]] specimen containing a large cancer of the breast (in this case, an invasive [[ductal carcinoma]]).]]
+
'''Cancer''' {{IPA-en|ˈkænsər||en-us-cancer.ogg}} (medical term: [[malignancy|malignant]] [[neoplasm]]) is a class of [[disease]]s in which a group of [[cell (biology)|cells]] display ''uncontrolled growth'' ([[cell division|division]] beyond the normal limits), ''invasion'' (intrusion on and destruction of adjacent tissues), and sometimes ''[[metastasis]]'' (spread to other locations in the body via lymph or blood). These three malignant properties of cancers differentiate them from [[benign tumor]]s, which are self-limited, and do not invade or metastasize. Most cancers form a [[tumor]] but some, like [[leukemia]], do not. The branch of medicine concerned with the study, diagnosis, treatment, and prevention of cancer is [[oncology]].
  
[[Image:Colon cancer 2.jpg|thumb|200px|right|[[Colectomy]] specimen containing an invasive [[colorectal carcinoma]] (the crater-like, reddish, irregularly-shaped tumor).]]
+
Cancer affects people at all ages with the risk for most types increasing with age.<ref name="Cancer Research UK">{{cite web | last =Cancer Research UK | title =UK cancer incidence statistics by age | month=January | year=2007 | url =http://info.cancerresearchuk.org/cancerstats/incidence/age/ | accessdate =2007-06-25 }}</ref> Cancer caused about 13% of [[causes of death|all human deaths]] in 2007<ref name="WHO">{{cite web | last =WHO | authorlink =World Health Organization | title =Cancer | publisher =World Health Organization |month=February | year=2006 | url =http://www.who.int/mediacentre/factsheets/fs297/en/ | accessdate =2007-06-25 }}</ref> (7.6&nbsp;million).<ref name="American Cancer Society">{{cite web | last =American Cancer Society | authorlink =Reuters | title =Report sees 7.6&nbsp;million global 2007 cancer deaths | publisher =Reuters |month=December | year=2007 | url =http://www.reuters.com/article/healthNews/idUSN1633064920071217 | accessdate =2008-08-07 }}</ref>
  
[[Image:Lung cancer.jpg|thumb|200px|right|[[Pneumonectomy]] specimen containing a [[lung cancer]], here a [[squamous cell carcinoma]] (the whitish tumor near the bronchi).]]
+
Cancers are caused by abnormalities in the [[genome|genetic material]] of the [[malignant transformation|transformed]] cells.<ref name="Kinz">{{cite book | author = Kinzler, Kenneth W.; Vogelstein, Bert | title = The genetic basis of human cancer | edition = 2nd, illustrated, revised| language = | publisher = McGraw-Hill, Medical Pub. Division | location = New York | year = 2002 | page = 5| isbn = 978-0-07-137050-9 | url = http://books.google.com/?id=pYG09OPbXp0C| chapter=Introduction |chapterurl=http://books.google.co.uk/books?id=pYG09OPbXp0C&pg=PA5&dq=%22from+defects+in+oncogenes%22&lr=&ei=EJ8pSujtDYWKygSqj8ikBw#PPA6,M1}}</ref> These abnormalities may be due to the effects of [[carcinogens]], such as [[tobacco smoke]], [[electromagnetic radiation|radiation]], [[chemicals]], or [[pathogen|infectious agents]]. Other cancer-promoting genetic abnormalities may randomly occur through errors in [[DNA replication]], or are [[genetic disorder|inherited]], and thus present in all cells from birth. The [[heritability]] of cancers is usually affected by complex interactions between carcinogens and the host's [[genome]].
 
 
[[Image:Renal cell carcinoma.jpg|thumb|200px|right|[[Nephrectomy]] specimen containing a [[renal cell carcinoma]] (the yellowish, spongy-looking tumor in the lower left).]]
 
 
 
'''Cancer''' (medical term: [[malignant]] [[neoplasm]]) is a class of [[disease]]s in which a group of [[cell (biology)|cells]] display ''uncontrolled growth'' ([[cell division|division]] beyond the normal limits), ''invasion'' (intrusion on and destruction of adjacent tissues), and sometimes ''[[metastasis]]'' (spread to other locations in the body via lymph or blood). These three [[malignant]] properties of cancers differentiate them from [[benign tumor]]s, which are self-limited, do not invade or metastasize. Most cancers form a [[tumor]] but some, like [[leukemia]], do not. The branch of medicine concerned with the study, diagnosis, treatment, and prevention of cancer is [[oncology]].
 
 
 
Cancer may affect people at all ages, even [[fetus]]es, but the risk for most varieties increases with age.<ref name="Cancer Research UK">{{cite web | last =Cancer Research UK | title =UK cancer incidence statistics by age | month=January | year=2007 | url =http://info.cancerresearchuk.org/cancerstats/incidence/age/ | accessdate =2007-06-25 }}</ref> Cancer causes about 13% of [[causes of death|all deaths]].<ref name="WHO">{{cite web | last =WHO | authorlink =World Health Organization | title =Cancer | publisher =World Health Organization |month=February | year=2006 | url =http://www.who.int/mediacentre/factsheets/fs297/en/ | accessdate =2007-06-25 }}</ref> According to the [[American Cancer Society]], 7.6&nbsp;million people died from cancer in the world during 2007.<ref name="American Cancer Society">{{cite web | last =American Cancer Society | authorlink =Reuters | title =Report sees 7.6&nbsp;million global 2007 cancer deaths | publisher =Reuters |month=December | year=2007 | url =http://today.reuters.com/news/articlenews.aspx?type=healthNews&storyid=2007-12-17T052342Z_01_N16330649_RTRUKOC_0_US-CANCER-WORLD.xml | accessdate =2007-12-17 }}</ref> Cancers can affect all animals.
 
 
 
Nearly all cancers are caused by abnormalities in the [[genome|genetic material]] of the [[malignant transformation|transformed]] cells. These abnormalities may be due to the effects of [[carcinogens]], such as [[tobacco smoke]], [[electromagnetic radiation|radiation]], [[chemicals]], or [[pathogen|infectious agents]]. Other cancer-promoting genetic abnormalities may be randomly acquired through errors in [[DNA replication]], or are [[genetic disorder|inherited]], and thus present in all cells from birth. The [[heritability]] of cancers are usually affected by complex interactions between carcinogens and the host's [[genome]]. New aspects of the genetics of cancer pathogenesis, such as [[DNA methylation]], and [[microRNAs]] are increasingly recognized as important.
 
  
 
Genetic abnormalities found in cancer typically affect two general classes of genes. Cancer-promoting ''[[oncogene]]s'' are typically activated in cancer cells, giving those cells new properties, such as hyperactive growth and division, protection against [[programmed cell death]], loss of respect for normal tissue boundaries, and the ability to become established in diverse tissue environments. ''[[Tumor suppressor gene]]s'' are then inactivated in cancer cells, resulting in the loss of normal functions in those cells, such as accurate DNA replication, control over the [[cell cycle]], orientation and adhesion within tissues, and interaction with protective cells of the [[immune system]].
 
Genetic abnormalities found in cancer typically affect two general classes of genes. Cancer-promoting ''[[oncogene]]s'' are typically activated in cancer cells, giving those cells new properties, such as hyperactive growth and division, protection against [[programmed cell death]], loss of respect for normal tissue boundaries, and the ability to become established in diverse tissue environments. ''[[Tumor suppressor gene]]s'' are then inactivated in cancer cells, resulting in the loss of normal functions in those cells, such as accurate DNA replication, control over the [[cell cycle]], orientation and adhesion within tissues, and interaction with protective cells of the [[immune system]].
  
Diagnosis usually requires the [[histology|histologic]] examination of a tissue [[biopsy]] specimen by a [[anatomical pathology|pathologist]], although the initial indication of malignancy can be symptoms or [[radiographic]] imaging abnormalities. Most cancers can be treated and some cured, depending on the specific type, location, and [[Cancer staging|stage]]. Once diagnosed, cancer is usually treated with a combination of [[surgery]], [[chemotherapy]] and [[radiation therapy|radiotherapy]]. As research develops, treatments are becoming more specific for different varieties of cancer. There has been significant progress in the development of [[targeted therapy]] drugs that act specifically on detectable molecular abnormalities in certain tumors, and which minimize damage to normal cells. The prognosis of cancer patients is most influenced by the type of cancer, as well as the [[cancer staging|stage]], or extent of the disease. In addition, [[histology|histologic]] [[Grading (tumors)|grading]] and the presence of specific molecular markers can also be useful in establishing prognosis, as well as in determining individual treatments.
+
Definitive diagnosis requires the [[histology|histologic]] examination of a [[biopsy]] specimen, although the initial indication of malignancy can be symptomatic or [[radiographic]] imaging abnormalities. Most cancers can be treated and some forced into [[remission]], depending on the specific type, location, and [[Cancer staging|stage]]. Once diagnosed, cancer is usually treated with a combination of [[surgery]], [[chemotherapy]] and [[radiation therapy|radiotherapy]]. As research develops, treatments are becoming more specific for different varieties of cancer. There has been significant progress in the development of [[targeted therapy]] drugs that act specifically on detectable molecular abnormalities in certain tumors, and which minimize damage to normal cells. The prognosis of cancer patients is most influenced by the type of cancer, as well as the [[cancer staging|stage]], or extent of the disease. In addition, [[histology|histologic]] [[grading (tumors)|grading]] and the presence of specific molecular markers can also be useful in establishing prognosis, as well as in determining individual treatments.
 
 
==Classification==
 
Cancer is generally classified according to the tissue from which the cancerous cells originate, the primary tumor, as well as the normal cell type they most resemble. These are location and histology, respectively.
 
 
 
===Nomenclature===
 
The following closely related terms may be used to designate abnormal growths:
 
* '''[[Tumor]]:''' originally, it meant any abnormal swelling, lump or mass. In current English, however, the word tumor has become synonymous with neoplasm, specifically solid neoplasm. Note that some neoplasms, such as [[leukemia]], do not form tumors.
 
* '''[[Neoplasia|Neoplasm]]:''' the scientific term to describe an abnormal proliferation of genetically altered cells. Neoplasms can be benign or malignant:
 
** '''Malignant neoplasm''' or '''malignant tumor''': synonymous with '''cancer'''.
 
** '''Benign neoplasm''' or '''[[benign tumor]]''': a tumor (solid neoplasm) that stops growing by itself, does not invade other tissues and does not form metastases.
 
* '''Invasive''' tumor is another synonym of '''cancer'''. The name refers to invasion of surrounding tissues.
 
* '''Pre-malignancy''', '''pre-cancer''' or '''non-invasive''' tumor: A neoplasm that is not invasive but has the potential to progress to cancer (become invasive) if left untreated. These lesions are, in order of increasing potential for cancer, [[atypia]], [[dysplasia]] and [[carcinoma in situ]].
 
 
 
The following terms can be used to describe a cancer:
 
* '''Screening''': a test done on healthy people to detect tumors before they become apparent. A [[mammogram]] is a screening test.
 
* '''Diagnosis''': the confirmation of the cancerous nature of a lump. This usually requires a [[biopsy]] or removal of the tumor by [[surgery]], followed by examination by a [[surgical pathology|pathologist]].
 
* '''Surgical excision''': the removal of a tumor by a [[surgery|surgeon]].
 
** '''Surgical margins''': the evaluation by a [[surgical pathology|pathologist]] of the edges of the tissue removed by the surgeon to determine if the tumor was removed completely ("negative margins") or if tumor was left behind ("positive margins").
 
* '''Grade''': a number (usually on a scale of 3) established by a [[surgical pathology|pathologist]] to describe the degree of resemblance of the tumor to the surrounding benign tissue.
 
* '''Stage''': a number (usually on a scale of 4) established by the [[oncology|oncologist]] to describe the degree of invasion of the body by the tumor.
 
* '''Recurrence''': new tumors that appear at the site of the original tumor after surgery.
 
* '''Metastasis''': new tumors that appear far from the original tumor.
 
* '''Transformation:''' the concept that a low-grade tumor transforms to a high-grade tumor over time. Example: [[Richter's transformation]].
 
* '''Chemotherapy''': treatment with drugs.
 
* '''Radiation therapy''': treatment with radiations.
 
* '''Adjuvant''' therapy: treatment, either chemotherapy or radiation therapy, given after surgery to kill the remaining cancer cells.
 
* '''Prognosis''': the probability of cure after the therapy. It is usually expressed as a probability of survival five years after diagnosis. Alternatively, it can be expressed as the number of years when 50% of the patients are still alive. Both numbers are derived from statistics accumulated with hundreds of similar patients to give a [[Kaplan-Meier estimator|Kaplan-Meier curve]].
 
  
Cancers are classified by the type of cell that resembles the tumor and, therefore, the tissue presumed to be the origin of the tumor. Examples of general categories include:
+
== Classification ==
 +
{{further|[[List of cancer types]]}}
 +
Cancers are classified by the [[List of distinct cell types in the adult human body|type of cell]] that resembles the tumor and, therefore, the tissue presumed to be the origin of the tumor. These are the histology and the location, respectively. Examples of general categories include:
 
* '''[[Carcinoma]]:''' Malignant tumors derived from [[epithelium|epithelial]] cells. This group represents the most common cancers, including the common forms of [[breast cancer|breast]], [[prostate cancer|prostate]], [[lung cancer|lung]] and [[Colorectal cancer|colon cancer]].
 
* '''[[Carcinoma]]:''' Malignant tumors derived from [[epithelium|epithelial]] cells. This group represents the most common cancers, including the common forms of [[breast cancer|breast]], [[prostate cancer|prostate]], [[lung cancer|lung]] and [[Colorectal cancer|colon cancer]].
 
* '''[[Sarcoma]]:''' Malignant tumors derived from [[connective tissue]], or [[mesenchyme|mesenchymal]] cells.
 
* '''[[Sarcoma]]:''' Malignant tumors derived from [[connective tissue]], or [[mesenchyme|mesenchymal]] cells.
 
* '''[[Lymphoma]]''' and '''[[leukemia]]:''' Malignancies derived from hematopoietic ([[blood]]-forming) cells
 
* '''[[Lymphoma]]''' and '''[[leukemia]]:''' Malignancies derived from hematopoietic ([[blood]]-forming) cells
 
* '''[[Germ cell tumor]]:''' Tumors derived from [[totipotent]] cells. In adults most often found in the [[testicle]] and [[ovary]]; in fetuses, babies, and young children most often found on the body midline, particularly at the tip of the tailbone; in horses most often found at the poll (base of the skull).
 
* '''[[Germ cell tumor]]:''' Tumors derived from [[totipotent]] cells. In adults most often found in the [[testicle]] and [[ovary]]; in fetuses, babies, and young children most often found on the body midline, particularly at the tip of the tailbone; in horses most often found at the poll (base of the skull).
* '''Blastic tumor:''' A tumor (usually malignant) which resembles an immature or embryonic tissue. Many of these tumors are most common in children.
+
* '''Blastic tumor or [[blastoma]]:''' A tumor (usually malignant) which resembles an immature or embryonic tissue. Many of these tumors are most common in children.
  
 
Malignant tumors (cancers) are usually named using '''-carcinoma''', '''-sarcoma''' or '''-blastoma''' as a suffix, with the Latin or Greek word for the organ of origin as the root. For instance, a cancer of the liver is called ''[[hepatocarcinoma]]''; a cancer of the fat cells is called ''liposarcoma''. For common cancers, the English organ name is used. For instance, the most common type of [[breast cancer]] is called ''ductal carcinoma of the breast'' or ''mammary ductal carcinoma''. Here, the adjective ''ductal'' refers to the appearance of the cancer under the microscope, resembling normal breast ducts.
 
Malignant tumors (cancers) are usually named using '''-carcinoma''', '''-sarcoma''' or '''-blastoma''' as a suffix, with the Latin or Greek word for the organ of origin as the root. For instance, a cancer of the liver is called ''[[hepatocarcinoma]]''; a cancer of the fat cells is called ''liposarcoma''. For common cancers, the English organ name is used. For instance, the most common type of [[breast cancer]] is called ''ductal carcinoma of the breast'' or ''mammary ductal carcinoma''. Here, the adjective ''ductal'' refers to the appearance of the cancer under the microscope, resembling normal breast ducts.
  
 
[[Benign tumor]]s (which are not cancers) are named using '''-oma''' as a suffix with the organ name as the root. For instance, a benign tumor of the smooth muscle of the uterus is called ''leiomyoma'' (the common name of this frequent tumor is ''fibroid''). Unfortunately, some cancers also use the '''-oma''' suffix, examples being [[melanoma]] and [[seminoma]].
 
[[Benign tumor]]s (which are not cancers) are named using '''-oma''' as a suffix with the organ name as the root. For instance, a benign tumor of the smooth muscle of the uterus is called ''leiomyoma'' (the common name of this frequent tumor is ''fibroid''). Unfortunately, some cancers also use the '''-oma''' suffix, examples being [[melanoma]] and [[seminoma]].
 
===Adult cancers===
 
In the U.S. and other developed countries, cancer is presently responsible for about 25% of all deaths.<ref name="CACancerJClin2005-Jemal">
 
{{cite journal | author=Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ | title=Cancer statistics, 2005 | journal=CA Cancer J Clin | year=2005 | pages=10&ndash;30 | volume=55 | issue=1 | url=http://caonline.amcancersoc.org/cgi/content/full/55/1/10 | pmid=15661684 | doi=10.3322/canjclin.55.1.10 | doi_brokendate=2008-06-26}}</ref> On a yearly basis, 0.5% of the population is diagnosed with cancer. The statistics below are for adults in the United States, and may vary substantially in other countries:
 
 
{| class="wikitable"
 
! colspan="2" | <big>Male</big>
 
| rowspan="7" |
 
! colspan="2" | <big>Female</big>
 
|-
 
! width="170px" | most common (by occurrence) !! width="170px" | most common (by mortality)<ref name="CACancerJClin2005-Jemal" />
 
! width="170px" | most common (by occurrence)!! width="170px" | most common (by mortality)<ref name="CACancerJClin2005-Jemal" />
 
|-
 
|[[prostate cancer]] (33%) || lung cancer (31%) || [[breast cancer]] (32%) || lung cancer (27%)
 
|-
 
| [[lung cancer]] (13%) || prostate cancer (10%) || lung cancer (12%) || breast cancer (15%)
 
|-
 
| [[colorectal cancer]] (10%) || colorectal cancer (10%) || colorectal cancer (11%) || colorectal cancer (10%)
 
|-
 
| [[bladder cancer]] (7%) || [[pancreatic cancer]] (5%) || [[endometrial cancer]] (6%) || [[ovarian cancer]] (6%)
 
|-
 
| cutaneous [[melanoma]] (5%) || [[leukemia]] (4%) || [[non-Hodgkin lymphoma]] (4%) || pancreatic cancer (6%)
 
|}
 
 
===Child cancers===
 
Cancer can also occur in young children and adolescents, but it is rare (about 150 cases per million yearly in the US). Statistics from the SEER program of the US [[National Cancer Institute|NCI]] demonstrate that childhood cancers increased 19% between 1975 and 1990, mainly due to an increased incidence in [[acute leukemia]]. Since 1990, incidence rates have decreased.<ref name="SEER1999">James G. Gurney, Malcolm A. Smith, Julie A. Ross (1999) ''Cancer Incidence and Survival among Children and Adolescents, United States SEER program 1975-1995'', Cancer Statistics Branch, National Cancer Institute, available online from the [http://www.seer.cancer.gov/publications/childhood/ SEER web site]</ref>
 
 
There is a reasonable doubt that children living near [[nuclear facility|nuclear facilities]] face an increased risk of cancer.<ref>http://www.globalresearch.ca/index.php?context=va%26aid=8785</ref>
 
 
===Infant cancers===
 
 
The age of peak incidence of cancer in children occurs during the first year of life, in [[infant]]s.  The average annual incidence in the United States, 1975-1995, was 233 per million infants.<ref name="SEER1999"/>  Several estimates of incidence exist.  According to SEER,<ref name="SEER1999"/> in the United States:
 
*[[Neuroblastoma]] comprised 28% of infant cancer cases and was the most common malignancy among these young children (65 per million infants).
 
*The [[Leukaemia|leukemias]] as a group (41 per million infants) represented the next most common type of cancer, comprising 17% of all cases.
 
*[[brain tumor|Central nervous system malignancies]] comprised 13% of infant cancer, with an average annual incidence rate of nearly 30 per million infants.
 
*The average annual incidence rates for malignant germ cell and malignant soft tissue tumors were essentially the same at 15 per million infants.  Each comprised about 6% of infant cancer.
 
 
According to another study:<ref name="CACancerJClin2005-Jemal" />
 
*[[Leukemia]] (usually [[Acute lymphoblastic leukemia|ALL]]) is the most common infant malignancy (30%), followed by the [[brain tumor|central nervous system cancers]] and [[neuroblastoma]]. The remainder consists of [[Wilms' tumor]], [[lymphoma]]s, [[rhabdomyosarcoma]] (arising from muscle), [[retinoblastoma]], [[osteosarcoma]] and [[Ewing's sarcoma]].
 
 
[[Teratoma]] (a [[germ cell tumor]]) often is cited as the most common tumor in this age group, but most teratomas are surgically removed while still benign, hence not necessarily cancer. Prior to the widespread routine use of prenatal ultrasound examinations, the incidence of [[sacrococcygeal teratoma]]s diagnosed at birth was 25 to 29 per million births<!-- 1:40,000 to 1:35,000 —>.
 
 
Female and male infants have essentially the same overall cancer incidence rates, a notable difference compared  to older children.
 
 
White infants have higher cancer rates than black infants.  Leukemias accounted for a substantial proportion of this difference: the average annual rate for white infants (48.7 per million) was 66% higher than for
 
black infants (29.4 per million).<ref name="SEER1999"/>
 
 
Relative survival for infants is very good for neuroblastoma, [[Wilms' tumor]] and [[retinoblastoma]], and fairly good (80%) for leukemia, but not for most other types of cancer.
 
  
 
== Signs and symptoms ==
 
== Signs and symptoms ==
 +
[[Image:Symptoms of cancer metastasis.svg|thumb|right|Symptoms of cancer metastasis depend on the location of the tumor.]]
 
Roughly, cancer symptoms can be divided into three groups:
 
Roughly, cancer symptoms can be divided into three groups:
* ''Local symptoms'': unusual lumps or swelling (''[[tumor]]''), [[hemorrhage]] (bleeding), [[pain]] and/or [[ulcer]]ation. Compression of surrounding tissues may cause symptoms such as [[jaundice]] (yellowing the eyes and skin).
+
* ''Local symptoms'': unusual lumps or swelling (''[[tumor]]''), [[hemorrhage]] (bleeding), [[pain]] and/or [[ulcer (dermatology)|ulceration]]. Compression of surrounding tissues may cause symptoms such as [[jaundice]] (yellowing the eyes and skin).
* ''Symptoms of [[metastasis]] (spreading)'': enlarged [[lymph node]]s, [[cough]] and [[hemoptysis]], [[hepatomegaly]] (enlarged [[liver]]), bone pain, [[fracture]] of affected bones and [[neurology|neurological]] symptoms. Although advanced cancer may cause [[pain]], it is often not the first symptom.
+
* ''[[Symptoms of metastasis]] (spreading)'': enlarged [[lymph node]]s, [[cough]] and [[hemoptysis]], [[hepatomegaly]] (enlarged [[liver]]), bone pain, [[fracture]] of affected bones and [[neurology|neurological]] symptoms. Although advanced cancer may cause [[pain]], it is often not the first symptom.
* ''Systemic symptoms'': [[weight loss]], [[anorexia (symptom)|poor appetite]], [[Fatigue (medical)|fatigue]] and [[cachexia]] ([[wasting]]), excessive [[sweating]] ([[sleep hyperhidrosis|night sweats]]), [[anemia]] and specific [[paraneoplastic phenomenon|paraneoplastic phenomena]], i.e. specific conditions that are due to an active cancer, such as [[thrombosis]] or hormonal changes.
+
* ''Systemic symptoms'': [[weight loss]], [[anorexia (symptom)|poor appetite]], [[fatigue (medical)|fatigue]] and [[cachexia]] ([[wasting]]), excessive [[sweating]] ([[sleep hyperhidrosis|night sweats]]), [[anemia]] and specific [[paraneoplastic phenomenon|paraneoplastic phenomena]], i.e. specific conditions that are due to an active cancer, such as [[thrombosis]] or hormonal changes.
  
 
Every symptom in the above list can be caused by a variety of conditions (a list of which is referred to as the [[differential diagnosis]]). Cancer may be a common or uncommon cause of each item.
 
Every symptom in the above list can be caused by a variety of conditions (a list of which is referred to as the [[differential diagnosis]]). Cancer may be a common or uncommon cause of each item.
  
== Diagnosis ==
+
== Causes ==
Most cancers are initially recognized either because signs or symptoms appear or through screening. Neither of these lead to a definitive diagnosis, which usually requires the opinion of a [[anatomical pathology|pathologist]], a type of physician (medical doctor) who specializes in the diagnosis of cancer and other diseases.
+
Cancer is a diverse class of diseases which differ widely in their causes and biology. Any organism, even [[plants]], can acquire cancer. Nearly all known cancers arise gradually, as errors build up in the cancer cell and its progeny (see [[Cancer#Mechanisms|mechanisms]] section for common types of errors).
  
=== Investigation ===
+
Anything which replicates (living cells) will [[probability|probabilistically]] suffer from errors (mutations). Unless error correction and prevention is properly carried out, the errors will survive, and might be passed along to [[cell division|daughter cells]]. Normally, the body safeguards against cancer via numerous methods, such as: [[apoptosis]], helper molecules (some DNA polymerases), possibly [[senescence]], etc. However these error-correction methods often fail in small ways, especially in environments that make errors more likely to arise and propagate. For example, such environments can include the presence of disruptive substances called [[carcinogens]], or periodic injury (physical, heat, etc.), or environments that cells did not evolve to withstand, such as [[hypoxia (medical)|hypoxia]]<ref>{{cite journal | author = Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E | title = Hypoxia and defective apoptosis drive genomic instability and tumorigenesis | journal = Genes & Development | volume = 18 | issue = 17 | pages = 2095–107 | year = 2004 | month = September | pmid = 15314031 | pmc = 515288 | doi = 10.1101/gad.1204904 | accessdate = 2009-06-06}}</ref> (see subsections). Cancer is thus a ''progressive'' disease, and these progressive errors slowly accumulate until a cell begins to act contrary to its function in the organism.
[[Image:Thorax pa peripheres Bronchialcarcinom li OF markiert.jpg|thumb|Chest x-ray showing lung cancer in the left lung.|right]]
 
  
People with suspected cancer are investigated with [[medical test]]s. These commonly include [[blood test]]s, [[X-ray]]s, [[CT scan]]s and [[endoscopy]].
+
The errors which cause cancer are often ''self-amplifying'', eventually compounding at an exponential rate. For example:
  
=== Biopsy ===
+
* A mutation in the error-correcting machinery of a cell might cause that cell and its children to accumulate errors more rapidly
A cancer may be suspected for a variety of reasons, but the definitive diagnosis of most malignancies must be confirmed by [[histology|histological]] examination of the cancerous cells by a [[anatomical pathology|pathologist]]. Tissue can be obtained from a [[biopsy]] or [[surgery]]. Many biopsies (such as those of the skin, breast or liver) can be done in a doctor's office. Biopsies of other organs are performed under [[anesthesia]] and require [[surgery]] in an [[operating room]].
+
* A mutation in signaling ([[endocrine]]) machinery of the cell can send error-causing signals to nearby cells
 +
* A mutation might cause cells to become [[neoplastic]], causing them to migrate and disrupt more healthy cells
 +
* A mutation may cause the cell to become immortal (see [[telomeres]]), causing them to disrupt healthy cells forever
  
The tissue [[diagnosis]] given by the pathologist indicates the type of cell that is proliferating, its [[histological grade]] and other features of the tumor. Together, this information is useful to evaluate the [[prognosis]] of this patient and to choose the best treatment. [[Cytogenetics]] and [[immunohistochemistry]] are other types of testing that the pathologist may perform on the tissue specimen. These tests may provide information about future behavior of the cancer (prognosis) and best treatment.
+
Thus cancer often explodes in something akin to a [[chain reaction]] caused by a few errors, which compound into more severe errors. Errors which produce more errors are effectively the root cause of cancer, and also the reason that cancer is so hard to treat: even if there were 10,000,000,000 cancerous cells and one killed all but 10 of those cells, those cells (and other error-prone precancerous cells) could still self-replicate or send error-causing signals to other cells, starting the process over again. This rebellion-like scenario is an undesirable [[survival of the fittest]], where the driving forces of [[evolution]] work against the body's design and enforcement of order. In fact, once cancer has begun to develop, this same force continues to drive the progression of cancer towards more invasive stages, and is called [[Cancer#Clonal evolution|clonal evolution]].<ref>{{cite journal |author=Merlo LM, Pepper JW, Reid BJ, Maley CC |title=Cancer as an evolutionary and ecological process |journal=Nat. Rev. Cancer |volume=6 |issue=12 |pages=924–35 |year=2006 |month=December |pmid=17109012 |doi=10.1038/nrc2013}}</ref>
  
== Treatment ==
+
[[Cancer research|Research about cancer]] causes often falls into the following categories:
Cancer can be treated by [[surgery]], [[chemotherapy]], [[radiation therapy]], [[immunotherapy]], [[monoclonal antibody therapy]] or other methods. The choice of therapy depends upon the location and grade of the tumor and the [[Cancer staging|stage]] of the disease, as well as the general state of the patient ([[performance status]]). A number of [[experimental cancer treatment]]s are also under development.
+
* Agents (e.g. viruses) and events (e.g. mutations) which cause or facilitate genetic changes in cells destined to become cancer.
 +
* The precise nature of the genetic damage, and the genes which are affected by it.
 +
* The consequences of those genetic changes on the biology of the cell, both in generating the defining properties of a cancer cell, and in facilitating additional genetic events which lead to further progression of the cancer.
  
Complete removal of the cancer without damage to the rest of the body is the goal of treatment. Sometimes this can be accomplished by surgery, but the propensity of cancers to invade adjacent tissue or to spread to distant sites by microscopic metastasis often limits its effectiveness. The effectiveness of chemotherapy is often limited by toxicity to other tissues in the body. Radiation can also cause damage to normal tissue.
+
=== Chemicals ===
 +
{{See|Carcinogen}}
 +
[[Image:Cancer smoking lung cancer correlation from NIH.svg|thumb|right|The incidence of lung cancer is highly correlated with smoking. Source:NIH.]]
 +
Cancer pathogenesis is traceable back to [[DNA mutations]] that impact cell growth and metastasis. Substances that cause [[DNA mutations]] are known as mutagens, and mutagens that cause cancers are known as carcinogens. Particular substances have been linked to specific types of cancer. [[Tobacco smoking]] is associated with many forms of cancer,<ref name=Sasco>{{cite journal |author=Sasco AJ, Secretan MB, Straif K |title=Tobacco smoking and cancer: a brief review of recent epidemiological evidence |journal=Lung cancer (Amsterdam, Netherlands) |volume=45 Suppl 2 |issue= |pages=S3–9 |year=2004 |month=August |pmid=15552776 |doi=10.1016/j.lungcan.2004.07.998}}</ref> and causes 90% of [[lung cancer]].<ref>{{cite journal |author= Biesalski HK, Bueno de Mesquita B, Chesson A, ''et al.'' |title=European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel |journal=CA: a cancer journal for clinicians |volume=48 |issue=3 |pages=167–76; discussion 164–6 |year=1998 |pmid=9594919 |doi=10.3322/canjclin.48.3.167 |url=http://caonline.amcancersoc.org/cgi/pmidlookup?view=long&pmid=9594919}}</ref> Prolonged exposure to [[asbestos]] fibers is associated with [[mesothelioma]].<ref>{{cite journal |author=O'Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ |title=Asbestos-related lung disease |journal=American family physician |volume=75 |issue=5 |pages=683–8 |year=2007 |month=March |pmid=17375514 |doi= |url=http://www.aafp.org/afp/20070301/683.html |format={{dead link|date=June 2010}}}}</ref>
  
Because "cancer" refers to a class of diseases, it is unlikely that there will ever be a single "[[cure for cancer]]" any more than there will be a single treatment for all [[infectious disease]]s.
+
Many [[mutagen]]s are also [[carcinogen]]s, but some carcinogens are not mutagens. [[Alcohol]] is an example of a chemical carcinogen that is not a mutagen.<ref>{{cite journal |author=Seitz HK, Pöschl G, Simanowski UA |title=Alcohol and cancer |journal=Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism |volume=14 |pages=67–95 |year=1998 |pmid=9751943}}</ref> Such chemicals may promote cancers through stimulating the rate of cell division. Faster rates of replication leaves less time for repair enzymes to repair damaged DNA during [[DNA replication]], increasing the likelihood of a mutation.
  
=== Surgery ===
+
Decades of research has demonstrated the link between [[tobacco]] use and cancer in the [[lung cancer|lung]], [[larynx]], head, neck, stomach, bladder, kidney, [[oesophagus]] and [[pancreas]].<ref>{{cite journal |author=Kuper H, Boffetta P, Adami HO |title=Tobacco use and cancer causation: association by tumour type |journal=Journal of internal medicine |volume=252 |issue=3 |pages=206–24 |year=2002 |month=September |doi=10.1046/j.1365-2796.2002.01022.x |pmid=12270001}}</ref> Tobacco smoke contains over fifty known carcinogens, including [[nitrosamine]]s and [[polycyclic aromatic hydrocarbon]]s.<ref name=Kuper/> Tobacco is responsible for about one in three of all cancer deaths in the developed world,<ref name=Sasco/> and about one in five worldwide.<ref name=Kuper>{{cite journal |author=Kuper H, Adami HO, Boffetta P |title=Tobacco use, cancer causation and public health impact |journal=Journal of internal medicine |volume=251 |issue=6 |pages=455–66 |year=2002 |month=June |doi=10.1046/j.1365-2796.2002.00993.x |pmid=12028500}}</ref> Indeed, [[lung cancer]] death rates in the United States have mirrored [[tobacco smoking|smoking]] patterns, with increases in smoking followed by dramatic increases in lung cancer death rates and, more recently{{When|date=May 2010}}, decreases in smoking followed by decreases in lung cancer death rates in men. However, the numbers of smokers worldwide is still rising, leading to what some organizations have described as the ''tobacco epidemic''.<ref>{{cite journal |author=Proctor RN |title=The global smoking epidemic: a history and status report |journal=Clinical lung cancer |volume=5 |issue=6 |pages=371–6 |year=2004 |month=May |doi=10.3816/CLC.2004.n.016 |pmid=15217537}}</ref>
In theory, non-[[hematological]] cancers can be cured if entirely removed by [[surgery]], but this is not always possible. When the cancer has [[metastasis|metastasized]] to other sites in the body prior to surgery, complete surgical excision is usually impossible. In the [[William Stewart Halsted|Halsted]]ian model of cancer progression, tumors grow locally, then spread to the lymph nodes, then to the rest of the body. This has given rise to the popularity of local-only treatments such as surgery for small cancers. Even small localized tumors are increasingly recognized as possessing metastatic potential.
 
  
Examples of surgical procedures for cancer include [[mastectomy]] for breast cancer and [[prostatectomy]] for prostate cancer. The goal of the surgery can be either the removal of only the tumor, or the entire organ. A single cancer cell is invisible to the naked eye but can regrow into a new tumor, a process called recurrence. For this reason, the [[anatomical pathology|pathologist]] will examine the surgical specimen to determine if a margin of healthy tissue is present, thus decreasing the chance that microscopic cancer cells are left in the patient.
+
=== Ionizing radiation ===
 
+
Sources of [[ionizing radiation]], such as [[radon]] gas, can cause cancer. Prolonged exposure to [[ultraviolet radiation]] from the [[sun]] can lead to [[melanoma]] and other skin malignancies.<ref>{{cite journal |author=English DR, Armstrong BK, Kricker A, Fleming C |title=Sunlight and cancer |journal=Cancer causes & control : CCC |volume=8 |issue=3 |pages=271–83 |year=1997 |month=May |doi=10.1023/A:1018440801577 |pmid=9498892}}</ref> It is estimated that 2% of future cancers will be due to current [[CT scan]]s.<ref>{{cite journal |author=Berrington de González A, Mahesh M, Kim KP, ''et al.'' |title=Projected cancer risks from computed tomographic scans performed in the United States in 2007 |journal=Arch. Intern. Med. |volume=169 |issue=22 |pages=2071–7 |year=2009 |month=December |pmid=20008689 |doi=10.1001/archinternmed.2009.440 |url=}}</ref>
In addition to removal of the primary tumor, surgery is often necessary for [[cancer staging|staging]], e.g. determining the extent of the disease and whether it has [[metastasis|metastasized]] to regional [[lymph node]]s. Staging is a major determinant of [[prognosis]] and of the need for [[adjuvant therapy]].
 
 
 
Occasionally, surgery is necessary to control symptoms, such as [[spinal cord compression]] or [[bowel obstruction]]. This is referred to as [[palliative treatment]].
 
 
 
=== Radiation therapy ===
 
{{main|Radiation therapy}}
 
 
 
[[Radiation therapy]] (also called radiotherapy, X-ray therapy, or irradiation) is the use of ionizing radiation to kill cancer cells and shrink tumors. Radiation therapy can be administered externally via [[external beam radiotherapy]] (EBRT) or internally via [[brachytherapy]]. The effects of radiation therapy are localised and confined to the region being treated. Radiation therapy injures or destroys cells in the area being treated (the "target tissue") by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue. Hence, it is given in many fractions, allowing healthy tissue to recover between fractions.
 
 
 
Radiation therapy may be used to treat almost every type of solid tumor, including cancers of the brain, breast, cervix, larynx, lung, pancreas, prostate, skin, stomach, uterus, or soft tissue sarcomas. Radiation is also used to treat leukemia and lymphoma. Radiation dose to each site depends on a number of factors, including the radiosensitivity of each cancer type and whether there are tissues and organs nearby that may be damaged by radiation. Thus, as with every form of treatment, radiation therapy is not without its side effects.
 
 
 
=== Chemotherapy ===
 
{{main|Chemotherapy}}
 
 
 
[[Chemotherapy]] is the treatment of cancer with [[medication|drugs]] ("anticancer drugs") that can destroy cancer cells. In current usage, the term "chemotherapy" usually refers to ''cytotoxic'' drugs which affect rapidly dividing cells in general, in contrast with ''targeted therapy'' (see below). Chemotherapy drugs interfere with cell division in various possible ways, e.g. with the duplication of [[DNA]] or the separation of newly formed [[chromosome]]s. Most forms of chemotherapy target all rapidly dividing cells and are not specific for cancer cells, although some degree of specificity may come from the inability of many cancer cells to repair [[DNA damage]], while normal cells generally can. Hence, chemotherapy has the potential to harm healthy tissue, especially those tissues that have a high replacement rate (e.g. intestinal lining). These cells usually repair themselves after chemotherapy.
 
 
 
Because some drugs work better together than alone, two or more drugs are often given at the same time. This is called "combination chemotherapy"; most chemotherapy regimens are given in a combination.
 
 
 
The treatment of some [[leukaemia]]s and [[lymphoma]]s requires the use of high-dose chemotherapy, and [[total body irradiation]] (TBI). This treatment ablates the bone marrow, and hence the body's ability to recover and repopulate the blood. For this reason, bone marrow, or peripheral blood stem cell harvesting is carried out before the ablative part of the therapy, to enable "rescue" after the treatment has been given. This is known as autologous [[stem cell transplantation]]. Alternatively, [[hematopoietic stem cells]] may be transplanted from a matched unrelated donor (MUD).
 
 
 
=== Targeted therapies ===
 
{{main|Targeted therapy}}
 
 
 
Targeted therapy, which first became available in the late 1990s, has had a significant impact in the treatment of some types of cancer, and is currently a very active research area. This constitutes the use of agents specific for the deregulated proteins of cancer cells. Small molecule targeted therapy drugs are generally inhibitors of [[enzyme|enzymatic]] domains on mutated, overexpressed, or otherwise critical proteins within the cancer cell. Prominent examples are the tyrosine kinase inhibitors [[imatinib]] and [[gefitinib]].
 
 
 
[[Monoclonal antibody therapy]] is another strategy in which the therapeutic agent is an [[antibody]] which specifically binds to a protein on the surface of the cancer cells. Examples include the anti-[[HER2/neu]] antibody [[trastuzumab]] (Herceptin) used in breast cancer, and the anti-CD20 antibody [[rituximab]], used in a variety of [[B-cell]] malignancies.
 
 
 
[[Targeted therapy]] can also involve small [[peptide]]s as "homing devices" which can bind to cell surface receptors or affected [[extracellular matrix]] surrounding the tumor. Radionuclides which are attached to this peptides (e.g. RGDs) eventually kill the cancer cell if the nuclide decays in the vicinity of the cell. Especially oligo- or multimers of these binding motifs are of great interest, since this can lead to enhanced tumor specificity and avidity.
 
 
 
[[Photodynamic therapy]] (PDT) is a ternary treatment for cancer involving a photosensitizer, tissue oxygen, and light (often using [[lasers]]). PDT can be used as treatment for [[basal cell carcinoma]] (BCC) or [[lung cancer]]; PDT can also be useful in removing traces of malignant tissue after surgical removal of large tumors.<ref>{{cite journal |last=Dolmans |first=DE |coauthors=Fukumura D, Jain RK |year=2003 |month=May |title=Photodynamic therapy for cancer |journal=Nat Rev Cancer |volume=3 |issue=5 |pages=380–7 |pmid=12724736 |url=http://www.nature.com/nrc/journal/v3/n5/abs/nrc1071_fs.html |doi=10.1038/nrc1071}}</ref>
 
 
 
=== Immunotherapy ===
 
{{main|Cancer immunotherapy}}
 
 
 
Cancer immunotherapy refers to a diverse set of therapeutic strategies designed to induce the patient's own [[immune system]] to fight the tumor. Contemporary methods for generating an immune response against tumours include intravesical [[Bacillus Calmette-Guérin|BCG]] immunotherapy for superficial bladder cancer, and use of [[interferon]]s and other [[cytokine]]s to induce an immune response in [[renal cell carcinoma]] and [[melanoma]] patients. [[Vaccine]]s to generate specific [[immune response]]s are the subject of intensive research for a number of tumours, notably [[malignant melanoma]] and [[renal cell carcinoma]]. [[Sipuleucel-T]] is a vaccine-like strategy in late clinical trials for [[prostate cancer]] in which [[dendritic cell]]s from the patient are loaded with [[prostatic acid phosphatase]] peptides to induce a specific immune response against prostate-derived cells.
 
 
 
Allogeneic [[hematopoietic stem cell transplantation]] ("bone marrow transplantation" from a genetically non-identical donor) can be considered a form of immunotherapy, since the donor's immune cells will often attack the tumor in a phenomenon known as [[Hematopoietic stem cell transplantation#Side effects and complications|graft-versus-tumor effect]]. For this reason, allogeneic HSCT leads to a higher cure rate than autologous transplantation for several cancer types, although the side effects are also more severe.
 
 
 
=== Hormonal therapy ===
 
{{main|Hormonal therapy (oncology)}}
 
 
 
The growth of some cancers can be inhibited by providing or blocking certain hormones. Common examples of hormone-sensitive tumors include certain types of breast and prostate cancers. Removing or blocking [[estrogen]] or [[testosterone]] is often an important additional treatment. In certain cancers, administration of hormone agonists, such as [[progestogen]]s may be therapeutically beneficial.
 
 
 
===Angiogenesis inhibitors===
 
{{Main|Angiogenesis inhibitor}}
 
Angiogenesis inhibitors prevent the extensive growth of blood vessels ([[angiogenesis]]) that tumors require to survive. Some, such as [[bevacizumab]], have been approved and are in clinical use. One of the main problems with anti-angiogenesis drugs is that many factors stimulate blood vessel growth, in normal cells and cancer. Anti-angiogenesis drugs only target one factor, so the other factors continue to stimulate blood vessel growth. Other problems include [[route of administration]], maintenance of stability and activity and targeting at the tumor vasculature.<ref>{{cite journal |author=Kleinman HK, Liau G |title=Gene therapy for antiangiogenesis |journal=J. Natl. Cancer Inst. |volume=93 |issue=13 |pages=965–7 |year=2001 |month=July |pmid=11438554 |doi=10.1093/jnci/93.13.965 |url=http://jnci.oxfordjournals.org/cgi/content/full/93/13/965}}</ref>
 
 
 
=== Symptom control ===
 
Although the control of the symptoms of cancer is not typically thought of as a treatment directed at the cancer, it is an important determinant of the [[quality of life]] of cancer patients, and plays an important role in the decision whether the patient is able to undergo other treatments. Although doctors generally have the therapeutic skills to reduce pain, nausea, vomiting, diarrhea, hemorrhage and other common problems in cancer patients, the multidisciplinary specialty of [[palliative care]] has arisen specifically in response to the symptom control needs of this group of patients.
 
 
 
[[analgesia|Pain medication]], such as [[morphine]] and [[oxycodone]], and [[antiemetic]]s, drugs to suppress nausea and vomiting, are very commonly used in patients with cancer-related symptoms. Improved [[antiemetics]] such as [[ondansetron]] and analogues, as well as [[aprepitant]] have made aggressive treatments much more feasible in cancer patients.
 
 
 
[[Chronic pain]] due to cancer is almost always associated with continuing tissue damage due to the disease process or the treatment (i.e. surgery, radiation, chemotherapy). Although there is always a role for environmental factors and affective disturbances in the genesis of pain behaviors, these are not usually the predominant etiologic factors in patients with cancer pain. Furthermore, many patients with severe pain associated with cancer are nearing the end of their lives and [[palliative]] therapies are required. Issues such as social stigma of using [[opioids]], work and functional status, and health care consumption are not likely to be important in the overall case management. Hence, the typical strategy for cancer pain management is to get the patient as comfortable as possible using opioids and other medications, surgery, and physical measures. Doctors have been reluctant to prescribe narcotics for pain in terminal cancer patients, for fear of contributing to addiction or suppressing respiratory function. The [[palliative care]] movement, a more recent offshoot of the [[hospice]] movement, has engendered more widespread support for preemptive pain treatment for cancer patients.
 
 
 
[[Fatigue (medical)|Fatigue]] is a very common problem for cancer patients, and has only recently become important enough for oncologists to suggest treatment, even though it plays a significant role in many patients' quality of life.
 
 
 
=== Treatment trials ===
 
{{Main|Experimental cancer treatment}}
 
[[Clinical trial]]s, also called research studies, test new treatments in people with cancer. The goal of this research is to find better ways to treat cancer and help cancer patients. Clinical trials test many types of treatment such as new drugs, new approaches to surgery or radiation therapy, new combinations of treatments, or new methods such as [[gene therapy]].
 
 
 
A clinical trial is one of the final stages of a long and careful cancer research process. The search for new treatments begins in the laboratory, where scientists first develop and test new ideas. If an approach seems promising, the next step may be testing a treatment in animals to see how it affects cancer in a living being and whether it has harmful effects. Of course, treatments that work well in the lab or in animals do not always work well in people. Studies are done with cancer patients to find out whether promising treatments are safe and effective.
 
 
 
Patients who take part may be helped personally by the treatment they receive. They get up-to-date care from cancer experts, and they receive either a new treatment being tested or the best available standard treatment for their cancer. At the same time, new treatments also may have unknown risks, but if a new treatment proves effective or more effective than standard treatment, study patients who receive it may be among the first to benefit. There is no guarantee that a new treatment being tested or a standard treatment will produce good results. In children with cancer, a survey of trials found that those enrolled in trials were on average not more likely to do better or worse than those on standard treatment; this confirms that success or failure of an experimental treatment cannot be predicted.<ref>{{cite journal |author=Kumar A, Soares H, Wells R, ''et al'' |title=Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group |journal=BMJ |volume=331 |issue=7528 |pages=1295 |year=2005 |month=December |pmid=16299015 |pmc=1298846 |doi=10.1136/bmj.38628.561123.7C |url=http://bmj.bmjjournals.com/cgi/content/full/331/7528/1295}}</ref>
 
 
 
=== Complementary and alternative ===
 
{{Main|Unproven cancer therapy}}
 
[[Alternative medicine|Complementary and alternative medicine]] (CAM) treatments are the diverse group of medical and health care systems, practices, and products that are not part of conventional medicine.<ref name="mnalt">{{cite journal |author=Cassileth BR, Deng G |title=Complementary and alternative therapies for cancer |journal=Oncologist |volume=9 |issue=1 |pages=80–9 |year=2004 |pmid=14755017 |url=http://theoncologist.alphamedpress.org/cgi/content/full/9/1/80 |doi=10.1634/theoncologist.9-1-80}}</ref> "Complementary medicine" refers to methods and substances used along with conventional medicine, while "alternative medicine" refers to compounds used instead of conventional medicine.<ref>[http://nccam.nih.gov/health/whatiscam/#2 What Is CAM?] [[National Center for Complementary and Alternative Medicine]]. retrieved [[3 February]] [[2008]].</ref> CAM use is common among people with cancer; a 2000 study found that 69% cancer patients had used at least one CAM therapy as part of their cancer treatment.<ref name=Richardson2000>{{cite journal |author=Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE |title=Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology |journal=J. Clin. Oncol. |volume=18 |issue=13 |pages=2505–14 |year=2000 |month=July |pmid=10893280 |url=http://jco.ascopubs.org/cgi/content/full/18/13/2505}}</ref> Most complementary and alternative medicines for cancer have not been rigorously studied or tested. Some alternative treatments which have been investigated and shown to be ineffective continue to be marketed and promoted.<ref name="pmid15061600">{{cite journal |author=Vickers A |title=Alternative cancer cures: "unproven" or "disproven"? |journal=CA Cancer J Clin |volume=54 |issue=2 |pages=110–8 |year=2004 |pmid=15061600 |doi= |url=http://caonline.amcancersoc.org/cgi/content/full/54/2/110}}</ref>
 
 
 
== Prognosis ==
 
Cancer has a reputation for being a deadly disease. While this certainly applies to certain particular types, the truths behind the historical connotations of cancer are increasingly being overturned by advances in medical care. Some types of cancer have a prognosis that is substantially better than nonmalignant diseases such as [[heart failure]] and [[stroke]].
 
 
 
Progressive and disseminated malignant disease has a substantial impact on a cancer patient's quality of life, and many cancer treatments (such as [[chemotherapy]]) may have severe side-effects. In the advanced stages of cancer, many patients need extensive care, affecting family members and friends. [[Palliative care]] solutions may include permanent or "respite" hospice nursing.
 
 
 
=== Emotional impact ===
 
Many local organizations offer a variety of practical and support services to people with cancer. Support can take the form of [[Cancer support group|support groups]], [[counseling]], advice, financial assistance, transportation to and from treatment, films or information about cancer. Neighborhood organizations, local health care providers, or area hospitals may have resources or services available.
 
 
 
Counseling can provide emotional support to cancer patients and help them better understand their illness. Different types of counseling include individual, group, family, peer counseling, bereavement, patient-to-patient, and sexuality.
 
 
 
Many governmental and charitable organizations have been established to help patients cope with cancer. These organizations often are involved in cancer prevention, cancer treatment, and cancer research.
 
 
 
== Causes ==
 
{{main|Carcinogenesis}}
 
 
 
Cancer is a diverse class of diseases which differ widely in their causes and biology. The common thread in all known cancers is the acquisition of abnormalities in the genetic material of the cancer cell and its progeny. Research into the pathogenesis of cancer can be divided into three broad areas of focus. The first area of research focuses on the agents and events which cause or facilitate genetic changes in cells destined to become cancer. Second, it is important to uncover the precise nature of the genetic damage, and the genes which are affected by it. The third focus is on the consequences of those genetic changes on the biology of the cell, both in generating the defining properties of a cancer cell, and in facilitating additional genetic events, leading to further progression of the cancer.
 
 
 
=== Chemical carcinogens ===
 
Cancer pathogenesis is traceable back to [[DNA mutations]] that impact cell growth and metastasis. Substances that cause [[DNA mutations]] are known as mutagens, and mutagens that cause cancers are known as carcinogens. Particular substances have been linked to specific types of cancer. [[Tobacco smoking]] is associated with [[lung cancer]] and [[bladder cancer]]. Prolonged exposure to [[asbestos]] fibers is associated with [[mesothelioma]].
 
 
 
Many [[mutagen]]s are also [[carcinogen]]s, but some carcinogens are not mutagens. [[Alcohol]] is an example of a chemical carcinogen that is not a mutagen. Such chemicals are thought to promote cancers through their stimulating effect on the rate of cell [[mitosis]]. Faster rates of mitosis leaves less time for repair enzymes to repair damaged DNA during [[DNA replication]], increasing the likelihood of a genetic mistake. A mistake made during mitosis can lead to the daughter cells receiving the wrong number of [[chromosomes]] (''see [[aneuploidy]] above'').
 
  
[[Image:Cancer smoking lung cancer correlation from NIH.svg|thumb|300px|right|The incidence of lung cancer is highly correlated with smoking. Source:NIH.]]
+
Non-ionizing radio frequency radiation from [[mobile phone]]s and other similar [[Radio frequency|RF]] sources has also been proposed as a cause of cancer, but there is currently little established evidence of such a link.<ref>{{cite journal |author=Feychting M, Ahlbom A, Kheifets L |title=EMF and health |journal=Annual review of public health |volume=26 |issue= |pages=165–89 |year=2005 |pmid=15760285 |doi=10.1146/annurev.publhealth.26.021304.144445}}</ref>
Decades of research have demonstrated the strong association between [[tobacco]] use and cancers of many sites, making it perhaps the most important human carcinogen. Hundreds of epidemiological studies have confirmed this association. Further support comes from the fact that [[lung cancer]] death rates in the United States have mirrored [[tobacco smoking|smoking]] patterns, with increases in smoking followed by dramatic increases in lung cancer death rates and, more recently, decreases in smoking followed by decreases in lung cancer death rates in men.
 
  
=== Ionizing radiation ===
+
=== Infection ===
Sources of [[ionizing radiation]], such as [[radon]] gas, can cause cancer. Prolonged exposure to [[ultraviolet radiation]] from the [[sun]] can lead to [[melanoma]] and other skin malignancies.
+
Some cancers can be caused by [[infection]].<ref>{{cite journal |author=Pagano JS, Blaser M, Buendia MA, ''et al.'' |title=Infectious agents and cancer: criteria for a causal relation |journal=Semin. Cancer Biol. |volume=14 |issue=6 |pages=453–71 |year=2004 |month=December |pmid=15489139 |doi=10.1016/j.semcancer.2004.06.009}}</ref>  This is especially true in animals such as [[bird]]s, but also in [[human]]s, with viruses responsible for up to 20% of human cancers worldwide.<ref name=Viral04>{{cite journal |author=Pagano JS, Blaser M, Buendia MA, ''et al.'' |title=Infectious agents and cancer: criteria for a causal relation |journal=Semin. Cancer Biol. |volume=14 |issue=6 |pages=453–71 |year=2004 |month=December |pmid=15489139 |doi=10.1016/j.semcancer.2004.06.009 |url=}}</ref> These include [[human papillomavirus]] ([[cervical carcinoma]]), [[human polyomaviruses]] ([[mesothelioma]], brain tumors), [[Epstein-Barr virus]] ([[B-cell lymphoproliferative disease]] and [[nasopharyngeal carcinoma]]), [[Kaposi's sarcoma herpesvirus]] ([[Kaposi's Sarcoma]] and primary effusion lymphomas), [[hepatitis B]] and [[hepatitis C]] viruses ([[hepatocellular carcinoma]]), [[Human T-cell leukemia virus-1]] (T-cell leukemias), and [[Helicobacter pylori]] ([[gastric carcinoma]]).<ref name=Viral04/>
  
Radiation from [[mobile phone]]s has been conjectured for some time as a cause but this theory has not gained mainstream support. Nevertheless some experts caution against prolonged exposure.<ref>''[http://www.cnn.com/2008/HEALTH/conditions/07/23/cancer.cell.phones.ap/index.html  Cancer expert warns employees on cell phones]'', [http://www.cnn.com CNN], 23 July 2008</ref>
+
Experimental and epidemiological data imply a causative role for viruses and they appear to be the second most important risk factor for cancer development in humans, exceeded only by tobacco usage.<ref name="zur Hausen-viruses">{{cite journal | author = zur Hausen H | title = Viruses in human cancers | journal = Science | volume = 254 | issue = 5035 | pages = 1167–73 | year = 1991 | pmid = 1659743| doi = 10.1126/science.1659743}}</ref> The mode of virally induced tumors can be divided into two, ''acutely transforming'' or ''slowly transforming''. In acutely transforming viruses, the virus carries an overactive oncogene called viral-oncogene (v-onc), and the infected cell is transformed as soon as v-onc is expressed. In contrast, in slowly transforming viruses, the virus genome is inserts near a proto-oncogene in the host genome. The viral [[Promoter (biology)|promoter]] or other transcription regulation elements then cause overexpression of that proto-oncogene. This induces uncontrolled cell division. Because the site of insertion is not specific to proto-oncogenes and the chance of insertion near any proto-oncogene is low, slowly transforming viruses will cause tumors much longer after infection than the acutely transforming viruses.
 
 
=== Infectious diseases ===
 
Some cancers can be caused by [[infection]] with [[pathogen]]s.<ref>{{cite journal |author=Pagano JS, Blaser M, Buendia MA, ''et al'' |title=Infectious agents and cancer: criteria for a causal relation |journal=Semin. Cancer Biol. |volume=14 |issue=6 |pages=453–71 |year=2004 |month=December |pmid=15489139 |doi=10.1016/j.semcancer.2004.06.009}}</ref> Many cancers originate from a [[virus|viral]] infection; this is especially true in animals such as [[bird]]s, but also in [[human]]s, as viruses are responsible for 15% of human cancers worldwide. The main viruses associated with human cancers are [[human papillomavirus]], [[hepatitis B]] and [[hepatitis C]] virus, [[Epstein-Barr virus]], and [[human T-lymphotropic virus]]. Experimental and epidemiological data imply a causative role for viruses and they appear to be the second most important risk factor for cancer development in humans, exceeded only by tobacco usage.<ref name="zur Hausen-viruses">{{cite journal | author = zur Hausen H | title = Viruses in human cancers | journal = Science | volume = 254 | issue = 5035 | pages = 1167| year = 1991 | pmid = 1659743| doi = 10.1126/science.1659743 }}</ref> The mode of virally-induced tumors can be divided into two, ''acutely-transforming'' or ''slowly-transforming''. In acutely transforming viruses, the virus carries an overactive oncogene called viral-oncogene (v-onc), and the infected cell is transformed as soon as v-onc is expressed. In contrast, in slowly-transforming viruses, the virus genome is inserts near a proto-oncogene in the host genome. The viral [[promoter]] or other transcription regulation elements then cause overexpression of that proto-oncogene. This induces uncontrolled cell division. Because the site of insertion is not specific to proto-oncogenes and the chance of insertion near any proto-oncogene is low, slowly-transforming viruses will cause tumors much longer after infection than the acutely-transforming viruses.
 
  
 
Hepatitis viruses, including [[hepatitis B]] and [[hepatitis C]], can induce a chronic viral infection that leads to [[Hepatocellular carcinoma|liver cancer]] in 0.47% of [[hepatitis B]] patients per year (especially in Asia, less so in North America), and in 1.4% of [[hepatitis C]] carriers per year. Liver cirrhosis, whether from chronic viral hepatitis infection or alcoholism, is associated with the development of [[Hepatocellular carcinoma|liver cancer]], and the combination of cirrhosis and viral hepatitis presents the highest risk of [[Hepatocellular carcinoma|liver cancer]] development. Worldwide, [[Hepatocellular carcinoma|liver cancer]] is one of the most common, and most deadly, cancers due to a huge burden of [[viral hepatitis]] transmission and disease.
 
Hepatitis viruses, including [[hepatitis B]] and [[hepatitis C]], can induce a chronic viral infection that leads to [[Hepatocellular carcinoma|liver cancer]] in 0.47% of [[hepatitis B]] patients per year (especially in Asia, less so in North America), and in 1.4% of [[hepatitis C]] carriers per year. Liver cirrhosis, whether from chronic viral hepatitis infection or alcoholism, is associated with the development of [[Hepatocellular carcinoma|liver cancer]], and the combination of cirrhosis and viral hepatitis presents the highest risk of [[Hepatocellular carcinoma|liver cancer]] development. Worldwide, [[Hepatocellular carcinoma|liver cancer]] is one of the most common, and most deadly, cancers due to a huge burden of [[viral hepatitis]] transmission and disease.
  
Advances in cancer research have made a vaccine designed to prevent cancer available. In 2006, the US [[FDA]] approved a [[human papilloma virus]] vaccine, called [[Gardasil]]. The vaccine protects against four HPV types, which together cause 70% of cervical cancers and 90% of genital warts. In March 2007, the US [[Centers for Disease Control and Prevention|CDC]] [[Advisory Committee on Immunization Practices]] (ACIP) officially recommended that females aged 11-12 receive the vaccine, and indicated that females as young as age 9 and as old as age 26 are also candidates for immunization.
+
Advances in cancer research have made a vaccine designed to prevent cancer available. In 2006, the [[U.S. Food and Drug Administration]] approved a [[human papilloma virus]] vaccine, called [[Gardasil]]. The vaccine protects against four HPV types, which together cause 70% of cervical cancers and 90% of genital warts. In March 2007, the US [[Centers for Disease Control and Prevention]] (CDC) [[Advisory Committee on Immunization Practices]] (ACIP) officially recommended that females aged 11–12 receive the vaccine, and indicated that females as young as age 9 and as old as age 26 are also candidates for immunization.
  
In addition to viruses, researchers have noted a connection between [[Cancer bacteria|bacteria and certain cancers]]. The most prominent example is the link between chronic infection of the wall of the stomach with ''[[Helicobacter pylori]]'' and [[gastric cancer]].<ref>{{cite journal |author=Peter S, Beglinger C |title=Helicobacter pylori and gastric cancer: the causal relationship |journal=Digestion |volume=75 |issue=1 |pages=25&ndash;35 |year=2007 |pmid=17429205 |doi=10.1159/000101564}}</ref><ref>{{cite journal |author=Wang C, Yuan Y, Hunt RH |title=The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis |journal=Am. J. Gastroenterol. |volume=102 |issue=8 |pages=1789–98 |year=2007 |month=August |pmid=17521398 |doi=10.1111/j.1572-0241.2007.01335.x}}</ref> Although only a minority of those infected with ''Helicobacter'' go on to develop cancer, since this pathogen is quite common it is probably responsible for the majority of these cancers.<ref>{{cite journal |author=Cheung TK, Xia HH, Wong BC |title=Helicobacter pylori eradication for gastric cancer prevention |journal=J. Gastroenterol. |volume=42 Suppl 17 |issue= |pages=10–5 |year=2007 |month=January |pmid=17238019 |doi=10.1007/s00535-006-1939-2}}</ref>
+
In addition to viruses, researchers have noted a connection between [[cancer bacteria|bacteria and certain cancers]]. The most prominent example is the link between chronic infection of the wall of the stomach with ''[[Helicobacter pylori]]'' and [[gastric cancer]].<ref>{{cite journal |author=Peter S, Beglinger C |title=Helicobacter pylori and gastric cancer: the causal relationship |journal=Digestion |volume=75 |issue=1 |pages=25–35 |year=2007 |pmid=17429205 |doi=10.1159/000101564}}</ref><ref>{{cite journal |author=Wang C, Yuan Y, Hunt RH |title=The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis |journal=Am. J. Gastroenterol. |volume=102 |issue=8 |pages=1789–98 |year=2007 |month=August |pmid=17521398 |doi=10.1111/j.1572-0241.2007.01335.x}}</ref> Although only a minority of those infected with ''Helicobacter'' go on to develop cancer, since this pathogen is quite common it is probably responsible for most of these cancers.<ref>{{cite journal |author=Cheung TK, Xia HH, Wong BC |title=Helicobacter pylori eradication for gastric cancer prevention |journal=J. Gastroenterol. |volume=42 Suppl 17 |issue= |pages=10–5 |year=2007 |month=January |pmid=17238019 |doi=10.1007/s00535-006-1939-2}}</ref>
  
 
=== Hormonal imbalances ===
 
=== Hormonal imbalances ===
Some hormones can act in a similar manner to non-mutagenic carcinogens in that they may stimulate excessive cell growth. A well-established example is the role of [[estrogen|hyperestrogenic]] states in promoting [[endometrial cancer]].
+
Some hormones can act in a similar manner to non-mutagenic carcinogens in that they may stimulate excessive cell growth.{{Clarify|date=May 2010}}
  
 
=== Immune system dysfunction ===
 
=== Immune system dysfunction ===
[[HIV]] is associated with a number of malignancies, including [[Kaposi's sarcoma]], [[non-Hodgkin's lymphoma]], and [[HPV]]-associated malignancies such as [[anal cancer]] and [[cervical cancer]]. [[AIDS]]-defining illnesses have long included these diagnoses. The increased incidence of malignancies in HIV patients points to the breakdown of immune surveillance as a possible etiology of cancer.<ref>{{cite journal |author=Wood C, Harrington W |title=AIDS and associated malignancies |journal=Cell Res. |volume=15 |issue=11-12 |pages=947–52 |year=2005 |pmid=16354573 |doi=10.1038/sj.cr.7290372}}</ref> Certain other immune deficiency states (e.g. [[common variable immunodeficiency]] and [[IgA deficiency]]) are also associated with increased risk of malignancy.<ref>{{cite journal |author=Mellemkjaer L, Hammarstrom L, Andersen V, ''et al'' |title=Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study |journal=Clin. Exp. Immunol. |volume=130 |issue=3 |pages=495–500 |year=2002 |pmid=12452841|doi=10.1046/j.1365-2249.2002.02004.x}}</ref>
+
[[HIV]] is associated with a number of malignancies, including [[Kaposi's sarcoma]], [[non-Hodgkin's lymphoma]], and [[HPV]]-associated malignancies such as [[anal cancer]] and [[cervical cancer]]. [[AIDS]]-defining illnesses have long included these diagnoses. The increased incidence of malignancies in HIV patients points to the breakdown of immune surveillance as a possible etiology of cancer.<ref>{{cite journal |author=Wood C, Harrington W |title=AIDS and associated malignancies |journal=Cell Res. |volume=15 |issue=11-12 |pages=947–52 |year=2005 |pmid=16354573 |doi=10.1038/sj.cr.7290372}}</ref> Certain other immune deficiency states (e.g. [[common variable immunodeficiency]] and [[IgA deficiency]]) are also associated with increased risk of malignancy.<ref>{{cite journal |author=Mellemkjaer L, Hammarstrom L, Andersen V, ''et al.'' |title=Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study |journal=Clin. Exp. Immunol. |volume=130 |issue=3 |pages=495–500 |year=2002 |pmid=12452841|doi=10.1046/j.1365-2249.2002.02004.x |pmc=1906562}}</ref>
  
 
=== Heredity ===
 
=== Heredity ===
Most forms of cancer are "sporadic", and have no basis in heredity. There are, however, a number of recognised [[syndrome]]s of cancer with a hereditary component, often a defective tumor suppressor [[allele]]. Famous examples are:
+
Most forms of cancer are ''sporadic'', meaning that there is no inherited cause of the cancer. There are, however, a number of recognised [[syndrome]]s where there is an inherited predisposition to cancer, often due to a defect in a gene that [[tumor suppressor|protects against tumor formation]]. Famous examples are:
* certain inherited mutations in the genes ''[[BRCA1]]'' and ''[[Lung cancer#Non-small cell lung carcinoma .28NSCLC.29|BRCA2]]'' are associated with an elevated risk of [[breast cancer]] and [[ovarian cancer]]
+
* certain inherited mutations in the genes ''[[BRCA1]]'' and ''[[Lung cancer#Non-small cell lung carcinoma (NSCLC)|BRCA2]]'' are associated with an elevated risk of [[breast cancer]] and [[ovarian cancer]]
 
* tumors of various endocrine organs in [[multiple endocrine neoplasia]] (MEN types 1, 2a, 2b)
 
* tumors of various endocrine organs in [[multiple endocrine neoplasia]] (MEN types 1, 2a, 2b)
 
* [[Li-Fraumeni syndrome]] (various tumors such as [[osteosarcoma]], breast cancer, [[soft tissue sarcoma]], [[brain tumor]]s) due to mutations of [[p53]]
 
* [[Li-Fraumeni syndrome]] (various tumors such as [[osteosarcoma]], breast cancer, [[soft tissue sarcoma]], [[brain tumor]]s) due to mutations of [[p53]]
 
* [[Turcot syndrome]] ([[brain tumor]]s and colonic polyposis)
 
* [[Turcot syndrome]] ([[brain tumor]]s and colonic polyposis)
 
* [[Familial adenomatous polyposis]] an inherited mutation of the ''APC'' gene that leads to early onset of [[colon carcinoma]].
 
* [[Familial adenomatous polyposis]] an inherited mutation of the ''APC'' gene that leads to early onset of [[colon carcinoma]].
* [[Hereditary nonpolyposis colorectal cancer]] (HNPCC, also known as Lynch syndrome) can include familial cases of [[Colorectal cancer|colon cancer]], uterine cancer, [[gastric cancer]], and [[ovarian cancer]], without a preponderance of [[Polyp (medicine)|colon polyps]].
+
* [[Hereditary nonpolyposis colorectal cancer]] (HNPCC, also known as Lynch syndrome) can include familial cases of [[Colorectal cancer|colon cancer]], uterine cancer, [[gastric cancer]], and [[ovarian cancer]], without a preponderance of [[polyp (medicine)|colon polyps]].
 
* [[Retinoblastoma]], when occurring in young children, is due to a hereditary mutation in the retinoblastoma gene.
 
* [[Retinoblastoma]], when occurring in young children, is due to a hereditary mutation in the retinoblastoma gene.
 
* [[Down syndrome]] patients, who have an extra [[chromosome 21]], are known to develop malignancies such as [[leukemia]] and [[testicular cancer]], though the reasons for this difference are not well understood.
 
* [[Down syndrome]] patients, who have an extra [[chromosome 21]], are known to develop malignancies such as [[leukemia]] and [[testicular cancer]], though the reasons for this difference are not well understood.
  
 
=== Other causes ===
 
=== Other causes ===
A few types of cancer in non-humans have been found to be caused by the tumor cells themselves. This phenomenon is seen in dogs with [[Sticker's sarcoma]], also known as canine transmissible venereal tumor<ref>{{cite journal |author=Murgia C, Pritchard JK, Kim SY, Fassati A, Weiss RA |title=Clonal origin and evolution of a transmissible cancer |journal=Cell |volume=126 |issue=3 |pages=477–87 |year=2006 |pmid=16901782 |doi=10.1016/j.cell.2006.05.051}}</ref>, as well as [[Devil facial tumour disease]] in [[Tasmanian Devil|Tasmanian devils]].  The closest known analogue to this in humans is individuals who have developed cancer from tumors hiding inside organ transplants.
+
Excepting the rare transmissions that occur with pregnancies and only a marginal few organ donors, cancer is generally not a [[transmission (medicine)|transmissible disease]]. The main reason for this is tissue graft rejection caused by [[major histocompatibility complex|MHC]] [[histocompatibility|incompatibility]].<ref name=Tolar>{{cite journal |author=Tolar J, Neglia JP |title=Transplacental and other routes of cancer transmission between individuals |journal=J Pediatr Hematol Oncol. |volume=25 |issue=6 |pages=430–4 |year=2003 |month=June |pmid=12794519 |doi=10.1097/00043426-200306000-00002 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1077-4114&volume=25&issue=6&spage=430}}</ref>  In humans and other vertebrates, the immune system uses MHC antigens to differentiate between "self" and "non-self" cells because these antigens are different from person to person.  When non-self antigens are encountered, the immune system reacts against the appropriate cell.  Such reactions may protect against tumour cell engraftment by eliminating implanted cells. In the United States, approximately 3,500 pregnant women have a malignancy annually, and transplacental transmission of [[acute leukaemia]], [[lymphoma]], [[melanoma]] and [[carcinoma]] from mother to fetus has been observed.<ref name=Tolar/>  The development of donor-derived tumors from organ transplants is exceedingly rare. The main cause of organ transplant associated tumors seems to be malignant melanoma, that was undetected at the time of organ harvest.<ref>{{cite journal |author=Dingli D, Nowak MA |title=Cancer biology: infectious tumour cells |journal=Nature |volume=443 |issue=7107 |pages=35–6 |year=2006 |month=September |pmid=16957717 |doi=10.1038/443035a |url= |pmc=2711443}}</ref> though other cases exist<ref>{{cite web |title= Cancer Spread By Transplantation Extremely Rare: In Very Rare Case, Woman Develops Leukemia from Liver Transplant|url=http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Cancer_Spread_By_Transplantation_Extremely_Rare.asp}}</ref> In fact, cancer from one organism will usually grow in another organism of that species, as long as they share the same [[histocompatibility]] genes,<ref>{{cite web |title= The Nobel Prize in Physiology or Medicine 1980|url=http://nobelprize.org/nobel_prizes/medicine/laureates/1980/presentation-speech.html}}</ref> proven using mice; however this would never happen in a real-world setting except as described above.
 +
 
 +
In non-humans, a few types of [[transmissible cancer]] have been described, wherein the cancer spreads between animals by transmission of the tumor cells themselves. This phenomenon is seen in dogs with [[Sticker's sarcoma]], also known as canine transmissible venereal tumor,<ref>{{cite journal |author=Murgia C, Pritchard JK, Kim SY, Fassati A, Weiss RA |title=Clonal origin and evolution of a transmissible cancer |journal=Cell |volume=126 |issue=3 |pages=477–87 |year=2006 |pmid=16901782 |doi=10.1016/j.cell.2006.05.051 |pmc=2593932}}</ref> as well as [[Devil facial tumour disease]] in [[Tasmanian Devil|Tasmanian devils]].
  
 
== Pathophysiology ==
 
== Pathophysiology ==
[[Image:Cancer requires multiple mutations from NIH.png|thumb|150px|right|Cancers are caused by a series of mutations. Each mutation alters the behavior of the cell somewhat.]]
+
{{Main|Oncogenesis}}
 +
[[File:Cancer requires multiple mutations from NIHen.png|thumb|right|Cancers are caused by a series of mutations. Each mutation alters the behavior of the cell somewhat.]]
  
Cancer is fundamentally a disease of regulation of tissue growth. In order for a normal cell to [[malignant transformation|transform]] into a cancer cell, [[genes]] which regulate cell growth and differentiation must be altered. Genetic changes can occur at many levels, from gain or loss of entire chromosomes to a mutation affecting a [[Single nucleotide polymorphism|single DNA nucleotide]]. There are two broad categories of genes which are affected by these changes. [[Oncogene]]s may be normal genes which are expressed at inappropriately high levels, or altered genes which have novel properties. In either case, expression of these genes promotes the malignant phenotype of cancer cells. [[Tumor suppressor gene]]s are genes which inhibit cell division, survival, or other properties of cancer cells. Tumor suppressor genes are often disabled by cancer-promoting genetic changes. Typically, changes in many genes are required to transform a normal cell into a cancer cell.
+
Cancer is fundamentally a disease of regulation of tissue growth. In order for a normal cell to [[malignant transformation|transform]] into a cancer cell, [[genes]] which regulate cell growth and differentiation must be altered.<ref>{{cite journal |author=Croce CM |title=Oncogenes and cancer |journal=The New England journal of medicine |volume=358 |issue=5 |pages=502–11 |year=2008 |month=January |pmid=18234754 |doi=10.1056/NEJMra072367 |url=http://content.nejm.org/cgi/content/full/358/5/502}}</ref> Genetic changes can occur at many levels, from gain or loss of entire chromosomes to a mutation affecting a [[Single nucleotide polymorphism|single DNA nucleotide]]. There are two broad categories of genes which are affected by these changes. [[Oncogene]]s may be normal genes which are expressed at inappropriately high levels, or altered genes which have novel properties. In either case, expression of these genes promotes the malignant phenotype of cancer cells. [[Tumor suppressor gene]]s are genes which inhibit cell division, survival, or other properties of cancer cells. Tumor suppressor genes are often disabled by cancer-promoting genetic changes. Typically, changes in many genes are required to transform a normal cell into a cancer cell.<ref>{{cite journal |author=Knudson AG |title=Two genetic hits (more or less) to cancer |journal=Nature reviews. Cancer |volume=1 |issue=2 |pages=157–62 |year=2001 |month=November |pmid=11905807 |doi=10.1038/35101031}}</ref>
  
 
There is a diverse classification scheme for the various genomic changes which may contribute to the generation of cancer cells. Most of these changes are [[mutation]]s, or changes in the [[nucleotide]] sequence of genomic DNA. [[Aneuploidy]], the presence of an abnormal number of chromosomes, is one genomic change which is not a mutation, and may involve either gain or loss of one or more [[chromosomes]] through errors in [[mitosis]].
 
There is a diverse classification scheme for the various genomic changes which may contribute to the generation of cancer cells. Most of these changes are [[mutation]]s, or changes in the [[nucleotide]] sequence of genomic DNA. [[Aneuploidy]], the presence of an abnormal number of chromosomes, is one genomic change which is not a mutation, and may involve either gain or loss of one or more [[chromosomes]] through errors in [[mitosis]].
  
Large-scale mutations involve the deletion or gain of a portion of a chromosome. [[Gene amplification|Genomic amplification]] occurs when a cell gains many copies (often 20 or more) of a small chromosomal locus, usually containing one or more oncogenes and adjacent genetic material. [[Chromosomal translocation|Translocation]] occurs when two separate chromosomal regions become abnormally fused, often at a characteristic location. A well-known example of this is the [[Philadelphia chromosome]], or translocation of chromosomes 9 and 22, which occurs in [[chronic myelogenous leukemia]], and results in production of the [[BCR gene|BCR]]-[[Abl gene|abl]] [[fusion protein]], an oncogenic [[tyrosine kinase]].
+
Large-scale mutations involve the deletion or gain of a portion of a chromosome. [[Gene amplification|Genomic amplification]] occurs when a cell gains many copies (often 20 or more) of a small chromosomal locus, usually containing one or more oncogenes and adjacent genetic material. [[Chromosomal translocation|Translocation]] occurs when two separate chromosomal regions become abnormally fused, often at a characteristic location. A well-known example of this is the [[Philadelphia chromosome]], or translocation of chromosomes 9 and 22, which occurs in [[chronic myelogenous leukemia]], and results in production of the [[BCR gene|BCR]]-[[abl gene|abl]] [[fusion protein]], an oncogenic [[tyrosine kinase]].
  
Small-scale mutations include point mutations, deletions, and insertions, which may occur in the [[promoter]] of a gene and affect its [[gene expression|expression]], or may occur in the gene's [[coding sequence]] and alter the function or stability of its [[protein]] product. Disruption of a single gene may also result from [[provirus|integration of genomic material]] from a [[DNA virus]] or [[retrovirus]], and such an event may also result in the expression of viral oncogenes in the affected cell and its descendants.
+
Small-scale mutations include point mutations, deletions, and insertions, which may occur in the [[Promoter (biology)|promoter]] of a gene and affect its [[gene expression|expression]], or may occur in the gene's [[coding sequence]] and alter the function or stability of its [[protein]] product. Disruption of a single gene may also result from [[provirus|integration of genomic material]] from a [[DNA virus]] or [[retrovirus]], and such an event may also result in the expression of viral oncogenes in the affected cell and its descendants.
  
===Epigenetics===
+
== Prevention ==
[[Epigenetic]]s is the study of the regulation of gene expression through chemical, non-mutational changes in DNA structure. The theory of [[epigenetics]] in cancer pathogenesis is that non-mutational changes to DNA can lead to alterations in gene expression. Normally, [[oncogenes]] are silent, for example, because of [[DNA methylation]]. Loss of that methylation can induce the aberrant expression of [[oncogenes]], leading to cancer pathogenesis. Known mechanisms of epigenetic change include [[DNA methylation]], and methylation or acetylation of [[histone]] proteins bound to chromosomal DNA at specific locations. Classes of medications, known as [[HDAC inhibitors]] and [[DNA methyltransferase]] inhibitors, can re-regulate the epigenetic signaling in the cancer cell.
+
Cancer prevention is defined as active measures to decrease the incidence of cancer.<ref>{{cite web | url=http://www.mayoclinic.com/health/cancer-prevention/CA00024 | title=Cancer prevention: 7 steps to reduce your risk | publisher=[[Mayo Clinic]] | date=2008-09-27 | accessdate=2010-01-30}}</ref>  Greater than 30% of cancer is preventable via avoiding risk factors including: [[tobacco]], [[overweight]] or [[obesity]], low fruit and vegetable intake, [[physical inactivity]], [[alcohol]], [[sexually transmitted infection]], [[air pollution]].<ref name="Cancer Cancer">{{cite web |url=http://www.who.int/mediacentre/factsheets/fs297/en/ |title=Cancer Cancer |work=World Health Organization |accessdate=}}</ref> This can be accomplished by avoiding [[carcinogen]]s or altering their [[metabolism]], pursuing a lifestyle or diet that modifies cancer-causing factors and/or medical intervention ([[chemoprevention]], treatment of pre-malignant lesions). The [[epidemiology|epidemiological]] concept of "prevention" is usually defined as either [[primary prevention]], for people who have not been diagnosed with a particular disease, or [[secondary prevention]], aimed at reducing recurrence or complications of a previously diagnosed illness.  
  
=== Oncogenes ===
+
But the EPIC study published in 2010, tracking the eating habits of 478,000 Europeans suggested that consuming lots of fruits and vegetables has little if any effect on preventing cancer.<ref>{{cite journal |author=Boffetta P, Couto E, Wichmann J et al. |title=Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).|journal=J Natl Cancer Inst,|year=2010|issue=102 |pages=529-37|pmid=20371762|volume=8}}</ref>
[[Oncogene]]s promote cell growth through a variety of ways. Many can produce [[hormone]]s, a "chemical messenger" between cells which encourage [[mitosis]], the effect of which depends on the [[signal transduction]] of the receiving tissue or cells. In other words, when a hormone receptor on a recipient cell is stimulated, the signal is conducted from the surface of the cell to the [[cell nucleus]] to effect some change in gene transcription regulation at the nuclear level. Some oncogenes are part of the signal transduction system itself, or the signal [[receptor (biochemistry)|receptors]] in cells and tissues themselves, thus controlling the sensitivity to such hormones. Oncogenes often produce [[mitogen]]s, or are involved in [[transcription (genetics)|transcription]] of DNA in [[protein biosynthesis|protein synthesis]], which creates the [[protein]]s and [[enzyme]]s responsible for producing the products and [[biochemistry|biochemicals]] cells use and interact with.
 
  
Mutations in proto-oncogenes, which are the normally quiescent counterparts of [[oncogenes]], can modify their [[gene expression|expression]] and function, increasing the amount or activity of the product protein. When this happens, the proto-oncogenes become [[oncogene]]s, and this transition upsets the normal balance of [[cell cycle]] regulation in the cell, making uncontrolled growth possible. The chance of cancer cannot be reduced by removing proto-oncogenes from the [[genome]], even if this were possible, as they are critical for growth, repair and [[homeostasis]] of the organism. It is only when they become mutated that the signals for growth become excessive.
 
  
One of the first [[oncogenes]] to be defined in cancer research is the [[ras oncogene]]. Mutations in the Ras family of [[proto-oncogene]]s (comprising H-Ras, N-Ras and K-Ras) are very common, being found in 20% to 30% of all human tumours.<ref>{{cite journal | author=Bos J | title=ras oncogenes in human cancer: a review | journal=Cancer Res | volume=49 | issue=17 | pages=4682–9 | year=1989 | pmid=2547513}}</ref> Ras was originally identified in the Harvey sarcoma virus genome, and researchers were surprised that not only was this gene present in the human genome but that, when ligated to a stimulating control element, could induce cancers in cell line cultures.<ref name="pmid6283358">{{cite journal |author=Chang EH, Furth ME, Scolnick EM, Lowy DR |title=Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus |journal=Nature |volume=297 |issue=5866 |pages=479–83 |year=1982 |pmid=6283358|doi=10.1038/297479a0}}</ref>
 
  
=== Tumor suppressor genes ===
+
=== Modifiable factors ===
[[Tumor suppressor gene]]s code for anti-proliferation signals and proteins that suppress mitosis and cell growth. Generally, tumor suppressors are [[transcription factor]]s that are activated by cellular [[stress (medicine)|stress]] or DNA damage. Often DNA damage will cause the presence of free-floating genetic material as well as other signs, and will trigger enzymes and pathways which lead to the activation of [[tumor suppressor genes]]. The functions of such genes is to arrest the progression of the cell cycle in order to carry out DNA repair, preventing mutations from being passed on to daughter cells. The [[p53]] protein, one of the most important studied tumor suppressor genes, is a transcription factor activated by many cellular stressors including [[Hypoxia (medical)|hypoxia]] and [[ultraviolet radiation]] damage.
+
{{See also|Alcohol and cancer}}
  
Despite nearly half of all cancers possibly involving alterations in p53, its tumor suppressor function is poorly understood. p53 clearly has two functions: one a nuclear role as a transcription factor, and the other a cytoplasmic role in regulating the cell cycle, cell division, and apoptosis.
+
The vast majority of cancer risk factors are environmental or lifestyle-related, leading to the claim that cancer is a largely preventable disease.<ref name=Danaei>{{cite journal |author= Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M |title= Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors |journal=Lancet |volume=366 |issue=9499 |pages=1784–93 |year=2005 |pmid=16298215 |doi=10.1016/S0140-6736(05)67725-2}}</ref> Examples of modifiable cancer risk factors include [[alcoholic beverage|alcohol]] consumption (associated with increased risk of oral, esophageal, breast, and other cancers), smoking (80% of women with lung cancer have smoked in the past, and 90% of men<ref>{{cite web | title= Lung Cancer in American Women: Facts | url=http://www.nationallungcancerpartnership.org/page.cfm?l=factsWomen | accessdate=2007-01-19 }}</ref>), physical inactivity (associated with increased risk of colon, breast, and possibly other cancers), and being [[overweight]] / [[obese]] (associated with colon, breast, endometrial, and possibly other cancers). Based on epidemiologic evidence, it is now thought that avoiding excessive alcohol consumption may contribute to reductions in risk of certain cancers; however, compared with tobacco exposure, the magnitude of effect is modest or small and the strength of evidence is often weaker. Other lifestyle and environmental factors known to affect cancer risk (either beneficially or detrimentally) include certain sexually transmitted diseases (such as those conveyed by the [[human papillomavirus]]), the use of exogenous hormones, exposure to [[ionizing radiation]] and [[ultraviolet]] radiation from the sun or from [[Tanning bed#Risks|tanning beds]], and certain occupational and chemical exposures.
  
The [[Warburg hypothesis]] is the preferential use of glycolysis for energy to sustain cancer growth. p53 has been shown to regulate the shift from the respiratory to the glycolytic pathway.<ref name="Mantoba-Warburg">{{cite journal | author = Matoba S, Kang J, Patino W, Wragg A, Boehm M, Gavrilova O, Hurley P, Bunz F, Hwang P | title = p53 regulates mitochondrial respiration | journal = Science | volume = 312 | issue = 5780 | pages = 1650–3 | year = 2006 | pmid = 16728594 | doi = 10.1126/science.1126863}}</ref>
+
Every year, at least 200,000 people die worldwide from cancer related to their workplace.<ref name=WHO_occup>{{cite press release |title=WHO calls for prevention of cancer through healthy workplaces |publisher=World Health Organization |date=2007-04-27 |url=http://www.who.int/mediacentre/news/notes/2007/np19/en/index.html |accessdate=2007-10-13}}</ref> Millions of workers run the risk of developing cancers such as [[lung cancer]] and [[mesothelioma]] from inhaling [[asbestos]] fibers and tobacco smoke, or [[leukemia]] from exposure to [[benzene]] at their workplaces.<ref name=WHO_occup/> Currently, most cancer deaths caused by occupational risk factors occur in the developed world.<ref name=WHO_occup/> It is estimated that approximately 20,000 cancer deaths and 40,000 new cases of cancer each year in the U.S. are attributable to occupation.<ref>{{cite web|url=http://www.cdc.gov/niosh/topics/cancer/|title=National Institute for Occupational Safety and Health- Occupational Cancer |accessdate=2007-10-13|publisher=United States National Institute for Occupational Safety and Health}}</ref>
  
However, a mutation can damage the tumor suppressor gene itself, or the signal pathway which activates it, "switching it off". The invariable consequence of this is that DNA repair is hindered or inhibited: DNA damage accumulates without repair, inevitably leading to cancer.
+
=== Diet ===
  
Mutations of tumor suppressor genes that occur in [[germline]] cells are passed along to [[offspring]], and increase the likelihood for cancer diagnoses in subsequent generations. Members of these families have increased incidence and decreased latency of multiple tumors. The tumor types are typical for each type of tumor suppressor gene mutation, with some mutations causing particular cancers, and other mutations causing others. The mode of inheritance of mutant tumor suppressors is that an affected member inherits a defective copy from one parent, and a normal copy from the other. For instance, individuals who inherit one mutant ''[[p53]]'' allele (and are therefore [[heterozygote|heterozygous]] for mutated ''p53'') can develop [[melanomas]] and [[pancreatic cancer]], known as [[Li-Fraumeni syndrome]]. Other inherited tumor suppressor gene syndromes include ''[[Retinoblastoma protein|Rb]]'' mutations, linked to [[retinoblastoma]], and ''[[Familial adenomatous polyposis#Pathophysiology|APC]]'' gene mutations, linked to [[Familial adenomatous polyposis|adenopolyposis colon cancer]]. Adenopolyposis colon cancer is associated with thousands of polyps in colon while young, leading to [[Colorectal cancer|colon cancer]] at a relatively early age. Finally, inherited mutations in ''[[BRCA1]]'' and ''[[BRCA2]]'' lead to early onset of [[breast cancer]].
+
{{Main|Diet and cancer}}
  
Development of cancer was proposed in 1971 to depend on at least two mutational events. In what became known as the [[Alfred G. Knudson|Knudson]] [[Knudson hypothesis|two-hit hypothesis]], an inherited, germ-line mutation in a [[tumor suppressor gene]] would only cause cancer if another mutation event occurred later in the organism's life, inactivating the other [[allele]] of that [[tumor suppressor gene]].<ref>{{cite journal |author=Knudson A |title=Mutation and cancer: statistical study of retinoblastoma |journal=[[PNAS|Proc Natl Acad Sci USA]] |volume=68 |issue=4 |pages=820–3 |year=1971 |pmid=5279523 |doi=10.1073/pnas.68.4.820}}</ref>
+
The consensus on diet and cancer is that [[obesity]] increases the risk of developing cancer. Particular dietary practices often explain differences in cancer incidence in different countries (e.g. [[gastric cancer]] is more common in Japan, while [[Colorectal cancer|colon cancer]] is more common in the United States. In this example the preceding consideration of [[Haplogroups]] are excluded). Studies have shown that immigrants develop the risk of their new country, often within one generation, suggesting a substantial link between diet and cancer.<ref>{{cite journal |author=Buell P, Dunn JE |title=Cancer mortality among Japanese Issei and Nisei of California |journal=Cancer |volume=18 |issue= |pages=656–64 |year=1965 |pmid=14278899|doi=10.1002/1097-0142(196505)18:5<656::AID-CNCR2820180515>3.0.CO;2-3}}</ref> Whether reducing obesity in a population also reduces cancer incidence is unknown.
  
Usually, oncogenes are [[dominant gene|dominant]], as they contain [[gain-of-function mutation]]s, while mutated tumor suppressors are [[recessive gene|recessive]], as they contain [[loss-of-function mutation]]s. Each cell has two copies of the same gene, one from each parent, and under most cases gain of function mutations in just one copy of a particular proto-oncogene is enough to make that gene a true oncogene. On the other hand, loss of function mutations need to happen in both copies of a tumor suppressor gene to render that gene completely non-functional. However, cases exist in which one mutated copy of a [[tumor suppressor gene]] can render the other, [[wild-type]] copy non-functional. This phenomenon is called the ''dominant negative effect'' and is observed in many p53 mutations.
+
Despite frequent reports of particular substances (including foods) having a beneficial or detrimental effect on cancer risk, few of these have an established link to cancer. These reports are often based on studies in cultured cell media or animals. Public health recommendations cannot be made based on these studies until they have been validated in an observational (or occasionally a prospective interventional) trial in humans.
  
Knudson’s two hit model has recently been challenged by several investigators. Inactivation of one allele of some tumor suppressor genes is sufficient to cause tumors. This phenomenon is called [[haploinsufficiency]] and has been demonstrated by a number of experimental approaches. Tumors caused by [[haploinsufficiency]] usually have a later age of onset when compared with those by a two hit process.<ref name="Fodde-Haploinsufficiency">{{cite journal | author = Fodde R, Smits R | title = Cancer biology. A matter of dosage | journal = Science | volume = 298 | issue = 5594 | pages = 761–3 | year = 2002 | pmid = 12399571 | doi = 10.1126/science.1077707}}</ref>
+
Proposed dietary interventions for primary cancer risk reduction generally gain support from epidemiological association studies. Examples of such studies include reports that reduced meat consumption is associated with decreased risk of colon cancer,<ref name="pmid9663397">{{cite journal |author=Slattery ML, Boucher KM, Caan BJ, Potter JD, Ma KN |title=Eating patterns and risk of colon cancer |journal=Am. J. Epidemiol. |volume=148 |issue=1 |pages=4–16 |year=1998 |pmid=9663397 |doi=}}</ref>
 +
and reports that consumption of coffee is associated with a reduced risk of liver cancer.<ref name="pmid17484871">{{cite journal |author=Larsson SC, Wolk A |title=Coffee consumption and risk of liver cancer: a meta-analysis |journal=Gastroenterology |volume=132 |issue=5 |pages=1740–5 |year=2007 |pmid=17484871 |doi=10.1053/j.gastro.2007.03.044}}</ref> Studies have linked consumption of grilled meat to an increased risk of [[stomach cancer]],<ref name="pmid9096659">{{cite journal |author=Ward MH, Sinha R, Heineman EF, ''et al.'' |title=Risk of adenocarcinoma of the stomach and esophagus with meat cooking method and doneness preference |journal=Int. J. Cancer |volume=71 |issue=1 |pages=14–9 |year=1997 |pmid=9096659|doi=10.1002/(SICI)1097-0215(19970328)71:1<14::AID-IJC4>3.0.CO;2-6}}</ref> [[Colorectal cancer|colon cancer]],<ref name="pmid16140978">{{cite journal |author=Sinha R, Peters U, Cross AJ, ''et al.'' |title=Meat, meat cooking methods and preservation, and risk for colorectal adenoma |journal=Cancer Res. |volume=65 |issue=17 |pages=8034–41 |year=2005 |pmid=16140978 |url=http://cancerres.aacrjournals.org/cgi/content/full/65/17/8034 |doi=10.1158/0008-5472.CAN-04-3429 |doi_brokendate=2010-01-06}}</ref> [[breast cancer]],<ref name="pmid17435448">{{cite journal |author=Steck SE, Gaudet MM, Eng SM, ''et al.'' |title=Cooked meat and risk of breast cancer—lifetime versus recent dietary intake |journal=Epidemiology (Cambridge, Mass.) |volume=18 |issue=3 |pages=373–82 |year=2007 |pmid=17435448 |doi=10.1097/01.ede.0000259968.11151.06}}</ref> and [[pancreatic cancer]],<ref name="pmid16172241">{{cite journal |author=Anderson KE, Kadlubar FF, Kulldorff M, ''et al.'' |title=Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer |journal=Cancer Epidemiol. Biomarkers Prev. |volume=14 |issue=9 |pages=2261–5 |year=2005 |pmid=16172241 |doi=10.1158/1055-9965.EPI-04-0514}}</ref> a phenomenon which could be due to the presence of carcinogens such as [[benzopyrene]] in foods cooked at high temperatures.
  
=== Cancer cell biology ===
+
A 2005 [[secondary prevention]] study showed that consumption of a plant-based diet and lifestyle changes resulted in a reduction in cancer markers in a group of men with prostate cancer who were using no conventional treatments at the time.<ref name="Ornish">{{cite journal | author = Ornish D et al. | title = Intensive lifestyle changes may affect the progression of prostate cancer | journal = The Journal of Urology | volume = 174 | issue = 3 | pages = 1065–9; discussion 1069–70 | year = 2005 | pmid = 16094059 | doi = 10.1097/01.ju.0000169487.49018.73}}</ref>
[[Image:Cancer progression from NIH.png|thumb|250px|left|Tissue can be organized in a continuous spectrum from normal to cancer.|right]]
+
These results were amplified by a 2006 study. Over 2,400 women were studied, half randomly assigned to a normal diet, the other half assigned to a diet containing less than 20% calories from fat. The women on the low fat diet were found to have a markedly lower risk of breast cancer recurrence, in the interim report of December, 2006.<ref>{{cite journal |author=Chlebowski RT, Blackburn GL, Thomson CA, ''et al.'' |title=Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study |journal=J. Natl. Cancer Inst. |volume=98 |issue=24 |pages=1767–76 |year=2006 |pmid=17179478 |doi=10.1093/jnci/djj494}}</ref>
 
 
Often, the multiple genetic changes which result in cancer may take many years to accumulate. During this time, the biological behavior of the pre-malignant cells slowly change from the properties of normal cells to cancer-like properties. Pre-malignant tissue can have a distinctive appearance under the [[microscope]]. Among the distinguishing traits are an increased number of dividing cells, variation in [[cell nucleus|nuclear]] size and shape, variation in cell size and shape, loss of specialized cell features, and loss of normal tissue organization. [[Dysplasia]] is an abnormal type of excessive cell proliferation characterized by loss of normal tissue arrangement and cell structure in pre-malignant cells. These early neoplastic changes must be distinguished from hyperplasia, a reversible increase in cell division caused by an external stimulus, such as a hormonal imbalance or chronic irritation.
 
 
 
The most severe cases of dysplasia are referred to as "[[carcinoma in situ]]." In Latin, the term "in situ" means "in place", so carcinoma in situ refers to an uncontrolled growth of cells that remains in the original location and has not shown invasion into other tissues. Nevertheless, carcinoma in situ may develop into an invasive malignancy and is usually removed surgically, if possible.
 
 
 
==== Clonal evolution ====
 
{{main | Somatic evolution in cancer}}
 
The process by which normal tissue becomes malignant is a process of [[Somatic evolution in cancer| somatic evolution]] within the body<ref>Nowell PC: The clonal evolution of tumor cell populations. Science 1976, 194(4260):23-28.</ref>. Millions of years of biological [[evolution]] insure that the cellular metabolic changes that enable cancer to grow occur only very rarely. Most changes in cellular metabolism that allow cells to grow in a disorderly fashion lead to cell death. Cancer cells undergo a process of [[natural selection]], in that the few cells with new genetic changes that enhance their survival or reproduction continue to multiply, and soon come to dominate the growing tumor, as cells with less favorable genetic change are out-competed<ref>Merlo LM, Pepper JW, Reid BJ, Maley CC: Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006, 6(12):924-935.</ref>. This process is called [[Somatic evolution in cancer| clonal evolution]]. Tumors often continue to evolve in response to chemotherapy treatments, and on occasion aberrant cells may [[Somatic_evolution_in_cancer#Somatic_evolution_in_therapeutic_resistance | acquire resistance]] to particular anti-cancer pharmaceuticals.
 
 
 
==== Biological properties of cancer cells ====
 
In a 2000 article by Hanahan and [[Robert Weinberg|Weinberg]], the biological properties of malignant tumor cells were summarized as follows:<ref name="pmid10647931">{{cite journal |author=Hanahan D, Weinberg RA |title=The hallmarks of cancer |journal=Cell |volume=100 |issue=1 |pages=57–70 |year=2000 |pmid=10647931|doi=10.1016/S0092-8674(00)81683-9}}</ref>
 
* Acquisition of self-sufficiency in [[growth factor|growth signals]], leading to unchecked growth.
 
* Loss of sensitivity to anti-growth signals, also leading to unchecked growth.
 
* Loss of capacity for [[apoptosis]], in order to allow growth despite genetic errors and external anti-growth signals.
 
* Loss of capacity for [[senescence]], leading to limitless replicative potential (immortality)
 
* Acquisition of sustained [[angiogenesis]], allowing the tumor to grow beyond the limitations of passive nutrient diffusion.
 
* Acquisition of ability to invade neighbouring [[biological tissue|tissues]], the defining property of invasive carcinoma.
 
* Acquisition of ability to build [[metastasis|metastases]] at distant sites, the classical property of malignant tumors (carcinomas or others).
 
 
 
The completion of these multiple steps would be a very rare event without :
 
* Loss of capacity to repair genetic errors, leading to an increased [[mutation]] rate (genomic instability), thus accelerating all the other changes.
 
 
 
These biological changes are classical in [[carcinoma]]s; other malignant tumor may not need all to achieve them all. For example, tissue invasion and displacement to distant sites are normal properties of [[leukocytes]]; these steps are not needed in the development of [[Leukemia]]. The different steps do not necessarily represent individual mutations. For example, inactivation of a single gene, coding for the [[P53]] protein, will cause genomic instability, evasion of apoptosis and increased angiogenesis.
 
 
 
== Prevention ==
 
Cancer prevention is defined as active measures to decrease the incidence of cancer. This can be accomplished by avoiding [[carcinogen]]s or altering their [[metabolism]], pursuing a lifestyle or diet that modifies cancer-causing factors and/or medical intervention ([[chemoprevention]], treatment of pre-malignant lesions). The [[epidemiology|epidemiological]] concept of "prevention" is usually defined as either [[primary prevention]], for people who have not been diagnosed with a particular disease, or [[secondary prevention]], aimed at reducing recurrence or complications of a previously diagnosed illness.
 
 
 
[[Observational study|Observational epidemiological studies]] that show associations between risk factors and specific cancers mostly serve to generate hypotheses about potential interventions that could reduce cancer incidence or [[morbidity]]. [[Randomized controlled trial]]s then test whether hypotheses generated by epidemiological trials and laboratory research actually result in reduced cancer incidence and mortality. In many cases, findings from observational [[epidemiological]] studies are not confirmed by randomized controlled trials.
 
 
 
About a third of the twelve most common cancers worldwide are due to nine potentially modifiable risk factors. Men with cancer are twice as likely as women to have a modifiable risk factor for their disease. The nine risk factors are [[tobacco smoking]], excessive [[alcoholic beverage|alcohol]] use, diet low in [[fruit]] and [[vegetables]], limited [[physical exercise]], [[human papillomavirus]] infection (unsafe sex), urban [[air pollution]], domestic use of solid fuels, and contaminated injections (hepatitis B and C).<ref>{{cite journal |author=Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M |title=Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors |journal=Lancet |volume=366 |issue=9499 |pages=1784–93 |year=2005 |pmid=16298215 |doi=10.1016/S0140-6736(05)67725-2| url=http://www.thelancet.com/journals/lancet/article/PIIS0140673605677252/fulltext}}</ref>
 
 
 
===Modifiable ("lifestyle") risk factors===
 
Examples of modifiable cancer risk factors include [[alcohol]] consumption (associated with increased risk of oral, esophageal, breast, and other cancers), smoking (although 20% of women with lung cancer have never smoked, versus 10% of men<ref>{{cite web | title= Lung Cancer in American Women: Facts | url=http://www.nationallungcancerpartnership.org/page.cfm?l=factsWomen | accessdate=2007-01-19 }}</ref>), physical inactivity (associated with increased risk of colon, breast, and possibly other cancers), and being [[obesity|overweight]] (associated with colon, breast, endometrial, and possibly other cancers). Based on epidemiologic evidence, it is now thought that avoiding excessive alcohol consumption may contribute to reductions in risk of certain cancers; however, compared with tobacco exposure, the magnitude of effect is modest or small and the strength of evidence is often weaker. Other lifestyle and environmental factors known to affect cancer risk (either beneficially or detrimentally) include certain sexually transmitted diseases, the use of exogenous hormones, exposure to [[ionizing radiation]] and [[ultraviolet]] radiation, and certain occupational and chemical exposures.
 
 
 
Every year, at least 200,000 people die worldwide from cancer related to their workplace.<ref name=WHO_occup>{{cite press release |title=WHO calls for prevention of cancer through healthy workplaces |publisher=World Health Organization |date=2007-04-27 |url=http://www.who.int/mediacentre/news/notes/2007/np19/en/index.html |accessdate=2007-10-13}} </ref> Millions of workers run the risk of developing cancers such as [[lung cancer]] and [[mesothelioma]] from inhaling asbestos fibers and tobacco smoke, or [[leukemia]] from exposure to [[benzene]] at their workplaces.<ref name=WHO_occup/> Currently, most cancer deaths caused by occupational risk factors occur in the developed world.<ref name=WHO_occup/> It is estimated that approximately 20,000 cancer deaths and 40,000 new cases of cancer each year in the U.S. are attributable to occupation.<ref>{{cite web|url=http://www.cdc.gov/niosh/topics/cancer/|title=National Institute for Occupational Safety and Health- Occupational Cancer |accessdate=2007-10-13|publisher=United States National Institute for Occupational Safety and Health}}</ref>
 
 
 
See [[alcohol and cancer]] for more on that topic.
 
 
 
===Diet===
 
 
 
{{main|Diet and cancer}}
 
  
The consensus on diet and cancer is that [[obesity]] increases the risk of developing cancer. Particular dietary practices often explain differences in cancer incidence in different countries (e.g. [[gastric cancer]] is more common in [[Japan]], while [[Colorectal cancer|colon cancer]] is more common in the United States). Studies have shown that immigrants develop the risk of their new country, often within one generation, suggesting a substantial link between diet and cancer.<ref>{{cite journal |author=Buell P, Dunn JE |title=Cancer mortality among Japanese Issei and Nisei of California |journal=Cancer |volume=18 |issue= |pages=656–64 |year=1965 |pmid=14278899|doi=10.1002/1097-0142(196505)18:5<656::AID-CNCR2820180515>3.0.CO;2-3}}</ref> Whether reducing obesity in a population also reduces cancer incidence is unknown.
+
Recent{{When|date=May 2010}} studies have also demonstrated potential links between some forms of cancer and high consumption of refined sugars and other simple carbohydrates.<ref>{{cite journal |author=Romieu I, Lazcano-Ponce E, Sanchez-Zamorano LM, Willett W, Hernandez-Avila M |title=Carbohydrates and the risk of breast cancer among Mexican women |journal=Cancer Epidemiol Biomarkers Prev |volume=13 |issue=8 |pages=1283–9 |date=1 August 2004|pmid=15298947 |url=http://cebp.aacrjournals.org/cgi/content/full/13/8/1283 }}</ref><ref>{{cite journal | author= Francesca Bravi, Cristina Bosetti, Lorenza Scotti, Renato Talamini, Maurizio Montella, Valerio Ramazzotti, Eva Negri, Silvia Franceschi, and Carlo La Vecchia | title=Food Groups and Renal Cell Carcinoma: A Case-Control Study from Italy | journal=International Journal of Cancer | year=2006 | month=October | volume=355:1991-2002 | url=http://www3.interscience.wiley.com/cgi-bin/abstract/113412400/ABSTRACT | doi=10.1002/ijc.22225 | page= 681}}</ref><ref>{{cite journal | author= Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM | title= Fasting serum glucose level and cancer risk in Korean men and women | journal=JAMA | volume = 293 |issue=2 | doi= 10.1001/jama.293.2.194 | year= 2005 |pages=194–202 | pmid= 15644546 }}</ref><ref>{{cite journal | author= Michaud DS, Liu S, Giovannucci E, Willett WC, Colditz GA, Fuchs CS | title= Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study | journal= J Natl Cancer Inst | volume= 94 |issue=17 | url=http://jnci.oxfordjournals.org/cgi/content/full/94/17/1293 | pmid= 12208894 | doi= 10.1093/jnci/94.17.1293 | year= 2002 |pages=1293–300}}</ref><ref>{{cite journal | author= Venkateswaran V, Haddad AQ, Fleshner NE ''et al.'' | title= Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts | volume= 99 |issue=23 |url=http://jnci.oxfordjournals.org/cgi/content/full/99/23/1793 | pmid=18042933| doi=10.1093/jnci/djm231| year=2007| journal=J Natl Cancer Inst |pages=1793–800}}</ref> Although the degree of correlation and the degree of causality is still debated,<ref>Friebe, Richard: ''[http://www.time.com/time/health/article/0,8599,1662484,00.html Can a High-Fat Diet Beat Cancer?]'', Time Magazine, Sep. 17, 2007</ref><ref>Hitti, Miranda: ''[http://www.webmd.com/cancer/news/20070227/high-blood-sugar-linked-cancer-risk High Blood Sugar Linked to Cancer Risk]'', [http://www.webmd.com WebMD], 22 February 2008</ref><ref>Moynihan, Timothy:''[http://www.mayoclinic.com/health/cancer-causes/CA00085 Cancer causes: Popular myths about the causes of cancer]'', MayoClinic.com, retrieved 22 Feb 2008</ref> some organizations have in fact begun to recommend reducing intake of refined sugars and starches as part of their cancer prevention regimens.<ref>''[http://www.aicr.org/site/PageServer?pagename=dc_recs_03_avoid_sugary_drinks Avoid Sugary Drinks. Limit Consumption of Energy-Dense Foods]'', American Institute for Cancer Research, retrieved 20 Feb 2008</ref><ref>''[http://www.apha.org/publications/tnh/archives/2005/02-05/WebExclusive/287.htm High sugar levels increase cancer and mortality risk]'', The Nation's Health: The Official Newspaper of the American Public Health Association, February 2005</ref><ref>{{cite journal |author=Kushi LH, Byers T, Doyle C, ''et al.'' |title=American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity |journal=CA Cancer J Clin |volume=56 |issue=5 |pages=254–81; quiz 313–4 |year=2006 |pmid=17005596 |doi=10.3322/canjclin.56.5.254 |url=http://caonline.amcancersoc.org/cgi/content/full/56/5/254}}</ref>
 
 
Despite frequent reports of particular substances (including foods) having a beneficial or detrimental effect on cancer risk, few of these have an established link to cancer. These reports are often based on studies in cultured cell media or animals. Public health recommendations cannot be made on the basis of these studies until they have been validated in an observational (or occasionally a prospective interventional) trial in humans.
 
 
 
Proposed dietary interventions for primary cancer risk reduction generally gain support from epidemiological association studies. Examples of such studies include reports that reduced meat consumption is associated with decreased risk of colon cancer,<ref name="pmid9663397">{{cite journal |author=Slattery ML, Boucher KM, Caan BJ, Potter JD, Ma KN |title=Eating patterns and risk of colon cancer |journal=Am. J. Epidemiol. |volume=148 |issue=1 |pages=4&ndash;16 |year=1998 |pmid=9663397 |doi=}}</ref>
 
and reports that consumption of coffee is associated with a reduced risk of liver cancer.<ref name="pmid17484871">{{cite journal |author=Larsson SC, Wolk A |title=Coffee consumption and risk of liver cancer: a meta-analysis |journal=Gastroenterology |volume=132 |issue=5 |pages=1740–5 |year=2007 |pmid=17484871 |doi=10.1053/j.gastro.2007.03.044}}</ref> Studies have linked consumption of grilled meat to an increased risk of [[stomach cancer]],<ref name="pmid9096659">{{cite journal |author=Ward MH, Sinha R, Heineman EF, ''et al'' |title=Risk of adenocarcinoma of the stomach and esophagus with meat cooking method and doneness preference |journal=Int. J. Cancer |volume=71 |issue=1 |pages=14&ndash;9 |year=1997 |pmid=9096659|doi=10.1002/(SICI)1097-0215(19970328)71:1<14::AID-IJC4>3.0.CO;2-6}}</ref> [[Colorectal cancer|colon cancer]],<ref name="pmid16140978">{{cite journal |author=Sinha R, Peters U, Cross AJ, ''et al'' |title=Meat, meat cooking methods and preservation, and risk for colorectal adenoma |journal=Cancer Res. |volume=65 |issue=17 |pages=8034–41 |year=2005 |pmid=16140978 |doi=10.1158/0008-5472.CAN-04-3429 |doi_brokendate=2008-06-26}}</ref> [[breast cancer]],<ref name="pmid17435448">{{cite journal |author=Steck SE, Gaudet MM, Eng SM, ''et al'' |title=Cooked meat and risk of breast cancer—lifetime versus recent dietary intake |journal=Epidemiology (Cambridge, Mass.) |volume=18 |issue=3 |pages=373–82 |year=2007 |pmid=17435448 |doi=10.1097/01.ede.0000259968.11151.06}}</ref> and [[pancreatic cancer]],<ref name="pmid16172241">{{cite journal |author=Anderson KE, Kadlubar FF, Kulldorff M, ''et al'' |title=Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer |journal=Cancer Epidemiol. Biomarkers Prev. |volume=14 |issue=9 |pages=2261–5 |year=2005 |pmid=16172241 |doi=10.1158/1055-9965.EPI-04-0514}}</ref> a phenomenon which could be due to the presence of carcinogens such as [[benzopyrene]] in foods cooked at high temperatures.
 
 
 
A 2005 [[secondary prevention]] study showed that consumption of a plant-based diet and lifestyle changes resulted in a reduction in cancer markers in a group of men with prostate cancer who were using no conventional treatments at the time.<ref name="Ornish">{{cite journal | author = Ornish D et al. | title = Intensive lifestyle changes may affect the progression of prostate cancer | journal = The Journal of Urology | volume = 174 | issue = 3 | pages = 1065–9; discussion 1069–70 | year = 2005 | pmid = 16094059 | doi = 10.1097/01.ju.0000169487.49018.73}}</ref>
 
These results were amplified by a 2006 study in which over 2,400 women were studied, half randomly assigned to a normal diet, the other half assigned to a diet containing less than 20% calories from fat. The women on the low fat diet were found to have a markedly lower risk of breast cancer recurrence, in the interim report of December, 2006.<ref>{{cite journal |author=Chlebowski RT, Blackburn GL, Thomson CA, ''et al'' |title=Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study |journal=J. Natl. Cancer Inst. |volume=98 |issue=24 |pages=1767–76 |year=2006 |pmid=17179478 |doi=10.1093/jnci/djj494}}</ref>
 
  
Recent studies have also demonstrated potential links between some forms of cancer and high consumption of refined sugars and other simple carbohydrates.<ref>{{cite journal |author=Romieu I, Lazcano-Ponce E, Sanchez-Zamorano LM, Willett W, Hernandez-Avila M |title=Carbohydrates and the risk of breast cancer among Mexican women |journal=Cancer Epidemiol. Biomarkers Prev. |volume=13 |issue=8 |pages=1283–9 |year=2004 |month=August |pmid=15298947 |url=http://cebp.aacrjournals.org/cgi/content/full/13/8/1283}}</ref><ref>{{cite journal | author= Francesca Bravi, Cristina Bosetti, Lorenza Scotti, Renato Talamini, Maurizio Montella, Valerio Ramazzotti, Eva Negri, Silvia Franceschi, and Carlo La Vecchia | title=Food Groups and Renal Cell Carcinoma: A Case-Control Study from Italy | journal=International Journal of Cancer | year=2006 | month=October | volume=355:1991-2002 | url=http://www3.interscience.wiley.com/cgi-bin/abstract/113412400/ABSTRACT | doi=10.1002/ijc.22225). | doi_brokendate=2008-06-26}}</ref><ref>{{cite journal | author= Sun Ha Jee, PhD, MHS; Heechoul Ohrr, MD, PhD; Jae Woong Sull, PhD, MHS; Ji Eun Yun, MPH; Min Ji, MPH; Jonathan M. Samet, MD, MS | title= Fasting Serum Glucose Level and Cancer Risk in Korean Men and Women | journal= Journal of the American Medical Association | volume = 293 No. 2 | doi= 10.1001/jama.293.2.194 | year= 2005 | pages= 194 | pmid= 15644546}}</ref><ref>{{cite journal | author= Dominique S. Michaud, Simin Liu, Edward Giovannucci, Walter C. Willett, Graham A. Colditz, Charles S. Fuchs | title= Dietary Sugar, Glycemic Load, and Pancreatic Cancer Risk in a Prospective Study | journal= Journal of the National Cancer Institute | volume= 94, Num 17| url=http://jnci.oxfordjournals.org/cgi/content/abstract/94/17/1293 | pmid= 12208894 | doi= 10.1093/jnci/94.17.1293 | year= 2002 | pages= 1293}}</ref><ref>{{cite journal | author= Vasundara Venkateswaran, Ahmed Q. Haddad, Neil E. Fleshner, Rong Fan, Linda M. Sugar, Rob Nam, Laurence H. Klotz, Michael Pollak| title=Association of Diet-Induced Hyperinsulinemia With Accelerated Growth of Prostate Cancer (LNCaP) Xenografts | volume= 99, Num 23 |url=http://jnci.oxfordjournals.org/cgi/content/short/99/23/1793| pmid=18042933| doi=10.1093/jnci/djm231| year=2007| journal=JNCI Journal of the National Cancer Institute| pages=1793}}</ref> Although the degree of correlation and the degree of causality is still debated,<ref>Friebe, Richard: ''[http://www.time.com/time/health/article/0,8599,1662484,00.html Can a High-Fat Diet Beat Cancer?]'', Time Magazine, Sep. 17, 2007</ref><ref>Hitti, Miranda: ''[http://www.webmd.com/cancer/news/20070227/high-blood-sugar-linked-cancer-risk High Blood Sugar Linked to Cancer Risk]'', [http://www.webmd.com WebMD], February 22, 2008</ref><ref>Moynihan, Timothy:''[http://www.mayoclinic.com/health/cancer-causes/CA00085 Cancer causes: Popular myths about the causes of cancer]'', MayoClinic.com, retrieved 22 Feb 2008</ref> some organizations have in fact begun to recommend reducing intake of refined sugars and starches as part of their cancer prevention regimens.<ref>''[http://www.aicr.org/site/PageServer?pagename=dc_recs_03_avoid_sugary_drinks Avoid Sugary Drinks. Limit Consumption of Energy-Dense Foods]'', American Institute for Cancer Research, retrieved 20 Feb 2008</ref><ref>''[http://www.apha.org/publications/tnh/archives/2005/02-05/WebExclusive/287.htm High sugar levels increase cancer and mortality risk]'', The Nation's Health: The Official Newspaper of the American Public Health Association, February 2005</ref><ref>{{cite journal |author=Kushi LH, Byers T, Doyle C, ''et al'' |title=American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity |journal=CA Cancer J Clin |volume=56 |issue=5 |pages=254–81; quiz 313–4 |year=2006 |pmid=17005596 |doi=10.3322/canjclin.56.5.254 |url=http://caonline.amcancersoc.org/cgi/content/full/56/5/254 |doi_brokendate=2008-06-26}}</ref><ref>Dummert, Erin RD, CD: ''[http://www.thedietchannel.com/Cancer-and-Diet-Does-Sugar-Feed-Cancer.htm Does Sugar Feed Cancer?]'', The Diet Channel, October 25, 2006</ref>
+
In November 2007, the [[American Institute for Cancer Research]] (AICR), in conjunction with the [[World Cancer Research Fund]] (WCRF), published ''[[Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective]]'', "the most current and comprehensive analysis of the literature on diet, physical activity and cancer".<ref>"[http://www.dietandcancerreport.org/?p=historical_overview Historical Overview]" ''dietandcancerreport.org''. Retrieved on 27 August 2008.</ref> The WCRF/AICR Expert Report lists 10 recommendations that people can follow to help reduce their risk of developing cancer, including the following dietary guidelines: (1) reducing intake of foods and drinks that promote weight gain, namely energy-dense foods and sugary drinks, (2) eating mostly foods of plant origin, (3) limiting intake of red meat and avoiding processed meat, (4) limiting consumption of alcoholic beverages, and (5) reducing intake of salt and avoiding mouldy cereals (grains) or pulses (legumes).<ref>"[http://www.dietandcancerreport.org/?p=recommendations Recommendations]". ''dietandcancerreport.org''. Retrieved on 27 August 2008.</ref><ref>Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. [http://www.dietandcancerreport.org/downloads/chapters/chapter_12.pdf Chapter 12] World Cancer Research Fund (2007). ISBN 978-0-9722522-2-5.</ref>
  
The WCRF/AICR Expert Report, ''Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective'' recommends (1) reducing intake of foods and drinks that promote weight gain, namely energy-dense foods and sugary drinks, (2) eating mostly foods of plant origin (3) limiting intake of red meat and avoiding processed meat, (4) limiting consumption of alcoholic beverages, and (5) reducing intake of salt and avoiding mouldy cereals (grains) or pulses (legumes).<ref>Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. [http://www.dietandcancerreport.org/downloads/chapters/chapter_12.pdf Chapter 12] World Cancer Research Fund (2007). ISBN 978-0-9722522-2-5.</ref>
+
Some mushrooms offer an anti-cancer effect, which is thought to be linked to their ability to up-regulate the immune system. Some mushrooms known for this effect include, [[Reishi]],<ref name="pmid16351502">{{Cite journal |author=Yuen JW, Gohel MD |title=Anticancer effects of ''Ganoderma lucidum'': a review of scientific evidence |journal=Nutr Cancer |volume=53 |issue=1 |pages=11–7 |year=2005 |pmid=16351502 |doi=10.1207/s15327914nc5301_2 |issn=0163-5581}}</ref><ref name="pmid18951965">{{Cite journal |author=Hsu SC, Ou CC, Li JW, ''et al'' |title=''Ganoderma tsugae'' extracts inhibit colorectal cancer cell growth via G(2)/M cell cycle arrest |journal=J Ethnopharmacol |volume=120 |issue= 3|page=394 |year=2008 |month=October |pmid=18951965 |doi=10.1016/j.jep.2008.09.025 |issn=0378-8741}}</ref> ''[[Agaricus blazei]]'',<ref>http://www3.interscience.wiley.com/cgi-bin/fulltext/121398729/PDFSTART?CRETRY=1&SRETRY=0</ref> [[Maitake]],<ref>http://www.ncbi.nlm.nih.gov/pubmed/12126464</ref> and ''[[Trametes versicolor]]''<ref>http://www.ncbi.nlm.nih.gov/pubmed/7606203</ref>. Research suggests the compounds in [[medicinal mushrooms]] most responsible for up-regulating the immune system and providing an anti-cancer effect, are a diverse collection of [[polysaccharide]] compounds, particularly [[beta-glucans]].  Beta-glucans are known as "biological response modifiers", and their ability to activate the immune system is well documented.  Specifically, beta-glucans stimulate the [[innate immune system|innate]] branch of the immune system.  Research has shown beta-glucans have the ability to stimulate [[macrophage]], [[NK cells]], [[T cells]], and immune system [[cytokines]]. The mechanisms in which beta-glucans stimulate the immune system is only partially understood.  One mechanism in which beta-glucans are able to activate the immune system, is by interacting with the [[Complement Receptor 3|Macrophage-1 antigen]] ([[CD18]]) [[cell receptor|receptor]] on immune cells.<ref name=pmid15084502>{{cite pmid|15084502}} (review)</ref>
  
===Vitamins===
+
=== Vitamins ===
The idea that cancer can be prevented through vitamin supplementation stems from early observations correlating human disease with vitamin deficiency, such as [[pernicious anemia]] with [[vitamin B12]] deficiency, and [[scurvy]] with [[Vitamin C]] deficiency. This has largely not been proven to be the case with cancer, and vitamin supplementation is largely not proving effective in preventing cancer. The cancer-fighting components of food are also proving to be more numerous and varied than previously understood, so patients are increasingly being advised to consume fresh, unprocessed fruits and vegetables for maximal health benefits.<ref>The Omnivore's Dilemma, Andrew Pollan</ref>
+
[[Vitamin]] supplementation has not been proven effective in the prevention of cancer.{{Citation needed|date=June 2010}} The components of food are also proving to be more numerous and varied than previously understood, so patients are increasingly advised to consume fruits and vegetables for maximal health benefits.<ref>{{cite book | author = Pollan, Michael | title = The Omnivore's Dilemma : A Natural History of Four Meals | publisher = Penguin Press | location = New York| year = 2006 | page = 450| isbn = 978-1-59420-082-3}}</ref>
  
[[epidemiology|Epidemiological studies]] have shown that low [[vitamin D]] status is correlated to increased cancer risk.<ref>{{cite journal |author=Giovannucci E, Liu Y, Rimm EB, ''et al'' |title=Prospective study of predictors of vitamin D status and cancer incidence and mortality in men |journal=J. Natl. Cancer Inst. |volume=98 |issue=7 |pages=451–9 |year=2006 |month=April |pmid=16595781 |doi=10.1093/jnci/djj101}}</ref><ref>{{cite web|url=http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Vitamin_D_Has_Role_in_Colon_Cancer_Prevention.asp|title=Vitamin D Has Role in Colon Cancer Prevention|accessdate=2007-07-27}}</ref> However, the results of such studies need to be treated with caution, as they cannot show whether a correlation between two factors means that one causes the other (''i.e.'' [[correlation does not imply causation]]).<ref>{{cite journal |author=Schwartz GG, Blot WJ |title=Vitamin D status and cancer incidence and mortality: something new under the sun |journal=J. Natl. Cancer Inst. |volume=98 |issue=7 |pages=428–30 |year=2006 |month=April |pmid=16595770 |doi=10.1093/jnci/djj127 |url=http://jnci.oxfordjournals.org/cgi/content/full/98/7/428}}</ref> The possibility that Vitamin D might protect against cancer has been contrasted with the risk of malignancy from sun exposure. Since exposure to the sun enhances natural human production of vitamin D, some cancer researchers have argued that the potential deleterious malignant effects of sun exposure are far outweighed by the cancer-preventing effects of extra vitamin D synthesis in sun-exposed skin. In 2002, Dr. William B. Grant claimed that 23,800 premature cancer deaths occur in the US annually due to insufficient UVB exposure (apparently via vitamin D deficiency).<ref>{{cite web|url=http://www3.interscience.wiley.com/cgi-bin/abstract/91016211/ABSTRACT?CRETRY=1&SRETRY=0|title=www3.interscience.wiley.com/cgi-bin/abstract/91016211/ABSTRACT?CRETRY=1&SRETRY=0<!--INSERT TITLE—>|accessdate=2007-07-27}}</ref> This is higher than 8,800 deaths occurred from melanoma or squamous cell carcinoma, so the overall effect of sun exposure might be beneficial. Another research group<ref>{{cite web|url=http://cat.inist.fr/?aModele=afficheN&cpsidt=17357586|title=cat.inist.fr/?aModele=afficheN&cpsidt=17357586<!--INSERT TITLE—>|accessdate=2007-07-27}}</ref><ref>
+
;Vitamin D
Grant WB, Garland CF, Holick MF. Comparisons of estimated economic burdens due to insufficient solar ultraviolet irradiance and vitamin D and excess solar UV irradiance for the United States. Photochem Photobiol. 2005 Nov-Dec;81(6):1276-86.</ref> estimates that 50,000&ndash;63,000 individuals in the United States and 19,000 - 25,000 in the UK die prematurely from cancer annually due to insufficient vitamin D.
+
Low levels of [[vitamin D]] is correlated with increased cancer risk.<ref>{{cite journal |author=Giovannucci E, Liu Y, Rimm EB, ''et al.'' |title=Prospective study of predictors of vitamin D status and cancer incidence and mortality in men |journal=J. Natl. Cancer Inst. |volume=98 |issue=7 |pages=451–9 |year=2006 |month=April |pmid=16595781 |doi=10.1093/jnci/djj101}}</ref><ref>{{cite web|url=http://www.cancer.org/docroot/NWS/content/NWS_1_1x_Vitamin_D_Has_Role_in_Colon_Cancer_Prevention.asp|title=Vitamin D Has Role in Colon Cancer Prevention|accessdate=2007-07-27}}</ref> Whether this relationship is causal is yet to be determined.<ref>{{cite journal |author=Schwartz GG, Blot WJ |title=Vitamin D status and cancer incidence and mortality: something new under the sun |journal=J. Natl. Cancer Inst. |volume=98 |issue=7 |pages=428–30 |year=2006 |month=April |pmid=16595770 |doi=10.1093/jnci/djj127 |url=http://jnci.oxfordjournals.org/cgi/content/full/98/7/428}}</ref>
  
The case of [[beta-carotene]] provides an example of the importance of [[clinical trial|randomized clinical trials]]. [[Epidemiology|Epidemiologists]] studying both diet and serum levels observed that high levels of [[beta-carotene]], a precursor to [[vitamin A]], were associated with a protective effect, reducing the risk of cancer. This effect was particularly strong in [[lung cancer]]. This [[hypothesis]] led to a series of large randomized [[clinical trials]] conducted in both [[Finland]] and the [[United States]] (CARET study) during the 1980s and 1990s. This study provided about 80,000 smokers or former smokers with daily supplements of beta-carotene or [[placebo]]s. Contrary to expectation, these tests found no benefit of [[beta-carotene]] supplementation in reducing lung cancer incidence and mortality. In fact, the risk of lung cancer was slightly, but not significantly, ''increased'' by beta-carotene, leading to an early termination of the study.<ref name="CancerTopics-Bcarotene">National Cancer Institute [http://www.cancer.gov/cancertopics/factsheet/Prevention/betacarotene Questions and Answers About Beta Carotene Chemoprevention Trials] U.S. National Institutes of Health</ref>
+
;Beta carotene
 +
[[Beta-carotene]] supplementation has been found to increase slightly, but not significantly risks of [[lung cancer]].<ref>{{cite web |publisher= National Cancer Institute |url=http://www.cancer.gov/PDF/FactSheet/fs4_13.pdf |format=PDF |title= Questions and answers about beta carotene chemoprevention trials |date=1997-06-27 |accessdate=2009-04-23}}</ref>
  
Results reported in the [[Journal of the American Medical Association]] (JAMA) in 2007 indicate that folic acid supplementation is not effective in preventing colon cancer, and folate consumers may be more likely to form colon polyps.<ref>{{cite journal |author=Cole BF, Baron JA, Sandler RS, ''et al'' |title=Folic acid for the prevention of colorectal adenomas: a randomized clinical trial |journal=JAMA |volume=297 |issue=21 |pages=2351–9 |year=2007 |pmid=17551129 |doi=10.1001/jama.297.21.2351}}</ref>
+
;Folic acid
 +
Folic acid supplementation has not been found effective in preventing colon cancer and may increase colon polyps.<ref>{{cite journal |author=Cole BF, Baron JA, Sandler RS, ''et al.'' |title=Folic acid for the prevention of colorectal adenomas: a randomized clinical trial |journal=JAMA |volume=297 |issue=21 |pages=2351–9 |year=2007 |pmid=17551129 |doi=10.1001/jama.297.21.2351}}</ref>
  
===Chemoprevention===
+
=== Chemoprevention ===
{{POV-section|date=June 2008}}
 
 
The concept that medications could be used to prevent cancer is an attractive one, and many high-quality clinical trials support the use of such chemoprevention in defined circumstances.
 
The concept that medications could be used to prevent cancer is an attractive one, and many high-quality clinical trials support the use of such chemoprevention in defined circumstances.
  
Daily use of [[tamoxifen]], a [[selective estrogen receptor modulator]] (SERM), typically for 5&nbsp;years, has been demonstrated to reduce the risk of developing [[breast cancer]] in high-risk women by about 50%. A recent study reported that the [[selective estrogen receptor modulator]] [[raloxifene]] has similar benefits to [[tamoxifen]] in preventing breast cancer in high-risk women, with a more favorable side effect profile.<ref name=STAR-P2>{{cite journal |author=Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J, Bevers T, Fehrenbacher L, Pajon E, Wade J, Robidoux A, Margolese R, James J, Lippman S, Runowicz C, Ganz P, Reis S, McCaskill-Stevens W, Ford L, Jordan V, Wolmark N |title=Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial |journal=JAMA |volume=295 |issue=23 |pages=2727–41 |year=2006 |pmid=16754727 |doi=10.1001/jama.295.23.joc60074}}</ref>
+
Daily use of [[tamoxifen]], a [[selective estrogen receptor modulator]] (SERM), typically for 5&nbsp;years, has been demonstrated to reduce the risk of developing [[breast cancer]] in high-risk women by about 50%. A recent{{When|date=May 2010}} study reported that the [[selective estrogen receptor modulator]] [[raloxifene]] has similar benefits to [[tamoxifen]] in preventing breast cancer in high-risk women, with a more favorable side effect profile.<ref name=STAR-P2>{{cite journal |author=Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J, Bevers T, Fehrenbacher L, Pajon E, Wade J, Robidoux A, Margolese R, James J, Lippman S, Runowicz C, Ganz P, Reis S, McCaskill-Stevens W, Ford L, Jordan V, Wolmark N |title=Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial |journal=JAMA |volume=295 |issue=23 |pages=2727–41 |year=2006 |pmid=16754727 |doi=10.1001/jama.295.23.joc60074}}</ref>
  
 
[[Raloxifene]] is a SERM like [[tamoxifen]]; it has been shown (in the STAR trial) to reduce the risk of breast cancer in high-risk women equally as well as tamoxifen. In this trial, which studied almost 20,000 women, [[raloxifene]] had fewer side effects than [[tamoxifen]], though it did permit more [[Ductal carcinoma|DCIS]] to form.<ref name=STAR-P2/>
 
[[Raloxifene]] is a SERM like [[tamoxifen]]; it has been shown (in the STAR trial) to reduce the risk of breast cancer in high-risk women equally as well as tamoxifen. In this trial, which studied almost 20,000 women, [[raloxifene]] had fewer side effects than [[tamoxifen]], though it did permit more [[Ductal carcinoma|DCIS]] to form.<ref name=STAR-P2/>
  
[[Finasteride]], a [[5-alpha-reductase inhibitor]], has been shown to lower the risk of prostate cancer, though it seems to mostly prevent low-grade tumors.<ref>{{cite journal |author=Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L, Lieber M, Cespedes R, Atkins J, Lippman S, Carlin S, Ryan A, Szczepanek C, Crowley J, Coltman C |title=The influence of finasteride on the development of prostate cancer |journal=N Engl J Med |volume=349 |issue=3 |pages=215&ndash;24 |year=2003 |pmid=12824459 |doi=10.1056/NEJMoa030660}}</ref>
+
[[Finasteride]], a [[5-alpha-reductase inhibitor]], has been shown to lower the risk of prostate cancer, though it seems to mostly prevent low-grade tumors.<ref>{{cite journal |author=Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L, Lieber M, Cespedes R, Atkins J, Lippman S, Carlin S, Ryan A, Szczepanek C, Crowley J, Coltman C |title=The influence of finasteride on the development of prostate cancer |journal=N Engl J Med |volume=349 |issue=3 |pages=215–24 |year=2003 |pmid=12824459 |doi=10.1056/NEJMoa030660}}</ref>
 
The effect of [[COX-2 selective inhibitor|COX-2 inhibitors]] such as [[rofecoxib]] and [[celecoxib]] upon the risk of colon polyps have been studied in [[familial adenomatous polyposis]] patients<ref>{{cite journal |author=Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, Halpern Z, Arber N |title=Rofecoxib reduces polyp recurrence in familial polyposis |journal=Dig Dis Sci |volume=48 |issue=10 |pages=1998–2002 |year=2003 |pmid=14627347 |doi=10.1023/A:1026130623186}}</ref>
 
The effect of [[COX-2 selective inhibitor|COX-2 inhibitors]] such as [[rofecoxib]] and [[celecoxib]] upon the risk of colon polyps have been studied in [[familial adenomatous polyposis]] patients<ref>{{cite journal |author=Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, Halpern Z, Arber N |title=Rofecoxib reduces polyp recurrence in familial polyposis |journal=Dig Dis Sci |volume=48 |issue=10 |pages=1998–2002 |year=2003 |pmid=14627347 |doi=10.1023/A:1026130623186}}</ref>
 
and in the general population.<ref>{{cite journal |author=Baron J, Sandler R, Bresalier R, Quan H, Riddell R, Lanas A, Bolognese J, Oxenius B, Horgan K, Loftus S, Morton D |title=A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas |journal=Gastroenterology |volume=131 |issue=6 |pages=1674–82 |year=2006 |pmid=17087947 |doi=10.1053/j.gastro.2006.08.079}}</ref><ref>{{cite journal |author=Bertagnolli M, Eagle C, Zauber A, Redston M, Solomon S, Kim K, Tang J, Rosenstein R, Wittes J, Corle D, Hess T, Woloj G, Boisserie F, Anderson W, Viner J, Bagheri D, Burn J, Chung D, Dewar T, Foley T, Hoffman N, Macrae F, Pruitt R, Saltzman J, Salzberg B, Sylwestrowicz T, Gordon G, Hawk E |title=Celecoxib for the prevention of sporadic colorectal adenomas |journal=N Engl J Med |volume=355 |issue=9 |pages=873–84 |year=2006 |pmid=16943400 |doi=10.1056/NEJMoa061355}}</ref>
 
and in the general population.<ref>{{cite journal |author=Baron J, Sandler R, Bresalier R, Quan H, Riddell R, Lanas A, Bolognese J, Oxenius B, Horgan K, Loftus S, Morton D |title=A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas |journal=Gastroenterology |volume=131 |issue=6 |pages=1674–82 |year=2006 |pmid=17087947 |doi=10.1053/j.gastro.2006.08.079}}</ref><ref>{{cite journal |author=Bertagnolli M, Eagle C, Zauber A, Redston M, Solomon S, Kim K, Tang J, Rosenstein R, Wittes J, Corle D, Hess T, Woloj G, Boisserie F, Anderson W, Viner J, Bagheri D, Burn J, Chung D, Dewar T, Foley T, Hoffman N, Macrae F, Pruitt R, Saltzman J, Salzberg B, Sylwestrowicz T, Gordon G, Hawk E |title=Celecoxib for the prevention of sporadic colorectal adenomas |journal=N Engl J Med |volume=355 |issue=9 |pages=873–84 |year=2006 |pmid=16943400 |doi=10.1056/NEJMoa061355}}</ref>
 
In both groups, there were significant reductions in [[colon polyp]] [[incidence (epidemiology)|incidence]], but this came at the price of increased cardiovascular toxicity.
 
In both groups, there were significant reductions in [[colon polyp]] [[incidence (epidemiology)|incidence]], but this came at the price of increased cardiovascular toxicity.
  
===Genetic testing===
+
=== Genetic testing ===
 
[[Genetic testing]] for high-risk individuals is already available for certain cancer-related genetic mutations. Carriers of genetic mutations that increase risk for cancer incidence can undergo enhanced surveillance, chemoprevention, or risk-reducing surgery. Early identification of inherited genetic risk for cancer, along with cancer-preventing interventions such as surgery or enhanced surveillance, can be lifesaving for high-risk individuals.
 
[[Genetic testing]] for high-risk individuals is already available for certain cancer-related genetic mutations. Carriers of genetic mutations that increase risk for cancer incidence can undergo enhanced surveillance, chemoprevention, or risk-reducing surgery. Early identification of inherited genetic risk for cancer, along with cancer-preventing interventions such as surgery or enhanced surveillance, can be lifesaving for high-risk individuals.
  
Line 417: Line 203:
 
|}
 
|}
  
===Vaccination===
+
=== Vaccination ===
Considerable {{ww}} research effort is now devoted to the development of [[vaccine]]s to prevent infection by oncogenic infectious agents, as well as to mount an immune response against cancer-specific [[epitope]]s) and to potential venues for [[gene therapy]] for individuals with genetic mutations or polymorphisms that put them at high risk of cancer.
+
Prophylactic [[vaccine]]s have been developed to prevent infection by oncogenic infectious agents such as viruses, and therapeutic vaccines are in development to stimulate an immune response against cancer-specific [[epitope]]s.<ref name=vacc_facts_nci>{{cite web | url=http://www.cancer.gov/cancertopics/factsheet/cancervaccine | title=Cancer Vaccine Fact Sheet | publisher=[[National Cancer Institute|NCI]] | date=2006-06-08 | accessdate=2008-11-15 }}</ref>
  
As reported above, a preventive [[human papillomavirus vaccine]] exists that targets certain sexually transmitted strains of [[human papillomavirus]] that are associated with the development of [[cervical cancer]] and [[genital warts]]. The only two HPV vaccines on the market as of October 2007 are [[Gardasil]] and [[Cervarix]].
+
As reported above, a preventive [[human papillomavirus vaccine]] exists that targets certain sexually transmitted strains of [[human papillomavirus]] that are associated with the development of [[cervical cancer]] and [[genital warts]]. The only two HPV vaccines on the market as of October 2007 are [[Gardasil]] and [[Cervarix]].<ref name=vacc_facts_nci/> There is also a [[hepatitis B vaccine]], which prevents infection with the hepatitis B virus, an infectious agent that can cause liver cancer.<ref name=vacc_facts_nci/> A canine melanoma vaccine has also been developed.<ref name="Liao">{{cite journal |author=Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ. |title=Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma |journal=Cancer Immun. |volume=6 |page=8 |year=2006 |pmid=16626110 |pmc=1976276}}</ref><ref>{{cite press release
 +
| title = USDA Grants Conditional Approval for First Therapeutic Vaccine to Treat Cancer
 +
| publisher = Animal Medical Centre
 +
| date = 2007-03-26
 +
| url = http://www.amcny.org/technology/melanomavaccine.aspx
 +
| accessdate = 2009-06-06
 +
}}</ref>
  
===Screening===
+
=== Screening ===
Cancer [[Screening (medicine)|screening]] is an attempt to detect unsuspected cancers in an asymptomatic population. Screening tests suitable for large numbers of healthy people must be relatively affordable, safe, noninvasive procedures with acceptably low rates of [[Type I and type II errors|false positive]] results. If signs of cancer are detected, more definitive and invasive follow up tests are performed to confirm the diagnosis.
+
{{Main|Cancer screening}}
 +
{{Unreferenced|date=May 2009}}
 +
Cancer [[screening (medicine)|screening]] is an attempt to detect unsuspected cancers in an asymptomatic population. Screening tests suitable for large numbers of healthy people must be relatively affordable, safe, noninvasive procedures with acceptably low rates of [[Type I and type II errors|false positive]] results. If signs of cancer are detected, more definitive and invasive follow up tests are performed to confirm the diagnosis.
  
 
Screening for cancer can lead to earlier diagnosis in specific cases. Early diagnosis may lead to extended life, but may also falsely prolong the lead time to death through [[lead time bias]] or [[length time bias]].
 
Screening for cancer can lead to earlier diagnosis in specific cases. Early diagnosis may lead to extended life, but may also falsely prolong the lead time to death through [[lead time bias]] or [[length time bias]].
  
A number of different screening tests have been developed for different malignancies. Breast cancer screening can be done by [[breast self-examination]], though this approach was discredited by a 2005 study in over 300,000 Chinese women. Screening for breast cancer with [[mammogram]]s has been shown to reduce the average stage of diagnosis of breast cancer in a population. Stage of diagnosis in a country has been shown to decrease within ten years of introduction of mammographic screening programs. Colorectal cancer can be detected through [[fecal occult blood test]]ing and [[colonoscopy]], which reduces both colon cancer incidence and mortality, presumably through the detection and removal of pre-malignant polyps. Similarly, cervical cytology testing (using the [[Pap smear]]) leads to the identification and excision of precancerous lesions. Over time, such testing has been followed by a dramatic reduction of [[cervical cancer]] incidence and mortality. [[Testicular self-examination]] is recommended for men beginning at the age of 15&nbsp;years to detect [[testicular cancer]]. Prostate cancer can be screened using a [[digital rectal exam]] along with [[prostate specific antigen]] (PSA) blood testing, though some authorities (such as the [[US Preventive Services Task Force]]) recommend against routinely screening all men.
+
A number of different screening tests have been developed for different malignancies. Breast cancer screening can be done by [[breast self-examination]], though this approach was discredited by a 2005 study in over 300,000 [[People's Republic of China|Chinese]] women. Screening for breast cancer with [[mammogram]]s has been shown to reduce the average stage of diagnosis of breast cancer in a population. Stage of diagnosis in a country has been shown to decrease within ten years of introduction of mammographic screening programs. Colorectal cancer can be detected through [[faecal occult blood|fecal occult blood testing]] and [[colonoscopy]], which reduces both colon cancer incidence and mortality, presumably through the detection and removal of pre-malignant polyps. Similarly, cervical cytology testing (using the [[Pap smear]]) leads to the identification and excision of precancerous lesions. Over time, such testing has been followed by a dramatic reduction of [[cervical cancer]] incidence and mortality. [[Testicular self-examination]] is recommended for men beginning at the age of 15&nbsp;years to detect [[testicular cancer]]. Prostate cancer can be screened using a [[digital rectal exam]] along with [[prostate specific antigen]] (PSA) blood testing, though some authorities (such as the [[US Preventive Services Task Force]]) recommend against routinely screening all men.
  
Screening for cancer is controversial in cases when it is not yet known if the test actually saves lives. The controversy arises when it is not clear if the benefits of screening outweigh the risks of follow-up diagnostic tests and cancer treatments. For example: when screening for [[prostate cancer]], the [[Prostate specific antigen|PSA]] test may detect small cancers that would never become life threatening, but once detected will lead to treatment. This situation, called overdiagnosis, puts men at risk for complications from unnecessary treatment such as surgery or radiation. Follow up procedures used to diagnose prostate cancer ([[prostate biopsy]]) may cause side effects, including bleeding and infection. Prostate cancer treatment may cause [[Urinary incontinence|incontinence]] (inability to control urine flow) and [[erectile dysfunction]] (erections inadequate for intercourse). Similarly, for [[breast cancer]], there have recently been criticisms that breast screening programs in some countries cause more problems than they solve. This is because screening of women in the general population will result in a large number of women with false positive results which require extensive follow-up investigations to exclude cancer, leading to having a high number-to-treat (or number-to-screen) to prevent or catch a single case of breast cancer early.
+
Screening for cancer is controversial in cases when it is not yet known if the test actually saves lives. The controversy arises when it is not clear if the benefits of screening outweigh the risks of follow-up diagnostic tests and cancer treatments. For example: when screening for [[prostate cancer]], the [[Prostate specific antigen|PSA]] test may detect small cancers that would never become life threatening, but once detected will lead to treatment. This situation, called overdiagnosis, puts men at risk for complications from unnecessary treatment such as surgery or radiation. Follow up procedures used to diagnose prostate cancer ([[prostate biopsy]]) may cause side effects, including bleeding and infection. Prostate cancer treatment may cause [[Urinary incontinence|incontinence]] (inability to control urine flow) and [[erectile dysfunction]] (erections inadequate for intercourse). Similarly, for [[breast cancer]], there have recently{{When|date=May 2010}} been criticisms that breast screening programs in some countries cause more problems than they solve. This is because screening of women in the general population will result in a large number of women with false positive results which require extensive follow-up investigations to exclude cancer, leading to having a high number-to-treat (or number-to-screen) to prevent or catch a single case of breast cancer early.
  
Cervical cancer screening via the [[Pap smear]] has the best cost-benefit profile of all the forms of cancer screening from a public health perspective as, being largely caused by a virus, it has clear risk factors (sexual contact), and the natural progression of cervical cancer is that it normally spreads slowly over a number of years therefore giving more time for the screening program to catch it early. Moreover, the test itself is easy to perform and relatively cheap.
+
Cervical cancer screening via the [[Pap smear]] has the best cost-benefit profile of all the forms of cancer screening from a public health perspective as, largely caused by a virus, it has clear risk factors (sexual contact), and the natural progression of cervical cancer is that it normally spreads slowly over a number of years therefore giving more time for the screening program to catch it early. Moreover, the test is easy to perform and relatively cheap.
  
 
For these reasons, it is important that the benefits and risks of diagnostic procedures and treatment be taken into account when considering whether to undertake cancer screening.
 
For these reasons, it is important that the benefits and risks of diagnostic procedures and treatment be taken into account when considering whether to undertake cancer screening.
  
Use of [[medical imaging]] to search for cancer in people without clear symptoms is similarly marred with problems. There is a significant risk of detection of what has been recently called an ''[[incidentaloma]]'' - a benign lesion that may be interpreted as a malignancy and be subjected to potentially dangerous investigations. Recent studies of [[CT scan]]-based screening for [[lung cancer]] in smokers have had equivocal results, and systematic screening is not recommended as of July 2007. [[Randomized clinical trials]] of plain-film [[chest X-rays]] to screen for lung cancer in smokers have shown no benefit for this approach.
+
Use of [[medical imaging]] to search for cancer in people without clear symptoms is similarly marred with problems. There is a significant risk of detection of what has been recently{{When|date=May 2010}} called an ''[[incidentaloma]]'' - a benign lesion that may be interpreted as a malignancy and be subjected to potentially dangerous investigations. Recent{{When|date=May 2010}} studies of [[CT scan]]-based screening for [[lung cancer]] in smokers have had equivocal results, and systematic screening is not recommended as of July 2007. [[Randomized clinical trials]] of plain-film [[chest X-rays]] to screen for lung cancer in smokers have shown no benefit for this approach.
  
 
[[Canine cancer detection]] has shown promise, but is still in the early stages of research.
 
[[Canine cancer detection]] has shown promise, but is still in the early stages of research.
  
== Epidemiology ==
+
== Diagnosis ==
[[Image:Cancer rate.gif|thumb|right|The risk of cancer rises with age]]
+
[[Image:Thorax pa peripheres Bronchialcarcinom li OF markiert.jpg|thumb|Chest x-ray showing lung cancer in the left lung.]]
 +
 
 +
Most cancers are initially recognized either because signs or symptoms appear or through screening. Neither of these lead to a definitive diagnosis, which usually requires the opinion of a [[anatomical pathology|pathologist]], a type of physician (medical doctor) who specializes in the diagnosis of cancer and other diseases.  People with suspected cancer are investigated with [[medical test]]s. These commonly include [[blood test]]s, [[X-ray]]s, [[CT scan]]s and [[endoscopy]].
 +
 
 +
=== Pathology ===
 +
A cancer may be suspected for a variety of reasons, but the definitive diagnosis of most malignancies must be confirmed by [[histology|histological]] examination of the cancerous cells by a [[anatomical pathology|pathologist]]. Tissue can be obtained from a [[biopsy]] or [[surgery]]. Many biopsies (such as those of the skin, breast or liver) can be done in a doctor's office. Biopsies of other organs are performed under [[anesthesia]] and require [[surgery]] in an [[operating room]].
 +
 
 +
The tissue [[medical diagnosis|diagnosis]] given by the pathologist indicates the type of cell that is proliferating, its [[histological grade]], genetic abnormalities, and other features of the tumor. Together, this information is useful to evaluate the [[prognosis]] of the patient and to choose the best treatment. [[Cytogenetics]] and [[immunohistochemistry]] are other types of testing that the pathologist may perform on the tissue specimen. These tests may provide information about the molecular changes (such as [[mutation]]s, [[fusion gene]]s, and numerical [[chromosome]] changes) that has happened in the cancer cells, and may thus also indicate the future behavior of the cancer (prognosis) and best treatment.
 +
 
 +
<gallery>
 +
Image:Breast cancer gross appearance.jpg|Typical macroscopic appearance of cancer. This invasive [[ductal carcinoma]] of the breast (pale area at the center) shows an oval tumor surrounded by spikes of whitish scar tissue in the surrounding yellow fatty tissue. The silhouette vaguely resembles a crab.
 +
Image:Colon cancer 2.jpg|An invasive [[colorectal carcinoma]] (top center) in a [[colectomy]] specimen.
 +
Image:Lung cancer.jpg|A [[squamous cell carcinoma]] (the whitish tumor) near the [[bronchi]] in a lung specimen.
 +
Image:BreastCancer.jpg|A large invasive [[Mammary ductal carcinoma|ductal carcinoma]] in a [[mastectomy]] specimen.
 +
</gallery>
 +
 
 +
== Management ==
 +
{{Main|Management of cancer}}
 +
 
 +
Many management options for cancer exist including: [[chemotherapy]], [[radiation therapy]], [[surgery]], [[immunotherapy]], [[monoclonal antibody therapy]] and other methods. Which are used depends upon the location and grade of the tumor and the [[Cancer staging|stage]] of the disease, as well as the general state of a person's health. [[Experimental cancer treatment]]s are also under development.
 +
 
 +
Complete removal of the cancer without damage to the rest of the body is the goal of treatment. Sometimes this can be accomplished by surgery, but the propensity of cancers to invade adjacent tissue or to spread to distant sites by microscopic metastasis often limits its effectiveness. Surgery often required the removal of a wide [[surgical margin]] or a [[free margin]].  The width of the free margin depends on the type of the cancer, the method of removal ([[CCPDMA]], [[Mohs surgery]], POMA, etc.).  The margin can be as little as 1&nbsp;mm for [[basal cell cancer]] using [[CCPDMA]] or [[Mohs surgery]], to several centimeters for aggressive cancers.  The effectiveness of chemotherapy is often limited by toxicity to other tissues in the body. Radiation can also cause damage to normal tissue.
 +
 
 +
Because "cancer" refers to a class of diseases,<ref name=WhatIsCancerNCI>{{cite web
 +
| url=http://www.cancer.gov/cancertopics/what-is-cancer
 +
| title=What Is Cancer?
 +
| publisher=[[National Cancer Institute]]
 +
| accessdate=2009-08-17
 +
}}</ref><ref>{{cite web
 +
| url=http://www.atsdr.cdc.gov/COM/cancer-fs.html
 +
| title=Cancer Fact Sheet
 +
| publisher=Agency for Toxic Substances &amp; Disease Registry
 +
| date=2002-08-30
 +
| accessdate=2009-08-17
 +
}}</ref>
 +
it is unlikely that there will ever be a single "[[cure for cancer]]" any more than there will be a single treatment for all [[infectious disease]]s.<ref>{{cite web
 +
| url=http://www.livescience.com/health/060919_bad_cancer.html
 +
| title=Exciting New Cancer Treatments Emerge Amid Persistent Myths
 +
| last=Wanjek
 +
| first= Christopher
 +
| date=2006-09-16
 +
| accessdate=2009-08-17
 +
}}</ref>
 +
[[Angiogenesis inhibitors]] were once thought to have potential as a "[[silver bullet]]" treatment applicable to many types of cancer, but this has not been the case in practice.<ref>{{cite journal
 +
| url=http://www.nature.com/news/2009/090408/full/458686b.html
 +
| title=Cutting off cancer's supply lines
 +
| last=Hayden
 +
| first=Erika C.
 +
| date=2009-04-08
 +
| journal=Nature
 +
| volume=458
 +
| pages=686–687
 +
| doi=10.1038/458686b
 +
| pmid=19360048
 +
| issue=7239
 +
| format={{Dead link|date=January 2010}}
 +
}}</ref>
 +
 
 +
== Prognosis ==
 +
{{See also|Cancer survivor}}
 +
Cancer has a reputation as a deadly disease. While this certainly applies to certain particular types, the truths behind the historical connotations of cancer are increasingly overturned by advances in medical care. Some types of cancer have a prognosis that is substantially better than nonmalignant diseases such as [[heart failure]] and [[stroke]].
 +
 
 +
Progressive and disseminated malignant disease has a substantial impact on a cancer patient's quality of life, and many cancer treatments (such as [[chemotherapy]]) may have severe side-effects. In the advanced stages of cancer, many patients need extensive care, affecting family members and friends. [[Palliative care]] solutions may include permanent or "respite" hospice nursing.
  
Cancer [[epidemiology]] is the study of the incidence of cancer as a way to infer possible trends and causes. The first such cause of cancer was identified by British surgeon [[Percivall Pott]], who discovered in 1775 that cancer of the [[scrotum]] was a common disease among [[chimney sweep]]s. The work of other individual physicians led to various insights, but when physicians started working together they could make firmer conclusions.
+
=== Emotional impact ===
 +
Many local organizations offer a variety of practical and support services to people with cancer. Support can take the form of [[Cancer support group|support groups]], [[counseling]], advice, financial assistance, transportation to and from treatment, films or information about cancer. Neighborhood organizations, local health care providers, or area hospitals may have resources or services available.
  
A founding paper of this discipline was the work of [[Janet Lane-Claypon]], who published a comparative study in 1926 of 500 breast cancer cases and 500 control patients of the same background and lifestyle for the British Ministry of Health. Her ground-breaking work on cancer epidemiology was carried on by [[Richard Doll]] and [[Austin Bradford Hill]], who published "[[Lung Cancer]] and Other Causes of Death In Relation to [[Smoking]]. A Second Report on the Mortality of British Doctors" followed in 1956 (otherwise known as the [[British doctors study]]). Richard Doll left the [[London]] Medical Research Center (MRC), to start the [[Oxford]] unit for Cancer epidemiology in 1968. With the use of [[computer]]s, the unit was the first to compile large amounts of cancer data. Modern epidemiological methods are closely linked to current concepts of disease and [[public health]] policy. Over the past 50&nbsp;years, great efforts have been spent on gathering data across medical practise, hospital, provincial, state, and even country boundaries, as a way to study the interdependence of environmental and cultural factors on cancer incidence.
+
Counseling can provide emotional support to cancer patients and help them better understand their illness. Different types of counseling include individual, group, family, peer counseling, bereavement, patient-to-patient, and sexuality.
  
Cancer epidemiology must contend with problems of [[lead time bias]] and [[length bias|length time bias]]. Lead time bias is the concept that early diagnosis may artificially inflate the survival statistics of a cancer, without really improving the natural history of the disease. Length bias is the concept that slower growing, more indolent tumors are more likely to be diagnosed by screening tests, but improvements in diagnosing more cases of indolent cancer may not translate into better patient outcomes after the implementation of screening programs. A similar epidemiological concern is [[overdiagnosis]], the tendency of screening tests to diagnose diseases that may not actually impact the patient's longevity. This problem especially applies to [[prostate cancer]] and [[PSA screening]].<ref name="pmid15283896">{{cite journal |author=Brawley OW |title=Prostate cancer screening: clinical applications and challenges |journal=Urol. Oncol. |volume=22 |issue=4 |pages=353–7 |year=2004 |pmid=15283896 |doi=10.1016/j.urolonc.2004.04.014}}</ref>
+
Many governmental and charitable organizations have been established to help patients cope with cancer. These organizations are often involved in cancer prevention, cancer treatment, and cancer research.
  
Some cancer researchers have argued that negative cancer clinical trials lack sufficient [[statistical power]] to discover a benefit to treatment. This may be due to fewer patients enrolled in the study than originally planned.<ref name="pmid17687153">{{cite journal |author=Bedard PL, Krzyzanowska MK, Pintilie M, Tannock IF |title=Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings |journal=J. Clin. Oncol. |volume=25 |issue=23 |pages=3482–7 |year=2007 |pmid=17687153 |doi=10.1200/JCO.2007.11.3670}}</ref>
+
== Epidemiology ==
 +
{{Main|Epidemiology of cancer}}
 +
[[Image:Malignant neoplasms world map - Death - WHO2004.svg|thumb|Death rate from malignant cancer per 100,000&nbsp;inhabitants in 2004.<ref>{{cite web |url=http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/index.html |title=WHO Disease and injury country estimates |year=2009 |work=World Health Organization |accessdate=Nov. 11, 2009}}</ref><div class="references-small" style="-moz-column-count:3; column-count:3;">
 +
{{legend|#b3b3b3|no data}}
 +
{{legend|#ffff65|≤&nbsp;55}}
 +
{{legend|#fff200|55-80}}
 +
{{legend|#ffdc00|80-105}}
 +
{{legend|#ffc600|105-130}}
 +
{{legend|#ffb000|130-155}}
 +
{{legend|#ff9a00|155-180}}
 +
{{legend|#ff8400|180-205}}
 +
{{legend|#ff6e00|205-230}}
 +
{{legend|#ff5800|230-255}}
 +
{{legend|#ff4200|255-280}}
 +
{{legend|#ff2c00|280-305}}
 +
{{legend|#cb0000|≥&nbsp;305}}
 +
</div>]]
 +
{{As of|2004}}, worldwide cancer caused 13% of all deaths (7.4 million). The leading causes were: [[lung cancer]] (1.3 million deaths/year), [[stomach cancer]] (803,000 deaths), [[colorectal cancer]] (639,000 deaths), [[liver cancer]] (610,000 deaths), and [[breast cancer]] (519,000 deaths).<ref>{{cite web |url=http://www.who.int/nmh/publications/fact_sheet_cancers_en.pdf |title=Cancer |format=PDF |work=World Health Organization |accessdate=}}</ref>  Greater than 30% of cancer is preventable via avoiding risk factors including: [[tobacco]], [[overweight]] or [[obesity]], low [[fruit]] and [[vegetable]] intake, [[physical inactivity]], [[alcohol]], [[sexually transmitted infection]]s, and [[air pollution]].<ref name="Cancer Cancer"/>
  
State and regional [[cancer registry|cancer registries]] are organizations that abstract clinical data about cancer from patient medical records. These institutions provide information to state and national public health groups to help track trends in cancer diagnosis and treatment. One of the largest and most important [[cancer registry|cancer registries]] is [[SEER]], administered by the [[US Federal government]].<ref>{{cite web |url=http://seer.cancer.gov/ |title=SEER Surveillance Epidemiology and End Results |accessdate=2007-11-02 |work=}}</ref> Health information privacy concerns have led to the restricted use of [[cancer registry]] data in the [[United States Department of Veterans Affairs]]<ref name="lancetva">Furlow, B, [http://www.thelancet.com/journals/lanonc/article/PIIS1470204507702589/fulltext Accuracy of US cancer surveillance under threat] ''Lancet Oncology'' 2007; 8:762-763. Retrieved [[2007-11-01]].</ref><ref name= "mpva">[http://www.medpagetoday.com/InfectiousDisease/PublicHealth/tb/6563 VA Cancer Data Blockade May Imperil Surveillance] ([[31 August]] [[2007]]). ''Medpage Today''. Retrieved [[2007-11-01]]. </ref><ref name="nytva">[http://www.nytimes.com/2007/10/10/health/10cancer.html States and V.A. at Odds on Cancer Data] ([[10 October]] [[2007]]). ''New York Times''. Retrieved [[2007-11-01]].</ref> and other institutions.<ref name="iomhip">[http://www.iom.edu/Object.File/Master/43/927/HIPAA%20IOM%20meeting%20607r.Howe.pdf Negative Impact of HIPAA on Population-Based Cancer Registry Research: Update of a Brief Survey] ([[14 June]] [[2007]]). ''IOM Presentation''. Retrieved [[2007-11-01]].</ref>
+
In the United States, cancer is responsible for 25% of all deaths with 30% of these from lung cancer. The most commonly occurring cancer in men is [[prostate cancer]] (about 25% of new cases) and in women is [[breast cancer]] (also about 25%). Cancer can occur in children and adolescents, but it is uncommon (about 150 cases per million in the U.S.), with [[leukemia]] the most common.<ref name="Jemal"/> In the first year of life the [[incidence (epidemiology)|incidence]] is about 230 cases per million in the U.S., with the most common being [[neuroblastoma]].<ref>{{cite book |editor= Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds) |year=1999 |title= Cancer Incidence and Survival among Children and Adolescents, United States SEER program 1975–1995 |publisher= National Cancer Institute, SEER Program |version= NIH Pub. No 99-4649 |location= Bethesda, MD |chapterurl=http://seer.cancer.gov/publications/childhood/infant.pdf |author= Gurney JG, Smith MA, Ross JA |chapter=Cancer among infants |pages=149–56}}</ref>
  
In some Western countries, such as the USA,<ref name="CACancerJClin2005-Jemal" /> and the UK<ref name="BBC2000-news">
+
In the developed world, one in three people will develop cancer during their lifetimes.  If ''all'' cancer patients survived and cancer occurred ''randomly'', the lifetime odds of developing an second primary cancer would be one in nine.<ref name="isbn1-55009-213-8" /> However, cancer survivors have an increased risk of developing a second primary cancer, and the odds are about two in nine.<ref name="isbn1-55009-213-8" /> About half of these second primaries can be attributed to the normal one-in-nine risk associated with random chance.<ref name="isbn1-55009-213-8" /> The increased risk is believed to be primarily due to the same risk factors that produced the first cancer, such as the person's genetic profile, alcohol and tobacco use, obesity, and environmental exposures, and partly due, to the treatment for the first cancer, which typically includes mutagenic chemotherapeutic drugs or radiation.<ref name="isbn1-55009-213-8" />  Cancer survivors may also be more likely to comply with recommended screening, and thus may be more likely than average to detect cancers.<ref name="isbn1-55009-213-8">{{cite book
[http://news.bbc.co.uk/1/hi/health/1015657.stm Cancer: Number one killer] ([[9 November]] [[2000]]). ''BBC News online''. Retrieved [[2005-01-29]].</ref> cancer is overtaking [[cardiovascular disease]] as the leading cause of death. In many [[Third World]] countries cancer incidence (insofar as this can be measured) appears much lower, most likely because of the higher death rates due to infectious disease or injury. With the increased control over [[malaria]] and [[tuberculosis]] in some Third World countries, incidence of cancer is expected to rise; this is termed the epidemiologic transition in [[epidemiology|epidemiological]] terminology.
+
|editor=Frei, Emil; Kufe, Donald W.; Holland, James F.
 +
|author=Rheingold, Susan; Neugut, Alfred; Meadows, Anna
 +
|title=Cancer medicine 6
 +
|publisher=BC Decker
 +
|location=Hamilton, Ont
 +
|year=2003
 +
|page=2399
 +
|isbn=1-55009-213-8
 +
|chapterurl=http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=cmed.section.41087
 +
|chapter=156: Secondary Cancers: Incidence, Risk Factors, and Management
 +
|accessdate=05 November 2009
 +
}}</ref>
  
Cancer epidemiology closely mirrors risk factor spread in various countries. [[Hepatocellular carcinoma]] ([[liver]] cancer) is rare in the West but is the main cancer in [[China]] and neighbouring countries, most likely due to the [[endemic (epidemiology)|endemic]] presence of [[hepatitis B]] and [[aflatoxin]] in that population. Similarly, with [[tobacco smoking]] becoming more common in various Third World countries, [[lung]] cancer incidence has increased in a parallel fashion.
+
<gallery widths="150px" heights="70px">
 +
File:Most common cancers - male, by occurence.png|Most common cancers in males, by occurrence<ref name=Jemal>{{cite journal |author= Jemal A, Siegel R, Ward E ''et al.'' |title= Cancer statistics, 2008 |journal= CA Cancer J Clin |year=2008 |pages=71–96 |volume=58 |issue=2 |url=http://caonline.amcancersoc.org/cgi/content/full/58/2/71 |pmid=18287387 |doi=10.3322/CA.2007.0010}}</ref>
 +
File:Most common cancers - female, by occurence.png|in females, by occurrence<ref name=Jemal/>
 +
File:Most common cancers - male, by mortality.png|in males, by mortality<ref name=Jemal/>
 +
File:Most common cancers - female, by mortality.png|in females, by mortality<ref name=Jemal/>
 +
</gallery>
  
 
== History ==
 
== History ==
[[Image:Breast cancer gross appearance.jpg|thumb|150px|right|Typical macroscopic appearance of cancer. This invasive [[ductal carcinoma]] of the breast (pale area at the center) shows an oval tumor surrounded by spikes of whitish scar tissue in the surrounding yellow fatty tissue. The silhouette vaguely resembles a crab.]]
+
Today, the Greek term [[carcinoma]] is the medical term for a malignant tumor derived from [[epithelium|epithelial]] cells. It is [[Aulus Cornelius Celsus|Celsus]] who translated ''carcinos'' into the [[Latin]] ''cancer'', also meaning crab. [[Galen]] used "''oncos''" to describe ''all'' tumours, the root for the modern word [[oncology]].<ref name="Galen">{{cite journal |author=Karpozilos A, Pavlidis N |title=The treatment of cancer in Greek antiquity |journal=European Journal of Cancer |volume=40 |issue=14 |pages=2033–40 |year=2004 |pmid=15341975 |doi=10.1016/j.ejca.2004.04.036}}</ref>
  
Today, the Greek term [[carcinoma]] is the medical term for a malignant tumor derived from [[epithelium|epithelial]] cells. It is [[Aulus Cornelius Celsus|Celsus]] who translated ''carcinos'' into the [[Latin]] ''cancer'', also meaning crab.
+
[[Hippocrates]] described several kinds of cancers. He called benign tumours ''oncos'', [[Greek language|Greek]] for swelling, and malignant tumours ''carcinos'', Greek for [[crab]] or [[crayfish]]. This name comes from the appearance of the cut surface of a solid malignant tumour, with "the veins stretched on all sides as the animal the crab has its feet, whence it derives its name".<ref>{{cite web
[[Galen]] used "''oncos''" to describe ''all'' tumours, the root for the modern word [[oncology]].<ref name="Galen">{{cite journal |author=Karpozilos A, Pavlidis N |title=The treatment of cancer in Greek antiquity |journal=Eur. J. Cancer |volume=40 |issue=14 |pages=2033–40 |year=2004 |pmid=15341975 |doi=10.1016/j.ejca.2004.04.036}}</ref>
+
| first      = Ralph W.
 +
| last        = Moss
 +
| title       = Galen on Cancer
 +
| url        = http://www.cancerdecisions.com/speeches/galen1989.html
 +
| publisher  = CancerDecisions
 +
| year       = 2004
 +
}}
 +
</ref> He later added the suffix ''-oma'', Greek for swelling, giving the name ''carcinoma''. Since it was against Greek tradition to open the body, Hippocrates only described and made drawings of outwardly visible tumors on the skin, nose, and breasts. Treatment was based on the [[humorism|humor theory]] of four bodily fluids (black and yellow bile, blood, and phlegm). According to the patient's humor, treatment consisted of diet, blood-letting, and/or laxatives. Through the centuries it was discovered that cancer could occur anywhere in the body, but humor-theory based treatment remained popular until the 19th century with the discovery of [[cell (biology)|cells]].
  
[[Hippocrates]] described several kinds of cancers. He called benign tumours ''oncos'', [[Greek language|Greek]] for swelling, and malignant tumours ''carcinos'', Greek for [[crab]] or [[crayfish]]. This name comes from the appearance of the cut surface of a solid malignant tumour, with ''the veins stretched on all sides as the animal the crab has its feet, whence it derives its name''<ref>Paul of Aegina, 7th Century AD, quoted in Shimkin, op.cit., p. 35., [http://www.ralphmoss.com/html/galen.shtml]</ref> (see picture). He later added the suffix ''-oma'', Greek for swelling, giving the name ''carcinoma''. Since it was against Greek tradition to open the body, Hippocrates only described and made drawings of outwardly visible tumors on the skin, nose, and breasts. Treatment was based on the [[Humorism|humor theory]] of four bodily fluids (black and yellow bile, blood, and phlegm). According to the patient's humor, treatment consisted of diet, blood-letting, and/or laxatives. Through the centuries it was discovered that cancer could occur anywhere in the body, but humor-theory based treatment remained popular until the 19th century with the discovery of [[cell (biology)|cells]].
+
The oldest known description and [[surgery|surgical]] treatment of cancer was discovered in [[Egypt]] and dates back to approximately 1600 B.C.E. The [[Papyrus]] describes 8 cases of ulcers of the breast that were treated by cauterization, with a tool called "the fire drill." The writing says about the disease, "There is no treatment."<ref name=CancerOrgHistory>{{cite web
 +
| title      = The History of Cancer
 +
| url        = http://www.cancer.org/docroot/CRI/content/CRI_2_6x_the_history_of_cancer_72.asp
 +
| publisher  = American Cancer Society
 +
| year        = 2009
 +
| month      = September
 +
}}
 +
</ref>
  
Our oldest description and [[Surgery|surgical]] treatment of cancer was discovered in Egypt and dates back to approximately 1600 B.C.E. The [[Papyrus]] describes 8 cases of ulcers of the breast that were treated by cauterization, with a tool called "the fire drill." The writing says about the disease, "There is no treatment."<ref name=CancerOrgHistory>American Cancer Society, [http://www.cancer.org/docroot/CRI/content/CRI_2_6x_the_history_of_cancer_72.asp], ''History of Cancer''</ref>
+
Another very early [[surgery|surgical]] treatment for cancer was described in the 1020s by [[Avicenna]] (Ibn Sina) in ''[[The Canon of Medicine]]''. He stated that the [[excision]] should be radical and that all diseased [[tissue (biology)|tissue]] should be removed, which included the use of [[amputation]] or the removal of [[vein]]s running in the direction of the [[tumor]]. He also recommended the use of [[cauterization]] for the area treated if necessary.<ref name=Patricia>Patricia Skinner (2001), [http://findarticles.com/p/articles/mi_g2603/is_0007/ai_2603000716 Unani-tibbi], ''Encyclopedia of Alternative Medicine''</ref>
 
 
Another very early [[Surgery|surgical]] treatment for cancer was described in the 1020s by [[Avicenna]] (Ibn Sina) in ''[[The Canon of Medicine]]''. He stated that the [[excision]] should be radical and that all diseased [[Tissue (biology)|tissue]] should be removed, which included the use of [[amputation]] or the removal of [[vein]]s running in the direction of the [[tumor]]. He also recommended the use of [[cauterization]] for the area being treated if necessary.<ref name=Patricia>Patricia Skinner (2001), [http://findarticles.com/p/articles/mi_g2603/is_0007/ai_2603000716 Unani-tibbi], ''Encyclopedia of Alternative Medicine''</ref>
 
  
 
In the 16th and 17th centuries, it became more acceptable for doctors to [[autopsy|dissect bodies]] to discover the cause of death. The German professor [[Wilhelm Fabry]] believed that breast cancer was caused by a milk clot in a mammary duct. The Dutch professor [[Francois de la Boe Sylvius]], a follower of [[Descartes]], believed that all disease was the outcome of chemical processes, and that acidic [[lymph]] fluid was the cause of cancer. His contemporary [[Nicolaes Tulp]] believed that cancer was a poison that slowly spreads, and concluded that it was [[infectious disease|contagious]].<ref name="Marilyn Yalom">
 
In the 16th and 17th centuries, it became more acceptable for doctors to [[autopsy|dissect bodies]] to discover the cause of death. The German professor [[Wilhelm Fabry]] believed that breast cancer was caused by a milk clot in a mammary duct. The Dutch professor [[Francois de la Boe Sylvius]], a follower of [[Descartes]], believed that all disease was the outcome of chemical processes, and that acidic [[lymph]] fluid was the cause of cancer. His contemporary [[Nicolaes Tulp]] believed that cancer was a poison that slowly spreads, and concluded that it was [[infectious disease|contagious]].<ref name="Marilyn Yalom">
 
Marilyn Yalom "A history of the breast" 1997. New York: Alfred A. Knopf. ISBN 0-679-43459-3</ref>
 
Marilyn Yalom "A history of the breast" 1997. New York: Alfred A. Knopf. ISBN 0-679-43459-3</ref>
  
With the widespread use of the microscope in the 18th century, it was discovered that the 'cancer poison' spread from the primary tumor through the lymph nodes to other sites ("[[metastasis]]"). This view of the disease was first formulated by the English surgeon [[Campbell De Morgan]] between 1871 and 1874.<ref>{{cite journal |author=Grange JM, Stanford JL, Stanford CA |title=Campbell De Morgan's 'Observations on cancer', and their relevance today |journal=Journal of the Royal Society of Medicine |volume=95 |issue=6 |pages=296&ndash;9 |year=2002 |url=http://www.jrsm.org/cgi/content/full/95/6/296|pmid=12042378|doi=10.1258/jrsm.95.6.296}}</ref> The use of [[surgery]] to treat cancer had poor results due to problems with hygiene. The renowned Scottish surgeon [[Alexander Monro]] saw only 2 breast tumor patients out of 60 surviving surgery for two years. In the 19th century, [[asepsis]] improved surgical hygiene and as the survival statistics went up, surgical removal of the tumor became the primary treatment for cancer. With the exception of [[William Coley]] who in the late 1800s felt that the rate of cure after surgery had been higher ''before'' asepsis (and who injected bacteria into tumors with mixed results), cancer treatment became dependent on the individual art of the surgeon at removing a tumor. During the same period, the idea that the body was made up of various [[tissue (biology)|tissues]], that in turn were made up of millions of cells, laid rest the humor-theories about chemical imbalances in the body. The age of [[cellular pathology]] was born.
+
The first cause of cancer was identified by British surgeon [[Percivall Pott]], who discovered in 1775 that cancer of the [[scrotum]] was a common disease among [[chimney sweep]]s. The work of other individual physicians led to various insights, but when physicians started working together they could make firmer conclusions.
  
When [[Marie Curie]] and [[Pierre Curie]] discovered [[radiation]] at the end of the 19th century, they stumbled upon the first effective non-surgical cancer treatment. With radiation came also the first signs of multi-disciplinary approaches to cancer treatment. The surgeon was no longer operating in isolation, but worked together with hospital radiologists to help patients. The complications in communication this brought, along with the necessity of the patient's treatment in a hospital facility rather than at home, also created a parallel process of compiling patient data into hospital files, which in turn led to the first statistical patient studies.
+
With the widespread use of the microscope in the 18th century, it was discovered that the 'cancer poison' spread from the primary tumor through the lymph nodes to other sites ("[[metastasis]]"). This view of the disease was first formulated by the English surgeon [[Campbell De Morgan]] between 1871 and 1874.<ref>{{cite journal |author=Grange JM, Stanford JL, Stanford CA |title=Campbell De Morgan's 'Observations on cancer', and their relevance today |journal=Journal of the Royal Society of Medicine |volume=95 |issue=6 |pages=296–9 |year=2002 |url=http://www.jrsm.org/cgi/content/full/95/6/296|pmid=12042378|doi=10.1258/jrsm.95.6.296 |pmc=1279913}}</ref> The use of [[surgery]] to treat cancer had poor results due to problems with hygiene. The renowned Scottish surgeon [[Alexander Monro]] saw only 2 breast tumor patients out of 60 surviving surgery for two years. In the 19th century, [[asepsis]] improved surgical hygiene and as the [[cancer survivor|survival]] statistics went up, surgical removal of the tumor became the primary treatment for cancer. With the exception of [[William Coley]] who in the late 1800s felt that the rate of cure after surgery had been higher ''before'' asepsis (and who injected bacteria into tumors with mixed results), cancer treatment became dependent on the individual art of the surgeon at removing a tumor. During the same period, the idea that the body was made up of various [[tissue (biology)|tissues]], that in turn were made up of millions of cells, laid rest the humor-theories about chemical imbalances in the body. The age of [[cellular pathology]] was born.
  
Cancer patient treatment and studies were restricted to individual physicians' practices until [[World War II]], when medical research centers discovered that there were large international differences in disease incidence. This insight drove national public health bodies to make it possible to compile health data across practises and hospitals, a process that many countries do today. The Japanese medical community observed that the bone marrow of bomb victims in [[Hiroshima]] and [[Nagasaki, Nagasaki|Nagasaki]] was completely destroyed. They concluded that diseased [[bone marrow]] could also be destroyed with radiation, and this led to the discovery of bone marrow transplants for [[leukemia]]. Since WWII, trends in [[cancer treatment]] are to improve on a micro-level the existing treatment methods, standardize them, and globalize them as a way to find cures through [[epidemiology]] and international partnerships.
+
The genetic basis of cancer was recognised in 1902 by the German zoologist [[Theodor Boveri]], professor of [[zoology]] at [[Munich]] and later in [[Würzburg]].<ref>
 +
{{Cite journal
 +
| title = Concerning The Origin of Malignant Tumours
 +
| first =  Theodor
 +
| last = Boveri
 +
| year = 2008
 +
|journal = [[Journal of Cell Science]]
 +
|volume = 121
 +
|issue = Supplement 1
 +
| pages = 1–84
 +
| url = http://jcs.biologists.org/cgi/content/full/121/Supplement_1/1 | doi = 10.1242/jcs.025742 | pmid = 18089652}}
 +
</ref> He discovered a method to generate cells with multiple copies of the [[centrosome]], a structure he discovered and named. He postulated that [[chromosome]]s were distinct and transmitted different inheritance factors. He suggested that mutations of the chromosomes could generate a cell with unlimited growth potential which could be passed onto its descendants. He proposed the existence of cell cycle check points, [[tumour suppressor gene]]s and [[oncogene]]s. He speculated that cancers might be caused or promoted by radiation, physical or chemical insults or by pathogenic microorganisms.
  
==Research==
+
When [[Marie Curie]] and [[Pierre Curie]] discovered [[radiation]] at the end of the 19th century, they stumbled upon the first effective non-surgical cancer treatment. With radiation also came the first signs of multi-disciplinary approaches to cancer treatment. The surgeon was no longer operating in isolation, but worked together with hospital radiologists to help patients. The complications in communication this brought, along with the necessity of the patient's treatment in a hospital facility rather than at home, also created a parallel process of compiling patient data into hospital files, which in turn led to the first statistical patient studies.
{{main|Cancer research}}
 
  
Cancer research is the intense scientific effort to understand disease processes and discover possible therapies. The improved understanding of [[molecular biology]] and [[cellular biology]] due to cancer research has led to a number of new, effective treatments for cancer since President Nixon declared "War on Cancer" in 1971.
+
A founding paper of cancer epidemiology was the work of [[Janet Lane-Claypon]], who published a comparative study in 1926 of 500 breast cancer cases and 500 control patients of the same background and lifestyle for the British Ministry of Health. Her ground-breaking work on cancer epidemiology was carried on by [[Richard Doll]] and [[Austin Bradford Hill]], who published "[[Lung Cancer]] and Other Causes of Death In Relation to [[Smoking]]. A Second Report on the Mortality of British Doctors" followed in 1956 (otherwise known as the [[British doctors study]]). Richard Doll left the [[London]] Medical Research Center (MRC), to start the [[Oxford]] unit for Cancer epidemiology in 1968. With the use of [[computer]]s, the unit was the first to compile large amounts of cancer data. Modern epidemiological methods are closely linked to current concepts of disease and [[public health]] policy. Over the past 50&nbsp;years, great efforts have been spent on gathering data across medical practise, hospital, provincial, state, and even country boundaries to study the interdependence of environmental and cultural factors on cancer incidence.
  
==See also==
+
Cancer patient treatment and studies were restricted to individual physicians' practices until [[World War II]], when medical research centers discovered that there were large international differences in disease incidence. This insight drove national public health bodies to make it possible to compile health data across practises and hospitals, a process that many countries do today. The Japanese medical community observed that the bone marrow of victims of the [[atomic bombings of Hiroshima and Nagasaki]] was completely destroyed. They concluded that diseased [[bone marrow]] could also be destroyed with radiation, and this led to the discovery of bone marrow transplants for [[leukemia]]. Since World War II, trends in cancer treatment are to improve on a micro-level the existing treatment methods, standardize them, and globalize them to find cures through [[epidemiology]] and international partnerships.
* [[List of cancer types]]
+
 
* [[List of oncology-related terms]]
+
== Research==
* [[American Association for Cancer Research]] (AACR)
+
{{Main|Cancer research}}
* [[American Cancer Society]] (ACS)
+
 
* [[American Society of Clinical Oncology]] (ASCO)
+
Cancer research is the intense scientific effort to understand disease processes and discover possible therapies. The improved understanding of [[molecular biology]] and [[cellular biology]] due to cancer research has led to a number of new, effective treatments for cancer since President Nixon declared "[[War on Cancer]]" in 1971. Since 1971 the [[United States]] has invested over $200 billion on cancer research; that total includes money invested by public and private sectors and foundations.<ref>{{cite web |author=Sharon Begley | url=http://www.newsweek.com/id/157548/page/2 |title=Rethinking the War on Cancer  |date=2008-09-16 | work=Newsweek |accessdate=2008-09-08}}</ref> Despite this substantial investment, the country has seen a five percent decrease in the cancer death rate (adjusting for size and age of the population) between 1950 and 2005.<ref>{{cite news|url=http://www.nytimes.com/2009/04/24/health/policy/24cancer.html|title=Advances Elusive in the Drive to Cure Cancer |last=Kolata|first=Gina|date=April 23, 2009 |publisher=The New York Times|accessdate=2009-05-05}}</ref>
* [[European Organisation for Research and Treatment of Cancer]] (EORTC)
+
 
* [[National Cancer Institute]] (NCI)
+
Leading cancer research organizations and projects include the [[American Association for Cancer Research]], the [[American Cancer Society]] (ACS), the [[American Society of Clinical Oncology]], the [[European Organisation for Research and Treatment of Cancer]], the [[National Cancer Institute]], the [[National Comprehensive Cancer Network]], and [[The Cancer Genome Atlas]] project at the NCI.
* [[National Comprehensive Cancer Network]] (NCCN)
+
== Glossary ==
* [[Oncology]]
+
{{further|[[List of oncology-related terms]]}}
 +
 
 +
The following closely related terms may be used to designate abnormal growths:
 +
* '''[[Tumor]] or tumour:''' originally, it meant any abnormal swelling, lump or mass. In current English, however, the word tumor has become synonymous with neoplasm, specifically solid neoplasm. Note that some neoplasms, such as [[leukemia]], do not form tumors.
 +
* '''[[Neoplasia|Neoplasm]]:''' the scientific term to describe an abnormal proliferation of genetically altered cells. Neoplasms can be benign or malignant:
 +
** '''Malignant neoplasm''' or '''malignant tumor''': synonymous with '''cancer'''.
 +
** '''Benign neoplasm''' or '''[[benign tumor]]''': a tumor (solid neoplasm) that stops growing, does not invade other tissues and does not form metastases.
 +
* '''Invasive''' tumor is another synonym of '''cancer'''. The name refers to invasion of surrounding tissues.
 +
* '''Pre-malignancy''', '''pre-cancer''' or '''non-invasive''' tumor: A neoplasm that is not invasive but has the potential to progress to cancer (become invasive) if left untreated. These lesions are, in order of increasing potential for cancer, [[atypia]], [[dysplasia]] and [[carcinoma in situ]].
 +
 
 +
The following terms can be used to describe a cancer:
 +
* '''Screening''': a test done on healthy people to detect tumors before they become apparent. A [[mammogram]] is a screening test.
 +
* '''Diagnosis''': the confirmation of the cancerous nature of a lump. This usually requires a [[biopsy]] or removal of the tumor by [[surgery]], followed by examination by a [[surgical pathology|pathologist]].
 +
* '''Surgical excision''': the removal of a tumor by a [[surgery|surgeon]].
 +
** '''Surgical margins''': the evaluation by a [[surgical pathology|pathologist]] of the edges of the tissue removed by the surgeon to determine if the tumor was removed completely ("negative margins") or if tumor was left behind ("positive margins").
 +
* '''Grade''': a number (usually on a scale of 3) established by a [[surgical pathology|pathologist]] to describe the degree of resemblance of the tumor to the surrounding benign tissue.
 +
* '''Stage''': a number (usually on a scale of 4) established by the [[oncology|oncologist]] to describe the degree of invasion of the body by the tumor.
 +
* '''Recurrence''': new tumors that appear at the site of the original tumor after surgery.
 +
* '''Metastasis''': new tumors that appear far from the original tumor.
 +
* '''Median survival time''': a period, often measured in months or years, over which 50% of the cancer patients are expected to be alive.<ref>http://www.cancer.gov/templates/db_alpha.aspx?CdrID=44158</ref>
 +
* '''Transformation:''' the concept that a low-grade tumor transforms to a high-grade tumor over time. Example: [[Richter's transformation]].
 +
* '''Chemotherapy''': treatment with drugs.
 +
* '''Radiation therapy''': treatment with radiations.
 +
* '''Adjuvant''' therapy: treatment, either chemotherapy or radiation therapy, given '''after''' surgery to kill the remaining cancer cells.
 +
* '''Neoadjuvant''' therapy: treatment  either chemotherapy or radiation therapy, given '''before''' surgery to shrink a tumor to make its resection  easier.
 +
* '''Prognosis''': the probability of cure/remission after the therapy. It is usually expressed as a probability of [[cancer survivor|survival]] five years after diagnosis. Alternatively, it can be expressed as the number of years when 50% of the patients are still alive. Both numbers are derived from statistics accumulated with hundreds of similar patients to give a [[Kaplan-Meier estimator|Kaplan-Meier curve]].
 +
* '''Cure''': A cancer patient is "cured" or "in remission" if they live past the time by which 95% of treated patients live after the date of their diagnosis of cancer. This period varies among different types of cancer; for example, in the case of Hodgkin's disease this period is 10 years, whereas for Burkitt's lymphoma this period would be 1 year.<ref>"Definition of Cure for Hodgkin's Disease." Cancer Research 31 1970 p 1828-1833</ref> The phrase "cure" used in oncology is based upon the statistical concept of a median survival time and disease-free median survival time.<ref>http://jco.ascopubs.org/cgi/content/full/23/34/8564</ref>
  
==References==
+
==Notes==
{{reflist|2}}
+
{{Reflist|colwidth=30em}}
  
===General references===
+
== References ==
* ''The Basic Science of Oncology.'' Tannock IF, Hill RP ''et al'' (eds) 4th ed.2005 McGraw-Hill. ISBN 0-07138-774-9.
+
{{Commons|Cancer (illness)|Cancer}}
 +
* Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, Eds. ''[http://www.cancernetwork.com/cancer-management-11 Cancer Management: A Multidisciplinary Approach]''. 11th ed. 2009.
 +
* ''The Basic Science of Oncology'' 4th ed. Tannock IF, Hill RP ''et al.'' (eds.) (2005). McGraw-Hill. ISBN 0-07138-774-9.
 
* ''Principles of Cancer Biology.'' Kleinsmith, LJ (2006). Pearson Benjamin Cummings. ISBN 0-80534-003-3.
 
* ''Principles of Cancer Biology.'' Kleinsmith, LJ (2006). Pearson Benjamin Cummings. ISBN 0-80534-003-3.
* {{cite journal | author = Parkin D, Bray F, Ferlay J, Pisani P | title = Global cancer statistics, 2002 | journal = CA Cancer J Clin | volume = 55 | issue = 2 | pages = 74&ndash;108 | year = | doi = 10.3322/canjclin.55.2.74 | doi_brokendate = 2008-06-26 }}''[http://caonline.amcancersoc.org/cgi/content/full/55/2/74 Full text]''
+
* {{cite journal |author= Parkin D, Bray F, Ferlay J, Pisani P |title= Global cancer statistics, 2002 |journal= CA Cancer J Clin |volume=55 |issue=2 |pages=74–108 |year=2005 |doi=10.3322/canjclin.55.2.74 |url=http://caonline.amcancersoc.org/cgi/content/full/55/2/74 |pmid=15761078 }}
 
* ''Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective''. World Cancer Research Fund (2007). ISBN 978-0-9722522-2-5. ''[http://www.wcrf-uk.org/research_science/expert_report.lasso Full text]''
 
* ''Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective''. World Cancer Research Fund (2007). ISBN 978-0-9722522-2-5. ''[http://www.wcrf-uk.org/research_science/expert_report.lasso Full text]''
* [http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View.ShowTOC&rid=cmed.TOC&depth=2 Cancer Medicine, 6th Edition] Textbook
+
* [http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View.ShowTOC&rid=cmed.TOC&depth=2 Cancer Medicine, 6th Edition]—Textbook
* {{cite journal | author=Robert A. Weinberg | title=How Cancer Arises; An explosion of research is uncovering the long-hidden molecular underpinnings of cancer—and suggesting new therapies | url=http://www.bme.utexas.edu/research/orly/teaching/BME303/Weinberg.pdf | publication=Scientific American | month=September | year=1996 | pages=62–70 | quote=Introductary explanation of cancer biology in layman's language | format=PDF }}
+
* [http://www.springer.com/biomed/cancer/book/978-3-540-36847-2 Encyclopedia of Cancer]—4 volume reference work
 +
* {{cite journal | author=Weinberg, Robert A. | title=How Cancer Arises; An explosion of research is uncovering the long-hidden molecular underpinnings of cancer—and suggesting new therapies | url=http://www.bme.utexas.edu/research/orly/teaching/BME303/Weinberg.pdf | journal=[[Scientific American]] | month=September | year=1996 | pages=62–70 | quote=Introductory explanation of cancer biology in layman's language | format=PDF }}
  
==External links==
+
== External links ==
{{wiktionary}}
 
{{Commons|Cancer (illness)}}
 
* {{dmoz|Health/Conditions_and_Diseases/Cancer/}}
 
* {{Yahoo directory|Health/Diseases_and_Conditions/Cancers/|Cancer}}
 
  
===Professional and research===
 
;Global
 
* [http://www.who.int/cancer/en/ The World Health Organization's cancer site] A review of worldwide strategies for the prevention and treatment of cancer.
 
* [http://www.who.int/mediacentre/factsheets/fs297/en/ World Health Organization's fact sheet on cancer]
 
* [http://www.who.int/nutrition/topics/dietnutrition_and_chronicdiseases/en/ Diet, Nutrition and the prevention of chronic diseases] (including cancer) by a Joint [[WHO]]/[[FAO]] Expert consultation (2003)
 
* [http://www.wcrf.org/World Cancer Research Fund International (WCRF International)] leads a global network of cancer charities. Its [http://www.wcrf-uk.org/research_science/expert_report.lasso UK website] carries detailed analysis on the global origins and prevention of cancer.
 
* [http://cancer.iaea.org/ PACT: Programme of Action for Cancer Therapy] An [[IAEA]] Program to establish cancer care capacity and comprehensive cancer control in developing world
 
  
;North America
+
{{Tumors|state=uncollapsed}}
* [http://www.cancer.org American Cancer Society Homepage]
+
{{Carcinogen}}
* [http://www.cancer.org/docroot/ETO/ETO_1.asp/ American Cancer Society resources on clinical trials]
 
* [http://www.cancer.org/docroot/ETO/eto_1_1a.asp?sitearea=ETO/ American Cancer Society Treatment Decision Tools] &ndash; Trusted tools for helping patients make informed decisions
 
* [http://www.asco.org American Society Clinical Oncology Homepage]
 
* [http://www.asco.org/guidelines ASCO Clinical practice guidelines]
 
* [http://www.cancer.net Cancer.net] &ndash; Oncologist-approved cancer information
 
* [http://www.ascocancerfoundation.org/ The ASCO Cancer Foundation Homepage]
 
* [http://www.cap.org/apps/docs/reference/myBiopsy/index2.html MyBiopsy.org] Information for patients diagnosed with cancer, provided by the College of American Pathologists.
 
* [http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2005.asp Cancer Facts & Figures 2005] - 2005 United States Cancer Statistics
 
* [http://www.leukemia-lymphoma.org/all_page?item_id=225865 The Leukemia and Lymphoma Society]
 
* [http://www.cancer.gov National Cancer Institute] US Government agency responsible for conducting and supporting research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
 
* [http://www.cancer.ca/ccs/internet/standard/0,3182,3172_14279_371283_langId-en,00.html Canadian Cancer Statistics 2006] - This publication reports cancer incidence and mortality in Canada, analyzed by gender, age and province/territory.
 
* [http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View.ShowTOC&rid=cmed.TOC&depth=2 Cancer Medicine, 6th Edition] Textbook
 
  
;South America
 
* [http://www.abcancer.org.br/ Associação Brasileira do Câncer]
 
  
;Europe
 
* [http://www.eortc.be EORTC] European Organization for Research and Treatment of Cancer. A European non-profit organization that sets up and executes clinical trials.
 
* [http://www.cancerbackup.org.uk/ Cancerbackup] UK cancer information charity.
 
* [http://www.icr.ac.uk The Institute of Cancer Research] One of the world's foremost independent cancer research organisations, based in the United Kingdom.
 
  
===Support and advocacy===
 
* [http://www.americancancersociety.org American Cancer Society] Patient advocate group
 
* [http://www.aacr.org/home/survivors—advocates.aspx American Association for Cancer Research Survivor and Patient Advocacy]
 
* [http://cancer.iaea.org/ PACT: Programme of Action for Cancer Therapy]: An [[IAEA]] Program to establish cancer care capacity and comprehensive cancer control in developing world
 
* [http://www.nlm.nih.gov/medlineplus/cancer.html Cancer] from [[MedlinePlus]] - provides links to news, general sites, diagnosis, treatment and alternative therapies, clinical trials, research, related issues, organizations, other MedlinePlus [http://www.nlm.nih.gov/medlineplus/cancers.html Cancers Topics] and [http://www.nlm.nih.gov/medlineplus/cancerlivingwithcancer.html Living with Cancer].
 
* [http://info.cancerresearchuk.org Cancer Research UK - Cancer Resources] - In-depth, up-to-date information for people with a professional or general interest in cancer and health.
 
* [http://www.cancer.org.au Cancer Council of Australia] - Australia's national non-government cancer control organisation, involved in research, information, prevention, patient treatment and support.
 
* [http://www.acor.org/ ACOR - Association of Cancer Online Resources] ACOR is a unique collection of online communities designed to provide timely and accurate information in a supportive environment. ACOR offers access to mailing lists that provide support, information, and community to everyone affected by cancer and related disorders.
 
* [http://www.insidecancer.org Inside Cancer] Multimedia guide to cancer biology from Cold Spring Harbor Laboratory
 
* [http://www.cancer.ie Irish Cancer Society]
 
  
{{Tumors}}
 
  
 
[[Category:Life sciences]]
 
[[Category:Life sciences]]
Line 559: Line 460:
 
[[Category:Diseases]]
 
[[Category:Diseases]]
  
{{credit|Cancer|233568914}}
+
{{credit|Cancer|379152205}}

Revision as of 00:39, 18 August 2010

For other uses, see Cancer (disambiguation).
Cancer
File:Tumor Mesothelioma2 legend.jpg

A coronal CT scan showing malignant cancer of the lung sac.
Legend: → tumor ←, ★ central pleural effusion, 1&3 lungs, 2 spine, 4 ribs, 5 aorta, 6 spleen, 7&8 kidneys, 9 liver.

DiseasesDB28843
MedlinePlus001289
MeSHD009369

Cancer IPA: /ˈkænsər/ (medical term: malignant neoplasm) is a class of diseases in which a group of cells display uncontrolled growth (division beyond the normal limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to other locations in the body via lymph or blood). These three malignant properties of cancers differentiate them from benign tumors, which are self-limited, and do not invade or metastasize. Most cancers form a tumor but some, like leukemia, do not. The branch of medicine concerned with the study, diagnosis, treatment, and prevention of cancer is oncology.

Cancer affects people at all ages with the risk for most types increasing with age.[1] Cancer caused about 13% of all human deaths in 2007[2] (7.6 million).[3]

Cancers are caused by abnormalities in the genetic material of the transformed cells.[4] These abnormalities may be due to the effects of carcinogens, such as tobacco smoke, radiation, chemicals, or infectious agents. Other cancer-promoting genetic abnormalities may randomly occur through errors in DNA replication, or are inherited, and thus present in all cells from birth. The heritability of cancers is usually affected by complex interactions between carcinogens and the host's genome.

Genetic abnormalities found in cancer typically affect two general classes of genes. Cancer-promoting oncogenes are typically activated in cancer cells, giving those cells new properties, such as hyperactive growth and division, protection against programmed cell death, loss of respect for normal tissue boundaries, and the ability to become established in diverse tissue environments. Tumor suppressor genes are then inactivated in cancer cells, resulting in the loss of normal functions in those cells, such as accurate DNA replication, control over the cell cycle, orientation and adhesion within tissues, and interaction with protective cells of the immune system.

Definitive diagnosis requires the histologic examination of a biopsy specimen, although the initial indication of malignancy can be symptomatic or radiographic imaging abnormalities. Most cancers can be treated and some forced into remission, depending on the specific type, location, and stage. Once diagnosed, cancer is usually treated with a combination of surgery, chemotherapy and radiotherapy. As research develops, treatments are becoming more specific for different varieties of cancer. There has been significant progress in the development of targeted therapy drugs that act specifically on detectable molecular abnormalities in certain tumors, and which minimize damage to normal cells. The prognosis of cancer patients is most influenced by the type of cancer, as well as the stage, or extent of the disease. In addition, histologic grading and the presence of specific molecular markers can also be useful in establishing prognosis, as well as in determining individual treatments.

Classification

Further information: List of cancer types

Cancers are classified by the type of cell that resembles the tumor and, therefore, the tissue presumed to be the origin of the tumor. These are the histology and the location, respectively. Examples of general categories include:

  • Carcinoma: Malignant tumors derived from epithelial cells. This group represents the most common cancers, including the common forms of breast, prostate, lung and colon cancer.
  • Sarcoma: Malignant tumors derived from connective tissue, or mesenchymal cells.
  • Lymphoma and leukemia: Malignancies derived from hematopoietic (blood-forming) cells
  • Germ cell tumor: Tumors derived from totipotent cells. In adults most often found in the testicle and ovary; in fetuses, babies, and young children most often found on the body midline, particularly at the tip of the tailbone; in horses most often found at the poll (base of the skull).
  • Blastic tumor or blastoma: A tumor (usually malignant) which resembles an immature or embryonic tissue. Many of these tumors are most common in children.

Malignant tumors (cancers) are usually named using -carcinoma, -sarcoma or -blastoma as a suffix, with the Latin or Greek word for the organ of origin as the root. For instance, a cancer of the liver is called hepatocarcinoma; a cancer of the fat cells is called liposarcoma. For common cancers, the English organ name is used. For instance, the most common type of breast cancer is called ductal carcinoma of the breast or mammary ductal carcinoma. Here, the adjective ductal refers to the appearance of the cancer under the microscope, resembling normal breast ducts.

Benign tumors (which are not cancers) are named using -oma as a suffix with the organ name as the root. For instance, a benign tumor of the smooth muscle of the uterus is called leiomyoma (the common name of this frequent tumor is fibroid). Unfortunately, some cancers also use the -oma suffix, examples being melanoma and seminoma.

Signs and symptoms

Symptoms of cancer metastasis depend on the location of the tumor.

Roughly, cancer symptoms can be divided into three groups:

  • Local symptoms: unusual lumps or swelling (tumor), hemorrhage (bleeding), pain and/or ulceration. Compression of surrounding tissues may cause symptoms such as jaundice (yellowing the eyes and skin).
  • Symptoms of metastasis (spreading): enlarged lymph nodes, cough and hemoptysis, hepatomegaly (enlarged liver), bone pain, fracture of affected bones and neurological symptoms. Although advanced cancer may cause pain, it is often not the first symptom.
  • Systemic symptoms: weight loss, poor appetite, fatigue and cachexia (wasting), excessive sweating (night sweats), anemia and specific paraneoplastic phenomena, i.e. specific conditions that are due to an active cancer, such as thrombosis or hormonal changes.

Every symptom in the above list can be caused by a variety of conditions (a list of which is referred to as the differential diagnosis). Cancer may be a common or uncommon cause of each item.

Causes

Cancer is a diverse class of diseases which differ widely in their causes and biology. Any organism, even plants, can acquire cancer. Nearly all known cancers arise gradually, as errors build up in the cancer cell and its progeny (see mechanisms section for common types of errors).

Anything which replicates (living cells) will probabilistically suffer from errors (mutations). Unless error correction and prevention is properly carried out, the errors will survive, and might be passed along to daughter cells. Normally, the body safeguards against cancer via numerous methods, such as: apoptosis, helper molecules (some DNA polymerases), possibly senescence, etc. However these error-correction methods often fail in small ways, especially in environments that make errors more likely to arise and propagate. For example, such environments can include the presence of disruptive substances called carcinogens, or periodic injury (physical, heat, etc.), or environments that cells did not evolve to withstand, such as hypoxia[5] (see subsections). Cancer is thus a progressive disease, and these progressive errors slowly accumulate until a cell begins to act contrary to its function in the organism.

The errors which cause cancer are often self-amplifying, eventually compounding at an exponential rate. For example:

  • A mutation in the error-correcting machinery of a cell might cause that cell and its children to accumulate errors more rapidly
  • A mutation in signaling (endocrine) machinery of the cell can send error-causing signals to nearby cells
  • A mutation might cause cells to become neoplastic, causing them to migrate and disrupt more healthy cells
  • A mutation may cause the cell to become immortal (see telomeres), causing them to disrupt healthy cells forever

Thus cancer often explodes in something akin to a chain reaction caused by a few errors, which compound into more severe errors. Errors which produce more errors are effectively the root cause of cancer, and also the reason that cancer is so hard to treat: even if there were 10,000,000,000 cancerous cells and one killed all but 10 of those cells, those cells (and other error-prone precancerous cells) could still self-replicate or send error-causing signals to other cells, starting the process over again. This rebellion-like scenario is an undesirable survival of the fittest, where the driving forces of evolution work against the body's design and enforcement of order. In fact, once cancer has begun to develop, this same force continues to drive the progression of cancer towards more invasive stages, and is called clonal evolution.[6]

Research about cancer causes often falls into the following categories:

  • Agents (e.g. viruses) and events (e.g. mutations) which cause or facilitate genetic changes in cells destined to become cancer.
  • The precise nature of the genetic damage, and the genes which are affected by it.
  • The consequences of those genetic changes on the biology of the cell, both in generating the defining properties of a cancer cell, and in facilitating additional genetic events which lead to further progression of the cancer.

Chemicals

Further information: Carcinogen
The incidence of lung cancer is highly correlated with smoking. Source:NIH.

Cancer pathogenesis is traceable back to DNA mutations that impact cell growth and metastasis. Substances that cause DNA mutations are known as mutagens, and mutagens that cause cancers are known as carcinogens. Particular substances have been linked to specific types of cancer. Tobacco smoking is associated with many forms of cancer,[7] and causes 90% of lung cancer.[8] Prolonged exposure to asbestos fibers is associated with mesothelioma.[9]

Many mutagens are also carcinogens, but some carcinogens are not mutagens. Alcohol is an example of a chemical carcinogen that is not a mutagen.[10] Such chemicals may promote cancers through stimulating the rate of cell division. Faster rates of replication leaves less time for repair enzymes to repair damaged DNA during DNA replication, increasing the likelihood of a mutation.

Decades of research has demonstrated the link between tobacco use and cancer in the lung, larynx, head, neck, stomach, bladder, kidney, oesophagus and pancreas.[11] Tobacco smoke contains over fifty known carcinogens, including nitrosamines and polycyclic aromatic hydrocarbons.[12] Tobacco is responsible for about one in three of all cancer deaths in the developed world,[7] and about one in five worldwide.[12] Indeed, lung cancer death rates in the United States have mirrored smoking patterns, with increases in smoking followed by dramatic increases in lung cancer death rates and, more recently, decreases in smoking followed by decreases in lung cancer death rates in men. However, the numbers of smokers worldwide is still rising, leading to what some organizations have described as the tobacco epidemic.[13]

Ionizing radiation

Sources of ionizing radiation, such as radon gas, can cause cancer. Prolonged exposure to ultraviolet radiation from the sun can lead to melanoma and other skin malignancies.[14] It is estimated that 2% of future cancers will be due to current CT scans.[15]

Non-ionizing radio frequency radiation from mobile phones and other similar RF sources has also been proposed as a cause of cancer, but there is currently little established evidence of such a link.[16]

Infection

Some cancers can be caused by infection.[17] This is especially true in animals such as birds, but also in humans, with viruses responsible for up to 20% of human cancers worldwide.[18] These include human papillomavirus (cervical carcinoma), human polyomaviruses (mesothelioma, brain tumors), Epstein-Barr virus (B-cell lymphoproliferative disease and nasopharyngeal carcinoma), Kaposi's sarcoma herpesvirus (Kaposi's Sarcoma and primary effusion lymphomas), hepatitis B and hepatitis C viruses (hepatocellular carcinoma), Human T-cell leukemia virus-1 (T-cell leukemias), and Helicobacter pylori (gastric carcinoma).[18]

Experimental and epidemiological data imply a causative role for viruses and they appear to be the second most important risk factor for cancer development in humans, exceeded only by tobacco usage.[19] The mode of virally induced tumors can be divided into two, acutely transforming or slowly transforming. In acutely transforming viruses, the virus carries an overactive oncogene called viral-oncogene (v-onc), and the infected cell is transformed as soon as v-onc is expressed. In contrast, in slowly transforming viruses, the virus genome is inserts near a proto-oncogene in the host genome. The viral promoter or other transcription regulation elements then cause overexpression of that proto-oncogene. This induces uncontrolled cell division. Because the site of insertion is not specific to proto-oncogenes and the chance of insertion near any proto-oncogene is low, slowly transforming viruses will cause tumors much longer after infection than the acutely transforming viruses.

Hepatitis viruses, including hepatitis B and hepatitis C, can induce a chronic viral infection that leads to liver cancer in 0.47% of hepatitis B patients per year (especially in Asia, less so in North America), and in 1.4% of hepatitis C carriers per year. Liver cirrhosis, whether from chronic viral hepatitis infection or alcoholism, is associated with the development of liver cancer, and the combination of cirrhosis and viral hepatitis presents the highest risk of liver cancer development. Worldwide, liver cancer is one of the most common, and most deadly, cancers due to a huge burden of viral hepatitis transmission and disease.

Advances in cancer research have made a vaccine designed to prevent cancer available. In 2006, the U.S. Food and Drug Administration approved a human papilloma virus vaccine, called Gardasil. The vaccine protects against four HPV types, which together cause 70% of cervical cancers and 90% of genital warts. In March 2007, the US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) officially recommended that females aged 11–12 receive the vaccine, and indicated that females as young as age 9 and as old as age 26 are also candidates for immunization.

In addition to viruses, researchers have noted a connection between bacteria and certain cancers. The most prominent example is the link between chronic infection of the wall of the stomach with Helicobacter pylori and gastric cancer.[20][21] Although only a minority of those infected with Helicobacter go on to develop cancer, since this pathogen is quite common it is probably responsible for most of these cancers.[22]

Hormonal imbalances

Some hormones can act in a similar manner to non-mutagenic carcinogens in that they may stimulate excessive cell growth.{{ safesubst:#invoke:Unsubst||date=__DATE__ |$B= {{#invoke:Category handler|main}}{{#invoke:Category handler|main}}[clarification needed] }}

Immune system dysfunction

HIV is associated with a number of malignancies, including Kaposi's sarcoma, non-Hodgkin's lymphoma, and HPV-associated malignancies such as anal cancer and cervical cancer. AIDS-defining illnesses have long included these diagnoses. The increased incidence of malignancies in HIV patients points to the breakdown of immune surveillance as a possible etiology of cancer.[23] Certain other immune deficiency states (e.g. common variable immunodeficiency and IgA deficiency) are also associated with increased risk of malignancy.[24]

Heredity

Most forms of cancer are sporadic, meaning that there is no inherited cause of the cancer. There are, however, a number of recognised syndromes where there is an inherited predisposition to cancer, often due to a defect in a gene that protects against tumor formation. Famous examples are:

  • certain inherited mutations in the genes BRCA1 and BRCA2 are associated with an elevated risk of breast cancer and ovarian cancer
  • tumors of various endocrine organs in multiple endocrine neoplasia (MEN types 1, 2a, 2b)
  • Li-Fraumeni syndrome (various tumors such as osteosarcoma, breast cancer, soft tissue sarcoma, brain tumors) due to mutations of p53
  • Turcot syndrome (brain tumors and colonic polyposis)
  • Familial adenomatous polyposis an inherited mutation of the APC gene that leads to early onset of colon carcinoma.
  • Hereditary nonpolyposis colorectal cancer (HNPCC, also known as Lynch syndrome) can include familial cases of colon cancer, uterine cancer, gastric cancer, and ovarian cancer, without a preponderance of colon polyps.
  • Retinoblastoma, when occurring in young children, is due to a hereditary mutation in the retinoblastoma gene.
  • Down syndrome patients, who have an extra chromosome 21, are known to develop malignancies such as leukemia and testicular cancer, though the reasons for this difference are not well understood.

Other causes

Excepting the rare transmissions that occur with pregnancies and only a marginal few organ donors, cancer is generally not a transmissible disease. The main reason for this is tissue graft rejection caused by MHC incompatibility.[25] In humans and other vertebrates, the immune system uses MHC antigens to differentiate between "self" and "non-self" cells because these antigens are different from person to person. When non-self antigens are encountered, the immune system reacts against the appropriate cell. Such reactions may protect against tumour cell engraftment by eliminating implanted cells. In the United States, approximately 3,500 pregnant women have a malignancy annually, and transplacental transmission of acute leukaemia, lymphoma, melanoma and carcinoma from mother to fetus has been observed.[25] The development of donor-derived tumors from organ transplants is exceedingly rare. The main cause of organ transplant associated tumors seems to be malignant melanoma, that was undetected at the time of organ harvest.[26] though other cases exist[27] In fact, cancer from one organism will usually grow in another organism of that species, as long as they share the same histocompatibility genes,[28] proven using mice; however this would never happen in a real-world setting except as described above.

In non-humans, a few types of transmissible cancer have been described, wherein the cancer spreads between animals by transmission of the tumor cells themselves. This phenomenon is seen in dogs with Sticker's sarcoma, also known as canine transmissible venereal tumor,[29] as well as Devil facial tumour disease in Tasmanian devils.

Pathophysiology

Cancers are caused by a series of mutations. Each mutation alters the behavior of the cell somewhat.

Cancer is fundamentally a disease of regulation of tissue growth. In order for a normal cell to transform into a cancer cell, genes which regulate cell growth and differentiation must be altered.[30] Genetic changes can occur at many levels, from gain or loss of entire chromosomes to a mutation affecting a single DNA nucleotide. There are two broad categories of genes which are affected by these changes. Oncogenes may be normal genes which are expressed at inappropriately high levels, or altered genes which have novel properties. In either case, expression of these genes promotes the malignant phenotype of cancer cells. Tumor suppressor genes are genes which inhibit cell division, survival, or other properties of cancer cells. Tumor suppressor genes are often disabled by cancer-promoting genetic changes. Typically, changes in many genes are required to transform a normal cell into a cancer cell.[31]

There is a diverse classification scheme for the various genomic changes which may contribute to the generation of cancer cells. Most of these changes are mutations, or changes in the nucleotide sequence of genomic DNA. Aneuploidy, the presence of an abnormal number of chromosomes, is one genomic change which is not a mutation, and may involve either gain or loss of one or more chromosomes through errors in mitosis.

Large-scale mutations involve the deletion or gain of a portion of a chromosome. Genomic amplification occurs when a cell gains many copies (often 20 or more) of a small chromosomal locus, usually containing one or more oncogenes and adjacent genetic material. Translocation occurs when two separate chromosomal regions become abnormally fused, often at a characteristic location. A well-known example of this is the Philadelphia chromosome, or translocation of chromosomes 9 and 22, which occurs in chronic myelogenous leukemia, and results in production of the BCR-abl fusion protein, an oncogenic tyrosine kinase.

Small-scale mutations include point mutations, deletions, and insertions, which may occur in the promoter of a gene and affect its expression, or may occur in the gene's coding sequence and alter the function or stability of its protein product. Disruption of a single gene may also result from integration of genomic material from a DNA virus or retrovirus, and such an event may also result in the expression of viral oncogenes in the affected cell and its descendants.

Prevention

Cancer prevention is defined as active measures to decrease the incidence of cancer.[32] Greater than 30% of cancer is preventable via avoiding risk factors including: tobacco, overweight or obesity, low fruit and vegetable intake, physical inactivity, alcohol, sexually transmitted infection, air pollution.[33] This can be accomplished by avoiding carcinogens or altering their metabolism, pursuing a lifestyle or diet that modifies cancer-causing factors and/or medical intervention (chemoprevention, treatment of pre-malignant lesions). The epidemiological concept of "prevention" is usually defined as either primary prevention, for people who have not been diagnosed with a particular disease, or secondary prevention, aimed at reducing recurrence or complications of a previously diagnosed illness.

But the EPIC study published in 2010, tracking the eating habits of 478,000 Europeans suggested that consuming lots of fruits and vegetables has little if any effect on preventing cancer.[34]


Modifiable factors

The vast majority of cancer risk factors are environmental or lifestyle-related, leading to the claim that cancer is a largely preventable disease.[35] Examples of modifiable cancer risk factors include alcohol consumption (associated with increased risk of oral, esophageal, breast, and other cancers), smoking (80% of women with lung cancer have smoked in the past, and 90% of men[36]), physical inactivity (associated with increased risk of colon, breast, and possibly other cancers), and being overweight / obese (associated with colon, breast, endometrial, and possibly other cancers). Based on epidemiologic evidence, it is now thought that avoiding excessive alcohol consumption may contribute to reductions in risk of certain cancers; however, compared with tobacco exposure, the magnitude of effect is modest or small and the strength of evidence is often weaker. Other lifestyle and environmental factors known to affect cancer risk (either beneficially or detrimentally) include certain sexually transmitted diseases (such as those conveyed by the human papillomavirus), the use of exogenous hormones, exposure to ionizing radiation and ultraviolet radiation from the sun or from tanning beds, and certain occupational and chemical exposures.

Every year, at least 200,000 people die worldwide from cancer related to their workplace.[37] Millions of workers run the risk of developing cancers such as lung cancer and mesothelioma from inhaling asbestos fibers and tobacco smoke, or leukemia from exposure to benzene at their workplaces.[37] Currently, most cancer deaths caused by occupational risk factors occur in the developed world.[37] It is estimated that approximately 20,000 cancer deaths and 40,000 new cases of cancer each year in the U.S. are attributable to occupation.[38]

Diet

The consensus on diet and cancer is that obesity increases the risk of developing cancer. Particular dietary practices often explain differences in cancer incidence in different countries (e.g. gastric cancer is more common in Japan, while colon cancer is more common in the United States. In this example the preceding consideration of Haplogroups are excluded). Studies have shown that immigrants develop the risk of their new country, often within one generation, suggesting a substantial link between diet and cancer.[39] Whether reducing obesity in a population also reduces cancer incidence is unknown.

Despite frequent reports of particular substances (including foods) having a beneficial or detrimental effect on cancer risk, few of these have an established link to cancer. These reports are often based on studies in cultured cell media or animals. Public health recommendations cannot be made based on these studies until they have been validated in an observational (or occasionally a prospective interventional) trial in humans.

Proposed dietary interventions for primary cancer risk reduction generally gain support from epidemiological association studies. Examples of such studies include reports that reduced meat consumption is associated with decreased risk of colon cancer,[40] and reports that consumption of coffee is associated with a reduced risk of liver cancer.[41] Studies have linked consumption of grilled meat to an increased risk of stomach cancer,[42] colon cancer,[43] breast cancer,[44] and pancreatic cancer,[45] a phenomenon which could be due to the presence of carcinogens such as benzopyrene in foods cooked at high temperatures.

A 2005 secondary prevention study showed that consumption of a plant-based diet and lifestyle changes resulted in a reduction in cancer markers in a group of men with prostate cancer who were using no conventional treatments at the time.[46] These results were amplified by a 2006 study. Over 2,400 women were studied, half randomly assigned to a normal diet, the other half assigned to a diet containing less than 20% calories from fat. The women on the low fat diet were found to have a markedly lower risk of breast cancer recurrence, in the interim report of December, 2006.[47]

Recent studies have also demonstrated potential links between some forms of cancer and high consumption of refined sugars and other simple carbohydrates.[48][49][50][51][52] Although the degree of correlation and the degree of causality is still debated,[53][54][55] some organizations have in fact begun to recommend reducing intake of refined sugars and starches as part of their cancer prevention regimens.[56][57][58]

In November 2007, the American Institute for Cancer Research (AICR), in conjunction with the World Cancer Research Fund (WCRF), published Food, Nutrition, Physical Activity and the Prevention of Cancer: a Global Perspective, "the most current and comprehensive analysis of the literature on diet, physical activity and cancer".[59] The WCRF/AICR Expert Report lists 10 recommendations that people can follow to help reduce their risk of developing cancer, including the following dietary guidelines: (1) reducing intake of foods and drinks that promote weight gain, namely energy-dense foods and sugary drinks, (2) eating mostly foods of plant origin, (3) limiting intake of red meat and avoiding processed meat, (4) limiting consumption of alcoholic beverages, and (5) reducing intake of salt and avoiding mouldy cereals (grains) or pulses (legumes).[60][61]

Some mushrooms offer an anti-cancer effect, which is thought to be linked to their ability to up-regulate the immune system. Some mushrooms known for this effect include, Reishi,[62][63] Agaricus blazei,[64] Maitake,[65] and Trametes versicolor[66]. Research suggests the compounds in medicinal mushrooms most responsible for up-regulating the immune system and providing an anti-cancer effect, are a diverse collection of polysaccharide compounds, particularly beta-glucans. Beta-glucans are known as "biological response modifiers", and their ability to activate the immune system is well documented. Specifically, beta-glucans stimulate the innate branch of the immune system. Research has shown beta-glucans have the ability to stimulate macrophage, NK cells, T cells, and immune system cytokines. The mechanisms in which beta-glucans stimulate the immune system is only partially understood. One mechanism in which beta-glucans are able to activate the immune system, is by interacting with the Macrophage-1 antigen (CD18) receptor on immune cells.[67]

Vitamins

Vitamin supplementation has not been proven effective in the prevention of cancer.[citation needed] The components of food are also proving to be more numerous and varied than previously understood, so patients are increasingly advised to consume fruits and vegetables for maximal health benefits.[68]

Vitamin D

Low levels of vitamin D is correlated with increased cancer risk.[69][70] Whether this relationship is causal is yet to be determined.[71]

Beta carotene

Beta-carotene supplementation has been found to increase slightly, but not significantly risks of lung cancer.[72]

Folic acid

Folic acid supplementation has not been found effective in preventing colon cancer and may increase colon polyps.[73]

Chemoprevention

The concept that medications could be used to prevent cancer is an attractive one, and many high-quality clinical trials support the use of such chemoprevention in defined circumstances.

Daily use of tamoxifen, a selective estrogen receptor modulator (SERM), typically for 5 years, has been demonstrated to reduce the risk of developing breast cancer in high-risk women by about 50%. A recent study reported that the selective estrogen receptor modulator raloxifene has similar benefits to tamoxifen in preventing breast cancer in high-risk women, with a more favorable side effect profile.[74]

Raloxifene is a SERM like tamoxifen; it has been shown (in the STAR trial) to reduce the risk of breast cancer in high-risk women equally as well as tamoxifen. In this trial, which studied almost 20,000 women, raloxifene had fewer side effects than tamoxifen, though it did permit more DCIS to form.[74]

Finasteride, a 5-alpha-reductase inhibitor, has been shown to lower the risk of prostate cancer, though it seems to mostly prevent low-grade tumors.[75] The effect of COX-2 inhibitors such as rofecoxib and celecoxib upon the risk of colon polyps have been studied in familial adenomatous polyposis patients[76] and in the general population.[77][78] In both groups, there were significant reductions in colon polyp incidence, but this came at the price of increased cardiovascular toxicity.

Genetic testing

Genetic testing for high-risk individuals is already available for certain cancer-related genetic mutations. Carriers of genetic mutations that increase risk for cancer incidence can undergo enhanced surveillance, chemoprevention, or risk-reducing surgery. Early identification of inherited genetic risk for cancer, along with cancer-preventing interventions such as surgery or enhanced surveillance, can be lifesaving for high-risk individuals.

Gene Cancer types Availability
BRCA1, BRCA2 Breast, ovarian, pancreatic Commercially available for clinical specimens
MLH1, MSH2, MSH6, PMS1, PMS2 Colon, uterine, small bowel, stomach, urinary tract Commercially available for clinical specimens

Vaccination

Prophylactic vaccines have been developed to prevent infection by oncogenic infectious agents such as viruses, and therapeutic vaccines are in development to stimulate an immune response against cancer-specific epitopes.[79]

As reported above, a preventive human papillomavirus vaccine exists that targets certain sexually transmitted strains of human papillomavirus that are associated with the development of cervical cancer and genital warts. The only two HPV vaccines on the market as of October 2007 are Gardasil and Cervarix.[79] There is also a hepatitis B vaccine, which prevents infection with the hepatitis B virus, an infectious agent that can cause liver cancer.[79] A canine melanoma vaccine has also been developed.[80][81]

Screening

Cancer screening is an attempt to detect unsuspected cancers in an asymptomatic population. Screening tests suitable for large numbers of healthy people must be relatively affordable, safe, noninvasive procedures with acceptably low rates of false positive results. If signs of cancer are detected, more definitive and invasive follow up tests are performed to confirm the diagnosis.

Screening for cancer can lead to earlier diagnosis in specific cases. Early diagnosis may lead to extended life, but may also falsely prolong the lead time to death through lead time bias or length time bias.

A number of different screening tests have been developed for different malignancies. Breast cancer screening can be done by breast self-examination, though this approach was discredited by a 2005 study in over 300,000 Chinese women. Screening for breast cancer with mammograms has been shown to reduce the average stage of diagnosis of breast cancer in a population. Stage of diagnosis in a country has been shown to decrease within ten years of introduction of mammographic screening programs. Colorectal cancer can be detected through fecal occult blood testing and colonoscopy, which reduces both colon cancer incidence and mortality, presumably through the detection and removal of pre-malignant polyps. Similarly, cervical cytology testing (using the Pap smear) leads to the identification and excision of precancerous lesions. Over time, such testing has been followed by a dramatic reduction of cervical cancer incidence and mortality. Testicular self-examination is recommended for men beginning at the age of 15 years to detect testicular cancer. Prostate cancer can be screened using a digital rectal exam along with prostate specific antigen (PSA) blood testing, though some authorities (such as the US Preventive Services Task Force) recommend against routinely screening all men.

Screening for cancer is controversial in cases when it is not yet known if the test actually saves lives. The controversy arises when it is not clear if the benefits of screening outweigh the risks of follow-up diagnostic tests and cancer treatments. For example: when screening for prostate cancer, the PSA test may detect small cancers that would never become life threatening, but once detected will lead to treatment. This situation, called overdiagnosis, puts men at risk for complications from unnecessary treatment such as surgery or radiation. Follow up procedures used to diagnose prostate cancer (prostate biopsy) may cause side effects, including bleeding and infection. Prostate cancer treatment may cause incontinence (inability to control urine flow) and erectile dysfunction (erections inadequate for intercourse). Similarly, for breast cancer, there have recently been criticisms that breast screening programs in some countries cause more problems than they solve. This is because screening of women in the general population will result in a large number of women with false positive results which require extensive follow-up investigations to exclude cancer, leading to having a high number-to-treat (or number-to-screen) to prevent or catch a single case of breast cancer early.

Cervical cancer screening via the Pap smear has the best cost-benefit profile of all the forms of cancer screening from a public health perspective as, largely caused by a virus, it has clear risk factors (sexual contact), and the natural progression of cervical cancer is that it normally spreads slowly over a number of years therefore giving more time for the screening program to catch it early. Moreover, the test is easy to perform and relatively cheap.

For these reasons, it is important that the benefits and risks of diagnostic procedures and treatment be taken into account when considering whether to undertake cancer screening.

Use of medical imaging to search for cancer in people without clear symptoms is similarly marred with problems. There is a significant risk of detection of what has been recently called an incidentaloma - a benign lesion that may be interpreted as a malignancy and be subjected to potentially dangerous investigations. Recent studies of CT scan-based screening for lung cancer in smokers have had equivocal results, and systematic screening is not recommended as of July 2007. Randomized clinical trials of plain-film chest X-rays to screen for lung cancer in smokers have shown no benefit for this approach.

Canine cancer detection has shown promise, but is still in the early stages of research.

Diagnosis

Chest x-ray showing lung cancer in the left lung.

Most cancers are initially recognized either because signs or symptoms appear or through screening. Neither of these lead to a definitive diagnosis, which usually requires the opinion of a pathologist, a type of physician (medical doctor) who specializes in the diagnosis of cancer and other diseases. People with suspected cancer are investigated with medical tests. These commonly include blood tests, X-rays, CT scans and endoscopy.

Pathology

A cancer may be suspected for a variety of reasons, but the definitive diagnosis of most malignancies must be confirmed by histological examination of the cancerous cells by a pathologist. Tissue can be obtained from a biopsy or surgery. Many biopsies (such as those of the skin, breast or liver) can be done in a doctor's office. Biopsies of other organs are performed under anesthesia and require surgery in an operating room.

The tissue diagnosis given by the pathologist indicates the type of cell that is proliferating, its histological grade, genetic abnormalities, and other features of the tumor. Together, this information is useful to evaluate the prognosis of the patient and to choose the best treatment. Cytogenetics and immunohistochemistry are other types of testing that the pathologist may perform on the tissue specimen. These tests may provide information about the molecular changes (such as mutations, fusion genes, and numerical chromosome changes) that has happened in the cancer cells, and may thus also indicate the future behavior of the cancer (prognosis) and best treatment.

Management

Many management options for cancer exist including: chemotherapy, radiation therapy, surgery, immunotherapy, monoclonal antibody therapy and other methods. Which are used depends upon the location and grade of the tumor and the stage of the disease, as well as the general state of a person's health. Experimental cancer treatments are also under development.

Complete removal of the cancer without damage to the rest of the body is the goal of treatment. Sometimes this can be accomplished by surgery, but the propensity of cancers to invade adjacent tissue or to spread to distant sites by microscopic metastasis often limits its effectiveness. Surgery often required the removal of a wide surgical margin or a free margin. The width of the free margin depends on the type of the cancer, the method of removal (CCPDMA, Mohs surgery, POMA, etc.). The margin can be as little as 1 mm for basal cell cancer using CCPDMA or Mohs surgery, to several centimeters for aggressive cancers. The effectiveness of chemotherapy is often limited by toxicity to other tissues in the body. Radiation can also cause damage to normal tissue.

Because "cancer" refers to a class of diseases,[82][83] it is unlikely that there will ever be a single "cure for cancer" any more than there will be a single treatment for all infectious diseases.[84] Angiogenesis inhibitors were once thought to have potential as a "silver bullet" treatment applicable to many types of cancer, but this has not been the case in practice.[85]

Prognosis

Cancer has a reputation as a deadly disease. While this certainly applies to certain particular types, the truths behind the historical connotations of cancer are increasingly overturned by advances in medical care. Some types of cancer have a prognosis that is substantially better than nonmalignant diseases such as heart failure and stroke.

Progressive and disseminated malignant disease has a substantial impact on a cancer patient's quality of life, and many cancer treatments (such as chemotherapy) may have severe side-effects. In the advanced stages of cancer, many patients need extensive care, affecting family members and friends. Palliative care solutions may include permanent or "respite" hospice nursing.

Emotional impact

Many local organizations offer a variety of practical and support services to people with cancer. Support can take the form of support groups, counseling, advice, financial assistance, transportation to and from treatment, films or information about cancer. Neighborhood organizations, local health care providers, or area hospitals may have resources or services available.

Counseling can provide emotional support to cancer patients and help them better understand their illness. Different types of counseling include individual, group, family, peer counseling, bereavement, patient-to-patient, and sexuality.

Many governmental and charitable organizations have been established to help patients cope with cancer. These organizations are often involved in cancer prevention, cancer treatment, and cancer research.

Epidemiology

Death rate from malignant cancer per 100,000 inhabitants in 2004.[86]
██ no data ██ ≤ 55 ██ 55-80 ██ 80-105 ██ 105-130 ██ 130-155 ██ 155-180 ██ 180-205 ██ 205-230 ██ 230-255 ██ 255-280 ██ 280-305 ██ ≥ 305

As of 2004, worldwide cancer caused 13% of all deaths (7.4 million). The leading causes were: lung cancer (1.3 million deaths/year), stomach cancer (803,000 deaths), colorectal cancer (639,000 deaths), liver cancer (610,000 deaths), and breast cancer (519,000 deaths).[87] Greater than 30% of cancer is preventable via avoiding risk factors including: tobacco, overweight or obesity, low fruit and vegetable intake, physical inactivity, alcohol, sexually transmitted infections, and air pollution.[33]

In the United States, cancer is responsible for 25% of all deaths with 30% of these from lung cancer. The most commonly occurring cancer in men is prostate cancer (about 25% of new cases) and in women is breast cancer (also about 25%). Cancer can occur in children and adolescents, but it is uncommon (about 150 cases per million in the U.S.), with leukemia the most common.[88] In the first year of life the incidence is about 230 cases per million in the U.S., with the most common being neuroblastoma.[89]

In the developed world, one in three people will develop cancer during their lifetimes. If all cancer patients survived and cancer occurred randomly, the lifetime odds of developing an second primary cancer would be one in nine.[90] However, cancer survivors have an increased risk of developing a second primary cancer, and the odds are about two in nine.[90] About half of these second primaries can be attributed to the normal one-in-nine risk associated with random chance.[90] The increased risk is believed to be primarily due to the same risk factors that produced the first cancer, such as the person's genetic profile, alcohol and tobacco use, obesity, and environmental exposures, and partly due, to the treatment for the first cancer, which typically includes mutagenic chemotherapeutic drugs or radiation.[90] Cancer survivors may also be more likely to comply with recommended screening, and thus may be more likely than average to detect cancers.[90]

History

Today, the Greek term carcinoma is the medical term for a malignant tumor derived from epithelial cells. It is Celsus who translated carcinos into the Latin cancer, also meaning crab. Galen used "oncos" to describe all tumours, the root for the modern word oncology.[91]

Hippocrates described several kinds of cancers. He called benign tumours oncos, Greek for swelling, and malignant tumours carcinos, Greek for crab or crayfish. This name comes from the appearance of the cut surface of a solid malignant tumour, with "the veins stretched on all sides as the animal the crab has its feet, whence it derives its name".[92] He later added the suffix -oma, Greek for swelling, giving the name carcinoma. Since it was against Greek tradition to open the body, Hippocrates only described and made drawings of outwardly visible tumors on the skin, nose, and breasts. Treatment was based on the humor theory of four bodily fluids (black and yellow bile, blood, and phlegm). According to the patient's humor, treatment consisted of diet, blood-letting, and/or laxatives. Through the centuries it was discovered that cancer could occur anywhere in the body, but humor-theory based treatment remained popular until the 19th century with the discovery of cells.

The oldest known description and surgical treatment of cancer was discovered in Egypt and dates back to approximately 1600 B.C.E. The Papyrus describes 8 cases of ulcers of the breast that were treated by cauterization, with a tool called "the fire drill." The writing says about the disease, "There is no treatment."[93]

Another very early surgical treatment for cancer was described in the 1020s by Avicenna (Ibn Sina) in The Canon of Medicine. He stated that the excision should be radical and that all diseased tissue should be removed, which included the use of amputation or the removal of veins running in the direction of the tumor. He also recommended the use of cauterization for the area treated if necessary.[94]

In the 16th and 17th centuries, it became more acceptable for doctors to dissect bodies to discover the cause of death. The German professor Wilhelm Fabry believed that breast cancer was caused by a milk clot in a mammary duct. The Dutch professor Francois de la Boe Sylvius, a follower of Descartes, believed that all disease was the outcome of chemical processes, and that acidic lymph fluid was the cause of cancer. His contemporary Nicolaes Tulp believed that cancer was a poison that slowly spreads, and concluded that it was contagious.[95]

The first cause of cancer was identified by British surgeon Percivall Pott, who discovered in 1775 that cancer of the scrotum was a common disease among chimney sweeps. The work of other individual physicians led to various insights, but when physicians started working together they could make firmer conclusions.

With the widespread use of the microscope in the 18th century, it was discovered that the 'cancer poison' spread from the primary tumor through the lymph nodes to other sites ("metastasis"). This view of the disease was first formulated by the English surgeon Campbell De Morgan between 1871 and 1874.[96] The use of surgery to treat cancer had poor results due to problems with hygiene. The renowned Scottish surgeon Alexander Monro saw only 2 breast tumor patients out of 60 surviving surgery for two years. In the 19th century, asepsis improved surgical hygiene and as the survival statistics went up, surgical removal of the tumor became the primary treatment for cancer. With the exception of William Coley who in the late 1800s felt that the rate of cure after surgery had been higher before asepsis (and who injected bacteria into tumors with mixed results), cancer treatment became dependent on the individual art of the surgeon at removing a tumor. During the same period, the idea that the body was made up of various tissues, that in turn were made up of millions of cells, laid rest the humor-theories about chemical imbalances in the body. The age of cellular pathology was born.

The genetic basis of cancer was recognised in 1902 by the German zoologist Theodor Boveri, professor of zoology at Munich and later in Würzburg.[97] He discovered a method to generate cells with multiple copies of the centrosome, a structure he discovered and named. He postulated that chromosomes were distinct and transmitted different inheritance factors. He suggested that mutations of the chromosomes could generate a cell with unlimited growth potential which could be passed onto its descendants. He proposed the existence of cell cycle check points, tumour suppressor genes and oncogenes. He speculated that cancers might be caused or promoted by radiation, physical or chemical insults or by pathogenic microorganisms.

When Marie Curie and Pierre Curie discovered radiation at the end of the 19th century, they stumbled upon the first effective non-surgical cancer treatment. With radiation also came the first signs of multi-disciplinary approaches to cancer treatment. The surgeon was no longer operating in isolation, but worked together with hospital radiologists to help patients. The complications in communication this brought, along with the necessity of the patient's treatment in a hospital facility rather than at home, also created a parallel process of compiling patient data into hospital files, which in turn led to the first statistical patient studies.

A founding paper of cancer epidemiology was the work of Janet Lane-Claypon, who published a comparative study in 1926 of 500 breast cancer cases and 500 control patients of the same background and lifestyle for the British Ministry of Health. Her ground-breaking work on cancer epidemiology was carried on by Richard Doll and Austin Bradford Hill, who published "Lung Cancer and Other Causes of Death In Relation to Smoking. A Second Report on the Mortality of British Doctors" followed in 1956 (otherwise known as the British doctors study). Richard Doll left the London Medical Research Center (MRC), to start the Oxford unit for Cancer epidemiology in 1968. With the use of computers, the unit was the first to compile large amounts of cancer data. Modern epidemiological methods are closely linked to current concepts of disease and public health policy. Over the past 50 years, great efforts have been spent on gathering data across medical practise, hospital, provincial, state, and even country boundaries to study the interdependence of environmental and cultural factors on cancer incidence.

Cancer patient treatment and studies were restricted to individual physicians' practices until World War II, when medical research centers discovered that there were large international differences in disease incidence. This insight drove national public health bodies to make it possible to compile health data across practises and hospitals, a process that many countries do today. The Japanese medical community observed that the bone marrow of victims of the atomic bombings of Hiroshima and Nagasaki was completely destroyed. They concluded that diseased bone marrow could also be destroyed with radiation, and this led to the discovery of bone marrow transplants for leukemia. Since World War II, trends in cancer treatment are to improve on a micro-level the existing treatment methods, standardize them, and globalize them to find cures through epidemiology and international partnerships.

Research

Cancer research is the intense scientific effort to understand disease processes and discover possible therapies. The improved understanding of molecular biology and cellular biology due to cancer research has led to a number of new, effective treatments for cancer since President Nixon declared "War on Cancer" in 1971. Since 1971 the United States has invested over $200 billion on cancer research; that total includes money invested by public and private sectors and foundations.[98] Despite this substantial investment, the country has seen a five percent decrease in the cancer death rate (adjusting for size and age of the population) between 1950 and 2005.[99]

Leading cancer research organizations and projects include the American Association for Cancer Research, the American Cancer Society (ACS), the American Society of Clinical Oncology, the European Organisation for Research and Treatment of Cancer, the National Cancer Institute, the National Comprehensive Cancer Network, and The Cancer Genome Atlas project at the NCI.

Glossary

Further information: List of oncology-related terms

The following closely related terms may be used to designate abnormal growths:

  • Tumor or tumour: originally, it meant any abnormal swelling, lump or mass. In current English, however, the word tumor has become synonymous with neoplasm, specifically solid neoplasm. Note that some neoplasms, such as leukemia, do not form tumors.
  • Neoplasm: the scientific term to describe an abnormal proliferation of genetically altered cells. Neoplasms can be benign or malignant:
    • Malignant neoplasm or malignant tumor: synonymous with cancer.
    • Benign neoplasm or benign tumor: a tumor (solid neoplasm) that stops growing, does not invade other tissues and does not form metastases.
  • Invasive tumor is another synonym of cancer. The name refers to invasion of surrounding tissues.
  • Pre-malignancy, pre-cancer or non-invasive tumor: A neoplasm that is not invasive but has the potential to progress to cancer (become invasive) if left untreated. These lesions are, in order of increasing potential for cancer, atypia, dysplasia and carcinoma in situ.

The following terms can be used to describe a cancer:

  • Screening: a test done on healthy people to detect tumors before they become apparent. A mammogram is a screening test.
  • Diagnosis: the confirmation of the cancerous nature of a lump. This usually requires a biopsy or removal of the tumor by surgery, followed by examination by a pathologist.
  • Surgical excision: the removal of a tumor by a surgeon.
    • Surgical margins: the evaluation by a pathologist of the edges of the tissue removed by the surgeon to determine if the tumor was removed completely ("negative margins") or if tumor was left behind ("positive margins").
  • Grade: a number (usually on a scale of 3) established by a pathologist to describe the degree of resemblance of the tumor to the surrounding benign tissue.
  • Stage: a number (usually on a scale of 4) established by the oncologist to describe the degree of invasion of the body by the tumor.
  • Recurrence: new tumors that appear at the site of the original tumor after surgery.
  • Metastasis: new tumors that appear far from the original tumor.
  • Median survival time: a period, often measured in months or years, over which 50% of the cancer patients are expected to be alive.[100]
  • Transformation: the concept that a low-grade tumor transforms to a high-grade tumor over time. Example: Richter's transformation.
  • Chemotherapy: treatment with drugs.
  • Radiation therapy: treatment with radiations.
  • Adjuvant therapy: treatment, either chemotherapy or radiation therapy, given after surgery to kill the remaining cancer cells.
  • Neoadjuvant therapy: treatment either chemotherapy or radiation therapy, given before surgery to shrink a tumor to make its resection easier.
  • Prognosis: the probability of cure/remission after the therapy. It is usually expressed as a probability of survival five years after diagnosis. Alternatively, it can be expressed as the number of years when 50% of the patients are still alive. Both numbers are derived from statistics accumulated with hundreds of similar patients to give a Kaplan-Meier curve.
  • Cure: A cancer patient is "cured" or "in remission" if they live past the time by which 95% of treated patients live after the date of their diagnosis of cancer. This period varies among different types of cancer; for example, in the case of Hodgkin's disease this period is 10 years, whereas for Burkitt's lymphoma this period would be 1 year.[101] The phrase "cure" used in oncology is based upon the statistical concept of a median survival time and disease-free median survival time.[102]

Notes

  1. Cancer Research UK (January 2007). UK cancer incidence statistics by age. Retrieved 2007-06-25.
  2. WHO (February 2006). Cancer. World Health Organization. Retrieved 2007-06-25.
  3. American Cancer Society (December 2007). Report sees 7.6 million global 2007 cancer deaths. Reuters. Retrieved 2008-08-07.
  4. Kinzler, Kenneth W.; Vogelstein, Bert (2002). "Introduction", The genetic basis of human cancer, 2nd, illustrated, revised, New York: McGraw-Hill, Medical Pub. Division. ISBN 978-0-07-137050-9. 
  5. Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E (September 2004). Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes & Development 18 (17): 2095–107.
  6. Merlo LM, Pepper JW, Reid BJ, Maley CC (December 2006). Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6 (12): 924–35.
  7. 7.0 7.1 Sasco AJ, Secretan MB, Straif K (August 2004). Tobacco smoking and cancer: a brief review of recent epidemiological evidence. Lung cancer (Amsterdam, Netherlands) 45 Suppl 2: S3–9.
  8. Biesalski HK, Bueno de Mesquita B, Chesson A, et al. (1998). European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel. CA: a cancer journal for clinicians 48 (3): 167–76; discussion 164–6.
  9. O'Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ (March 2007). Asbestos-related lung disease. American family physician 75 (5): 683–8.
  10. Seitz HK, Pöschl G, Simanowski UA (1998). Alcohol and cancer. Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism 14: 67–95.
  11. Kuper H, Boffetta P, Adami HO (September 2002). Tobacco use and cancer causation: association by tumour type. Journal of internal medicine 252 (3): 206–24.
  12. 12.0 12.1 Kuper H, Adami HO, Boffetta P (June 2002). Tobacco use, cancer causation and public health impact. Journal of internal medicine 251 (6): 455–66.
  13. Proctor RN (May 2004). The global smoking epidemic: a history and status report. Clinical lung cancer 5 (6): 371–6.
  14. English DR, Armstrong BK, Kricker A, Fleming C (May 1997). Sunlight and cancer. Cancer causes & control : CCC 8 (3): 271–83.
  15. Berrington de González A, Mahesh M, Kim KP, et al. (December 2009). Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch. Intern. Med. 169 (22): 2071–7.
  16. Feychting M, Ahlbom A, Kheifets L (2005). EMF and health. Annual review of public health 26: 165–89.
  17. Pagano JS, Blaser M, Buendia MA, et al. (December 2004). Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol. 14 (6): 453–71.
  18. 18.0 18.1 Pagano JS, Blaser M, Buendia MA, et al. (December 2004). Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol. 14 (6): 453–71.
  19. zur Hausen H (1991). Viruses in human cancers. Science 254 (5035): 1167–73.
  20. Peter S, Beglinger C (2007). Helicobacter pylori and gastric cancer: the causal relationship. Digestion 75 (1): 25–35.
  21. Wang C, Yuan Y, Hunt RH (August 2007). The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am. J. Gastroenterol. 102 (8): 1789–98.
  22. Cheung TK, Xia HH, Wong BC (January 2007). Helicobacter pylori eradication for gastric cancer prevention. J. Gastroenterol. 42 Suppl 17: 10–5.
  23. Wood C, Harrington W (2005). AIDS and associated malignancies. Cell Res. 15 (11-12): 947–52.
  24. Mellemkjaer L, Hammarstrom L, Andersen V, et al. (2002). Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin. Exp. Immunol. 130 (3): 495–500.
  25. 25.0 25.1 Tolar J, Neglia JP (June 2003). Transplacental and other routes of cancer transmission between individuals. J Pediatr Hematol Oncol. 25 (6): 430–4.
  26. Dingli D, Nowak MA (September 2006). Cancer biology: infectious tumour cells. Nature 443 (7107): 35–6.
  27. Cancer Spread By Transplantation Extremely Rare: In Very Rare Case, Woman Develops Leukemia from Liver Transplant.
  28. The Nobel Prize in Physiology or Medicine 1980.
  29. Murgia C, Pritchard JK, Kim SY, Fassati A, Weiss RA (2006). Clonal origin and evolution of a transmissible cancer. Cell 126 (3): 477–87.
  30. Croce CM (January 2008). Oncogenes and cancer. The New England journal of medicine 358 (5): 502–11.
  31. Knudson AG (November 2001). Two genetic hits (more or less) to cancer. Nature reviews. Cancer 1 (2): 157–62.
  32. Cancer prevention: 7 steps to reduce your risk. Mayo Clinic (2008-09-27). Retrieved 2010-01-30.
  33. 33.0 33.1 Cancer Cancer. World Health Organization.
  34. Boffetta P, Couto E, Wichmann J et al. (2010). Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).. J Natl Cancer Inst, 8 (102): 529-37.
  35. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M (2005). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 366 (9499): 1784–93.
  36. Lung Cancer in American Women: Facts. Retrieved 2007-01-19.
  37. 37.0 37.1 37.2 World Health Organization (2007-04-27). WHO calls for prevention of cancer through healthy workplaces. Press release. Retrieved on 2007-10-13.
  38. National Institute for Occupational Safety and Health- Occupational Cancer. United States National Institute for Occupational Safety and Health. Retrieved 2007-10-13.
  39. Buell P, Dunn JE (1965). Cancer mortality among Japanese Issei and Nisei of California. Cancer 18: 656–64.
  40. Slattery ML, Boucher KM, Caan BJ, Potter JD, Ma KN (1998). Eating patterns and risk of colon cancer. Am. J. Epidemiol. 148 (1): 4–16.
  41. Larsson SC, Wolk A (2007). Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 132 (5): 1740–5.
  42. Ward MH, Sinha R, Heineman EF, et al. (1997). Risk of adenocarcinoma of the stomach and esophagus with meat cooking method and doneness preference. Int. J. Cancer 71 (1): 14–9.
  43. Sinha R, Peters U, Cross AJ, et al. (2005). Meat, meat cooking methods and preservation, and risk for colorectal adenoma. Cancer Res. 65 (17): 8034–41.
  44. Steck SE, Gaudet MM, Eng SM, et al. (2007). Cooked meat and risk of breast cancer—lifetime versus recent dietary intake. Epidemiology (Cambridge, Mass.) 18 (3): 373–82.
  45. Anderson KE, Kadlubar FF, Kulldorff M, et al. (2005). Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 14 (9): 2261–5.
  46. Ornish D et al. (2005). Intensive lifestyle changes may affect the progression of prostate cancer. The Journal of Urology 174 (3): 1065–9; discussion 1069–70.
  47. Chlebowski RT, Blackburn GL, Thomson CA, et al. (2006). Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J. Natl. Cancer Inst. 98 (24): 1767–76.
  48. Romieu I, Lazcano-Ponce E, Sanchez-Zamorano LM, Willett W, Hernandez-Avila M (1 August 2004). Carbohydrates and the risk of breast cancer among Mexican women. Cancer Epidemiol Biomarkers Prev 13 (8): 1283–9.
  49. Francesca Bravi, Cristina Bosetti, Lorenza Scotti, Renato Talamini, Maurizio Montella, Valerio Ramazzotti, Eva Negri, Silvia Franceschi, and Carlo La Vecchia (October 2006). Food Groups and Renal Cell Carcinoma: A Case-Control Study from Italy. International Journal of Cancer 355:1991-2002.
  50. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005). Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293 (2): 194–202.
  51. Michaud DS, Liu S, Giovannucci E, Willett WC, Colditz GA, Fuchs CS (2002). Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 94 (17): 1293–300.
  52. Venkateswaran V, Haddad AQ, Fleshner NE et al. (2007). Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99 (23): 1793–800.
  53. Friebe, Richard: Can a High-Fat Diet Beat Cancer?, Time Magazine, Sep. 17, 2007
  54. Hitti, Miranda: High Blood Sugar Linked to Cancer Risk, WebMD, 22 February 2008
  55. Moynihan, Timothy:Cancer causes: Popular myths about the causes of cancer, MayoClinic.com, retrieved 22 Feb 2008
  56. Avoid Sugary Drinks. Limit Consumption of Energy-Dense Foods, American Institute for Cancer Research, retrieved 20 Feb 2008
  57. High sugar levels increase cancer and mortality risk, The Nation's Health: The Official Newspaper of the American Public Health Association, February 2005
  58. Kushi LH, Byers T, Doyle C, et al. (2006). American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 56 (5): 254–81; quiz 313–4.
  59. "Historical Overview" dietandcancerreport.org. Retrieved on 27 August 2008.
  60. "Recommendations". dietandcancerreport.org. Retrieved on 27 August 2008.
  61. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Chapter 12 World Cancer Research Fund (2007). ISBN 978-0-9722522-2-5.
  62. Yuen JW, Gohel MD (2005). Anticancer effects of Ganoderma lucidum: a review of scientific evidence. Nutr Cancer 53 (1): 11–7.
  63. Hsu SC, Ou CC, Li JW, et al (October 2008). Ganoderma tsugae extracts inhibit colorectal cancer cell growth via G(2)/M cell cycle arrest. J Ethnopharmacol 120 (3).
  64. http://www3.interscience.wiley.com/cgi-bin/fulltext/121398729/PDFSTART?CRETRY=1&SRETRY=0
  65. http://www.ncbi.nlm.nih.gov/pubmed/12126464
  66. http://www.ncbi.nlm.nih.gov/pubmed/7606203
  67. Template:Cite pmid (review)
  68. Pollan, Michael (2006). The Omnivore's Dilemma : A Natural History of Four Meals. New York: Penguin Press. ISBN 978-1-59420-082-3. 
  69. Giovannucci E, Liu Y, Rimm EB, et al. (April 2006). Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J. Natl. Cancer Inst. 98 (7): 451–9.
  70. Vitamin D Has Role in Colon Cancer Prevention. Retrieved 2007-07-27.
  71. Schwartz GG, Blot WJ (April 2006). Vitamin D status and cancer incidence and mortality: something new under the sun. J. Natl. Cancer Inst. 98 (7): 428–30.
  72. Questions and answers about beta carotene chemoprevention trials (PDF). National Cancer Institute (1997-06-27). Retrieved 2009-04-23.
  73. Cole BF, Baron JA, Sandler RS, et al. (2007). Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297 (21): 2351–9.
  74. 74.0 74.1 Vogel V, Costantino J, Wickerham D, Cronin W, Cecchini R, Atkins J, Bevers T, Fehrenbacher L, Pajon E, Wade J, Robidoux A, Margolese R, James J, Lippman S, Runowicz C, Ganz P, Reis S, McCaskill-Stevens W, Ford L, Jordan V, Wolmark N (2006). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 (23): 2727–41.
  75. Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L, Lieber M, Cespedes R, Atkins J, Lippman S, Carlin S, Ryan A, Szczepanek C, Crowley J, Coltman C (2003). The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (3): 215–24.
  76. Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, Halpern Z, Arber N (2003). Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 48 (10): 1998–2002.
  77. Baron J, Sandler R, Bresalier R, Quan H, Riddell R, Lanas A, Bolognese J, Oxenius B, Horgan K, Loftus S, Morton D (2006). A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131 (6): 1674–82.
  78. Bertagnolli M, Eagle C, Zauber A, Redston M, Solomon S, Kim K, Tang J, Rosenstein R, Wittes J, Corle D, Hess T, Woloj G, Boisserie F, Anderson W, Viner J, Bagheri D, Burn J, Chung D, Dewar T, Foley T, Hoffman N, Macrae F, Pruitt R, Saltzman J, Salzberg B, Sylwestrowicz T, Gordon G, Hawk E (2006). Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 (9): 873–84.
  79. 79.0 79.1 79.2 Cancer Vaccine Fact Sheet. NCI (2006-06-08). Retrieved 2008-11-15.
  80. Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, Leung C, Houghton AN, Bergman PJ. (2006). Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun. 6.
  81. Animal Medical Centre (2007-03-26). USDA Grants Conditional Approval for First Therapeutic Vaccine to Treat Cancer. Press release. Retrieved on 2009-06-06.
  82. What Is Cancer?. National Cancer Institute. Retrieved 2009-08-17.
  83. Cancer Fact Sheet. Agency for Toxic Substances & Disease Registry (2002-08-30). Retrieved 2009-08-17.
  84. Wanjek, Christopher (2006-09-16). Exciting New Cancer Treatments Emerge Amid Persistent Myths. Retrieved 2009-08-17.
  85. Hayden, Erika C. (2009-04-08). Cutting off cancer's supply lines. Nature 458 (7239): 686–687.
  86. WHO Disease and injury country estimates. World Health Organization (2009). Retrieved Nov. 11, 2009.
  87. Cancer (PDF). World Health Organization.
  88. 88.0 88.1 88.2 88.3 88.4 Jemal A, Siegel R, Ward E et al. (2008). Cancer statistics, 2008. CA Cancer J Clin 58 (2): 71–96.
  89. Gurney JG, Smith MA, Ross JA (1999). "Cancer among infants", in Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds): Cancer Incidence and Survival among Children and Adolescents, United States SEER program 1975–1995. Bethesda, MD: National Cancer Institute, SEER Program, 149–56. 
  90. 90.0 90.1 90.2 90.3 90.4 Rheingold, Susan; Neugut, Alfred; Meadows, Anna (2003). "156: Secondary Cancers: Incidence, Risk Factors, and Management", in Frei, Emil; Kufe, Donald W.; Holland, James F.: Cancer medicine 6. Hamilton, Ont: BC Decker. ISBN 1-55009-213-8. Retrieved 05 November 2009. 
  91. Karpozilos A, Pavlidis N (2004). The treatment of cancer in Greek antiquity. European Journal of Cancer 40 (14): 2033–40.
  92. Moss, Ralph W. (2004). Galen on Cancer. CancerDecisions.
  93. The History of Cancer. American Cancer Society (September 2009).
  94. Patricia Skinner (2001), Unani-tibbi, Encyclopedia of Alternative Medicine
  95. Marilyn Yalom "A history of the breast" 1997. New York: Alfred A. Knopf. ISBN 0-679-43459-3
  96. Grange JM, Stanford JL, Stanford CA (2002). Campbell De Morgan's 'Observations on cancer', and their relevance today. Journal of the Royal Society of Medicine 95 (6): 296–9.
  97. Boveri, Theodor (2008). Concerning The Origin of Malignant Tumours. Journal of Cell Science 121 (Supplement 1): 1–84.
  98. Sharon Begley (2008-09-16). Rethinking the War on Cancer. Newsweek. Retrieved 2008-09-08.
  99. Kolata, Gina, "Advances Elusive in the Drive to Cure Cancer", The New York Times, April 23, 2009. Retrieved 2009-05-05.
  100. http://www.cancer.gov/templates/db_alpha.aspx?CdrID=44158
  101. "Definition of Cure for Hodgkin's Disease." Cancer Research 31 1970 p 1828-1833
  102. http://jco.ascopubs.org/cgi/content/full/23/34/8564

References
ISBN links support NWE through referral fees

Commons
Wikimedia Commons has media related to::

External links

Tumors (and related structures), Cancer, and Oncology
Benign - Premalignant - Carcinoma in situ - Malignant

Topography: Anus - Bladder - Bone - Brain - Breast - Cervix - Colon/rectum - Duodenum - Endometrium - Esophagus - Eye - Gallbladder - Head/Neck - Liver - Larynx - Lung - Mouth - Pancreas - Penis - Prostate - Kidney - Ovaries - Skin - Stomach - Testicles - Thyroid

Morphology: Papilloma/carcinoma - Adenoma/adenocarcinoma - Soft tissue sarcoma - Melanoma - Fibroma/fibrosarcoma - Lipoma/liposarcoma - Leiomyoma/leiomyosarcoma - Rhabdomyoma/rhabdomyosarcoma - Mesothelioma - Angioma/angiosarcoma - Osteoma/osteosarcoma - Chondroma/chondrosarcoma - Glioma - Lymphoma/leukemia

Treatment: Chemotherapy - Radiation therapy - Immunotherapy - Experimental cancer treatment

Related structures: Cyst - Dysplasia - Hamartoma - Neoplasia - Nodule - Polyp - Pseudocyst

Misc: Tumor suppressor genes/oncogenes - Staging/grading - Carcinogenesis/metastasis - Carcinogen - Research - Paraneoplastic phenomenon - ICD-O - List of oncology-related terms

Template:Carcinogen

Credits

New World Encyclopedia writers and editors rewrote and completed the Wikipedia article in accordance with New World Encyclopedia standards. This article abides by terms of the Creative Commons CC-by-sa 3.0 License (CC-by-sa), which may be used and disseminated with proper attribution. Credit is due under the terms of this license that can reference both the New World Encyclopedia contributors and the selfless volunteer contributors of the Wikimedia Foundation. To cite this article click here for a list of acceptable citing formats.The history of earlier contributions by wikipedians is accessible to researchers here:

The history of this article since it was imported to New World Encyclopedia:

Note: Some restrictions may apply to use of individual images which are separately licensed.